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Introduction
1

1. G Protein-Coupled Receptors
1.1. GPCR background
G Protein-Coupled Receptors (GPCRs) form one of the largest and most studied gene families of
mammalian genomes. GPCRs are found only in eukaryotes, including yeast, plants, choanoflag-
ellates, and animals. From the sequenced human genome over 800 GPCR genes were identified
[1].
Figure 1.1.: GPCR signaling.
GPCRs bind to a very broad range of ligands such as hormones, neurotransmitters, cytokines,
lipids, various small molecules such as odors and are reactive to light (Figure 1.1) [2, 3]. GPCRs
modulate variety of cell functions through coupling to heterotrimeric G proteins and regulating
downstream effectors such as adenylyl cyclases, phospholipases, protein kinases, ion channels and
other intracellular messengers [4].
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1.1.1. Topology
Members of the GPCR superfamily share a common membrane topology: an extracellular N-
terminal domain, an intracellular C-terminal domain and seven hydrophobic transmembrane
(TM) helices, which are connected by three intracellular loops (ICL) and three extracellular
loops (ECL) (Figure 1.2). Each transmembrane helical domain is composed of about 24 amino
acids, while the C- and N- terminal regions as well as the loops can widely vary in length with
up to hundreds of amino acids. Each of these variable regions provides specific properties to
GPCRs.
Figure 1.2.: GPCR common topology.
Most of the GPCRs have two well-conserved cysteine residues, one in extracellular loop 1 (ECL1)
and one in extracellular loop 2 (ECL2). They form a disulphide bridge important for packing and
stabilization of the helical bundle. The extracellular parts of the receptor can be glycosylated.
1.1.2. Ligands of GPCRs
Ligands that bind and activate the GPCRs can be classified by type as follows [5]:
• biogenic amines such as noradrenaline, dopamine, histamine;
• amino acids and ions such as glutamate, GABA, calcium;
• lipids such as LPA, prostaglandins;
• peptides and proteins such as chemokines, angiotensin, thrombin;
• others such as light, odorants, and nucleotides.
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GPCRs naturally exist in multiple conformations ranging from the fully inactive ground state
(R) to the fully active state (R*), which couples to G proteins and leads to signal transduction.
For any given receptor, equilibrium exists between these two states that determine the basal
level of its activity in cells.
Depending on the GPCR activation state the ligands can be divided into five classes: full agonist,
partial agonist, antagonist, inverse partial agonist and inverse full agonist. Figure 1.3 represents
the receptor activation effects produced by different types of ligands.
Figure 1.3.: Schematic representation of dose response curves by different types of GPCR ligands.
Full agonist binds and activates the receptor displaying its full efficacy. Efficacy in this case
refers to the maximum response achievable from a ligand. Partial agonist binds and activates
the receptor but has only partial efficacy compared to full agonist. Both agonists increase the
percentage of receptors in the active state above basal activity level. Inverse agonist inhibits
the basal activity of the receptor. Antagonist does not provoke a biological response itself upon
binding to the receptor but inhibits the action of other ligands and the receptor basal activity
state is restored.
GPCR ligands can also be classified according to the receptor-binding site. The majority of
known GPCR ligands bind to the same site as the endogenous agonists, the orthosteric site.
However, recent studies have described the identification of allosteric ligands for GPCRs, which
interact at a distinct site from the orthosteric one [6, 7]. The allosteric sites are of particular
pharmacological interest for selective drug design as these sites have not been under specific
selective pressure during evolution. Besides, the allosteric sites are quite distinct between highly
homologous receptors. Accordingly, they provide excellent targets for highly selective drugs.
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1.1.3. Classification of G Protein-Coupled Receptors
Several classification systems have been used to organize the GPCR superfamily. Some are based
on the ligand binding modalities others on physiological and structural features.
One of the most frequently used systems uses A, B, C, D, E, and F, classes, which is based on
sequence homology and functional similarity [4, 8, 9]. This A–F classification system covers all
GPCRs, from vertebrates and invertebrates. Therefore, some families in the A–F classification
system do not exist in humans.
More recently, GPCRs have been classified into five distinct groups based on phylogenetic
analyses of sequences, from the human genome. This classification system has been named
GRAFS, which is an acronym for the five different groups: Glutamate, Rhodopsin, Adhesion,
Frizzled/Taste2 and Secretin [1]. The different groups of GRAFS classification system are de-
scribed below.
1.1.3.1. Glutamate group
Glutamate family contains 22 members; more than half of these family members remain orphan
receptors1.
Figure 1.4.: Schematic representation of Glutamate family receptor.
The ICL3 is short and contains highly conserved amino acids [10].
The Glutamate family (also referred to as Class C or Family 3) (Figure 1.4) comprises in
metabotropic glutamate receptors, GABA receptors, calcium sensing receptor, taste receptors
1Orphan receptors are those for which endogenous ligand has not yet been identified.
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(for sweet and umami2) and several orphan receptors. Ligands of Glutamate receptors family
are cations, amino acids, carbohydrates, and other small organic compounds.
These receptors are characterized by a long N- and C- termini and a short and highly con-
served third intracellular loop. The N-terminus forms two distinct lobes separated by a cavity in
which ligand binds, forming a so-called Venus fly trap domain. The extracellular region also has a
cysteine-rich domain (CRD), which contains nine conserved cysteine residues forming three disul-
phide bridges, which connect the ligand-binding domain and the intracellular signaling domain
located within TM regions [11].
GPCRs that belong to the Glutamate family, form constitutive dimers and are used as model
proteins to study functional relevance of GPCR dimerization [12].
1.1.3.2. Rhodopsin group
The Rhodopsin family contains 672 members in the human genome including 388 odorant recep-
tors. Despite the fact that this is the largest family there are only 63 orphan receptors[13].
Figure 1.5.: Schematic representation of Rhodopsin family receptor.
Conserved amino acids among the members of the family are represented as well as the
palmitoylated cysteine residue in the C-terminal part [10].
Rhodopsin family (Figure 1.5) (also referred to as Class A or Family 1) is by far the largest
subgroup and contains receptors for odorants, important neurotransmitters, such as dopamine
and serotonin, as well as neuropeptides and glycoprotein hormones. These family members are
characterized by several highly conserved amino acids such as NSxxNPxxY motif in the trans-
membrane helix 7 (TMVII) and the DRY motif or D(E)-R-Y(E) at the border between TMIII
and ICL2 [1]. These conserved sequences have been proposed to be important for the receptor
2Umami is one of the five basic tastes together with sweet, sour, bitter, and salty. Umami is a loanword from the
Japanese umami meaning "pleasant savory taste". This particular writing was chosen by Professor Kikunae
Ikeda from umai "delicious" and mi "taste".
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activation or for maintaining the receptor in the inactive state [14]. A conserved disulphide
bridge connects the first and second extracellular loops. Most of these receptors also have a
palmitoylated cysteine residue in the intracellular C-terminal tail, which serves as an anchor to
the membrane.
For small molecules, the ligand binding site is located within the transmembrane part, whereas
in the case of peptides and glycoproteins, it is located at the N-terminal part and extracellular
loops.
The determination of the crystal structure of rhodopsin [15] has indicated that the transmem-
brane domains of rhodopsin family receptors are ’tilted’ and ’kinked’, due to the presence of
amino acids such as proline that distort the helical transmembrane domain.
Chemokine receptors belong to this GPCR family.
1.1.3.3. Adhesion group
In the A-F classification system the adhesion receptors belong to class B but in the new GRAFS
classification system they are considered as a separate group. Among 33 members of the group
there are only 3 receptors, which are no longer orphans. The ligands of these receptors are
extracellular matrix molecules such as peptides and glycosaminoglycans.
The family name “adhesion” relates to the long N-terminal part, which contains motifs that
participate to cell adhesion. The N-terminal domain is variable in length, from about 200 to
2800 amino acid long and is often rich in glycosylation sites and proline residues that might be
important for cell-cell contact [1].
Adhesion GPCRs display the GPCR proteolytic site (GPS). The GPS domain acts as an intra-
cellular autocatalytic processing site that produces two non-covalently attached subunits. The
proteolytic cleavage of the receptor protein occurs in the endoplasmic reticulum or in the early
compartment of the Golgi apparatus and is necessary to transport the receptor to the membrane
[16].
1.1.3.4. Frizzled/Taste2 group
This group includes two distinct clusters without any obvious similarities, the Frizzled receptors
and the Taste2 receptors (also referred to as Class F or family 6). However, Taste2 and Frizzled
receptors, share several consensus sequences: IFL in the second TM, SFLL in the fifth TM, and
SxKTL in the seventh TM. Frizzled/Taste2 family includes 36 members. There are no orphans
among the 11 Frizzled family members, but most of the Taste2 GPCRs remain orphans.
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Frizzled/Smoothened This family includes ten Frizzled receptors (FZD1-10) and the Smoothened
receptor (Smo). The Frizzled receptors mediate signals from secreted glycoproteins and in this
way they control cell fate, proliferation, and are involved in embryonic development, particu-
larly, in cell polarity and segmentation. The Frizzled family receptors have a 200-amino acid
long N-terminus which contains several conserved cysteines. Their ligands are proteins.
Taste2 receptors The human genome contains 25 functional Taste2 receptors. They are ex-
pressed in the tongue and palate epithelium and function as bitter taste receptors. Their ligands
are small organic compounds. Several of the Taste2 receptors are still orphans. Taste2 receptors
consist of 290 - 340 amino acids and display short N- and C- termini domains. Taste2 receptors
lack the well-conserved cysteine bridge between extracellular loops 1 and 2. Despite few con-
served residues that are common for the ligand binding site, these receptors are highly variable
between the species.
1.1.3.5. Secretin group
Secretin family comprises 50 members with none of them being orphan receptors (also referred
to as Class B or Family 2). Secretin family GPCRs (Figure 1.6) are characterized by a relatively
long N-terminus, which contains several cysteines that form a network of disulphide bridges. This
extended N-terminal domain together with extracellular loops is implicated in ligand binding.
Ligands of secretin family GPCRs include high molecular weight hormones such as glucagon,
secretine, calcitonin and Black widow spider toxin.
Figure 1.6.: Schematic representation of Secretin family receptor.
Relatively long N-terminus contains several conserved cysteins [10].
The topology of secretin family receptors is similar to some of the rhodopsin family receptors,
however the palmitoylation site is missing and the conserved residues and motifs are different
from those in the rhodopsin family receptors.
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Little is known about the orientation of the TM domains, but given the divergence in amino-acid
sequence, they are likely to be different from rhodopsin family receptors. As in rhodopsin family,
the secretin family receptors contain several conserved proline residues within the TM segments,
which are essential for the conformational dynamics of the receptors.
1.2. GPCR activation
Receptor activation studies started early before the term of receptor was applied. The studies
started by observing how different tissues reacted to the drugs. J. N. Langley in 1878 postulated
that a drug has to bind to a specific part of the tissue in order to produce an action on that
tissue. After a while, he described “side chain molecules” present on different muscles that reacted
differently to the drug (nicotine). He named them “receptive substances” that are diverse in
different muscles [17]. Lately this term was widely adapted as “receptor”.
For a long time receptor activation was represented by a simple model with a bimodal switch
between inactive and active forms. However, increasing experimental evidence provided infor-
mation that GPCRs are dynamic and exist in different conformational states [18].
1.2.1. Simple linear Two-State Model
The first models used to describe the activation mechanism of GPCRs were based on the law
of mass action. The interaction between the receptor (R) and the agonist (A) depends on the
equilibrium association constant (Ka) resulting in receptor activation (Figure 1.7).
Figure 1.7.: Simple linear two-state model.
A - Agonist, R - Receptor, R* - Activated Receptor.
An agonist (A) binds to the receptor (R) to form an agonist-receptor complex (AR). The level of
the AR complex present at thermodynamic equilibrium can be defined by the value of the Ka.
A physiological response can be expected only when the AR complex is formed, and a maximal
response will occur when the agonist occupies all receptor sites.
In 1980, this idea was modified taking into account receptor properties such as intrinsic activity,
efficiency, conformational changes and G protein binding.
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1.2.2. Ternary Complex Model
Studying the β2 Adrenergic Receptor (β2AR), A. De Lean and co-workers established the Ternary
Complex (TC) Model [19] (Figure 1.8). This model originated form the simple linear two-state
model.
Figure 1.8.: Ternary complex model.
A - Agonist, R - Receptor, G - G Protein.
The initial ternary complex model describes the interactions between ligand, receptor, and G
protein. This model implies that the receptor recognizes the agonist and the G protein in a
random order.
1.2.3. Extended Ternary Complex Model
Continuous research and discoveries led to the further model development. In 1993, the studies of
the β2AR activation indicated that a GPCR could activate G proteins without being stimulated
by a ligand [20, 21]. At this stage the Extended Ternary Complex (ETC) model was introduced
to include the spontaneous activation of a receptor that can interact with a G protein even in
the absence of agonist binding (Figure 1.9).
Figure 1.9.: Extended ternary complex model.
A - Agonist, R - Receptor, R* - Activated Receptor, G - G Protein.
This model allows both the spontaneous and ligand induced active-state receptor (R*). R*
can then interact with the ligand or activated G protein. In this model, the agonists have
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stronger affinity to R* than for R, shifting the equilibrium toward the active form of the receptor.
Antagonists have similar affinity for both forms and do not affect the balance. Inverse agonists
have a tendency to bind to R and therefore move the equilibrium towards the inactive-state R
form.
1.2.4. Cubic Ternary Complex Model
In 1996, to introduce receptor activation and G protein coupling the Cubic Ternary Complex
(CTC) was established [22]. The CTC model adds a possibility of an active receptor and G
protein association that does not cause signaling. This non-signaling complex is required ther-
modynamically.
The CTC model takes into account that receptor can be in active (R*) or inactive (R) conforma-
tion and bound to the G protein (R*G and RG) or not (Figure 1.10). In this model, the receptor
can interact with a G protein and/or a ligand at the same time. In addition, different receptors
both active and inactive receptors may compete for the same ligand or G protein.
Figure 1.10.: Cubic ternary complex model.
A - Agonist, R - Receptor, R* - Activated Receptor, G - G Protein.
However, the model does not include receptor homo- or hetero-oligomerization [23, 10, 24, 25,
26, 27], or the possibility that GPCRs can form stable complexes with downstream proteins [28].
1.2.5. Constitutive activity
The constitutive activity of GPCRs can be defined as the ability of a receptor to present an
intrinsic activity in the absence of agonist. The evidence of constitutive activity of GPCRs has
been described in the studies of the δ-opioid receptor [29], and purified β2AR [30]. Inverse agonist
binding can block the constitutive activity of receptors.
12
1.3. G PROTEIN SIGNALING PATHWAY
Most if not all GPCRs can exist in at least two states: an active state favored by agonist and an
inactive state favored by inverse agonist [31, 32, 33].
Mutants with increased constitutive activity of GPCRs were later discovered. GPCR mutations
in the region near the interface at the end of the third intracellular loop and at the beginning of
transmembrane helix VI result in the elevated levels of constitutive activity [34, 35].
1.3. G protein signaling pathway
Heterotrimeric G proteins composed of Gα, Gβ and Gγ subunits constitute one of the most im-
portant components of the cell signaling cascade [36]. They transmit signals from transmembrane
receptors, ion channels and further to intracellular effector enzymes.
Figure 1.11.: GPCR activation cycle.
In the receptor inactive state (A), the Gα subunit in a GDP bound form is associated to the
Gβγ complex. Upon agonist binding (B), the receptor undergoes a conformational change that
activates its Guanine nucleotide Exchange Factor (GEF) , which catalyzes the exchange of
GDP to GTP in the Gα subunit. GTP-bound Gα and the Gβγ complex dissociates and that
activates downstream signaling (C). Hydrolysis of GTP to GDP, which may be stimulated by
Regulators of G protein Signaling (RGS) proteins, leads to re-association of Gα and Gβγ
subunits and termination of G protein signaling (D).
In the absence of a stimulus, the GDP-bound Gα subunit (Gα·GDP) and the Gβγ complex are
associated (Figure 1.11). Ligand binding to the GPCR causes a conformational change in the
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GPCR, which allows it to act as a Guanine nucleotide Exchange Factor (GEF). The GPCR can
then activate an associated heterotrimeric G protein by exchanging its bound GDP to GTP [37].
The binding of GTP to the Gα subunit results in conformational changes within the three flex-
ible switch regions of Gα (see Section 1.3.1.1), and leads to the dissociation of Gβγ from the
heterotrimeric complex. Activated Gα and Gβγ proteins bind to various effectors that trans-
mit signals to different second messengers such as adenylyl cyclases, phospholipases, and ion
channels.
Gα signaling is terminated upon GTP hydrolysis. Although Gα has a slow capability to hy-
drolyze GTP, the rate of this reaction is often accelerated by allosteric modulating proteins
called Regulators of G protein Signaling (RGS) (Figure 1.11 D). Re-association of Gβγ with
Gα·GDP terminates all interactions with effectors and form the initial inactive heterotrimeric
complex [38, 39].
1.3.1. G-protein subunits
At present, there have been 16 Gα, 5 Gβ and 12 Gγ subunit genes identified [40]. Various
combinations of heterotrimeric G proteins are possible. Each of the subunits possesses specific
properties, which enable the transmission of specific signals.
1.3.1.1. The Gα subunit
There are at least 16 Gα genes in the human genome. When alternative splicing and post-
translation modifications are taken into account - there are at least 23 known Gα proteins [41].
The molecular mass of Gα subunit varies from 39 to 45 kDa. Crystallographic studies revealed
that the Gα subunit is composed of two major domains: a GTPase binding domain and an
α-helical domain (Figure 1.12).
Figure 1.12.: Structure of Bos taurus Gα subunit.
PBD code: 1GOT [42].
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GTPase domain is conserved among all members of the G protein superfamily. This domain
hydrolyses GTP and provides the binding surfaces for the Gβγ dimer, GPCRs and effector
proteins. GTPase domain contains three flexible loops, named switches I, II and III, where
significant structural differences between GDP-bound and GTP-bound conformations of Gα were
identified [43, 44, 45, 46]. The N- and C- terminal parts of the Gα subunit are important for the
interaction with GPCRs [47].
The helical domain is unique for each Gα protein and is composed of a bundle of six α-helices
that form a cover over the nucleotide-binding pocket, hiding them in the core of the protein
(Figure 1.12).
On the basis of the sequence homology Gα proteins are divided into four major classes. Each
class can be subdivided into several families (Table 1.1) [48, 41].
Class Family Effector
GαS αSL1, αSL2, αSS1, αSS2, αOlf Adenylyl cyclase (+)
Gαi/o
αi1, αi2, αi3 Adenylyl cyclase (-), Cl- and K- channels
(+), Phospholipase C and A2 (+)
αt1, αt2, αGus cGMP phosphodiesterase (+)
αo1, αo2 Voltage dependent Ca2+ channels (-), K+
channels (+)
αz Adenylyl cyclase (-)
Gαq,11 αq, α11, α14, α15, α16 Phospholipase C (+)
Gα12,13 α12, α13 Phospholipase A2 (+), c-Jun
NH(2)-terminal kinase (+)
Table 1.1.: Gα subunit classes and their effectors.
(+) Activation, (-) Inhibition.
All Gα subunits, except Gαt, are post-translationally modified with the fatty acid palmitate at
the N-terminus. Members of the Gαi family are also myristoylated at the N terminus. All these
modifications regulate membrane localization and protein – protein interactions [49].
Each Gα class is involved in specific signaling mechanisms (Figure 1.13). Although there are
many exceptions and the signaling pathways are not that distinct between different classes of Gα
proteins, however, three basic signaling patterns could be identified.
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Figure 1.13.: Typical patterns of Receptor-Gα protein signaling in the cells.
AC- Adenylyl Cyclase, PKA - Protein Kinase A, EPAC - Exchange Proteins directly activated
by cAMP, PDE - Phosphodiesterase, PLC - Phospholipase C, PIP2 - phosphatidylinositol
4,5-biphosphate, DAG - diacylglycerol, IP3 inositol triphosphate.
The GαS class
The GαS class contains several families of GαS and a GαOlf family, which couples to the olfactory
receptors. They activate the Adenylyl Cyclase (AC), which stimulates the production of cAMP
from ATP.
The downstream signaling of cAMP is mediated by its interactions with effector molecules,
Protein Kinase A (PKA) or EPAC (Exchange Proteins directly activated by cAMP), which have
been shown to modulate phagocyte functions.
The production of cAMP could be regulated by microbial pathogens [50]. Pertussis toxin and
cholera toxin cause elevated cAMP levels through ADP-ribosylation of either the Gαi subunit
to prevent its inhibition of Adenylyl Cyclase or of the GαS subunit to constitutively activate
Adenylyl Cyclase, respectively. Phosphodiesterase (PDE), which degrades cAMP to AMP, is an-
other regulator of intracellular cAMP levels. PDE inhibitors prevent such degradation, resulting
in accumulation of intracellular cAMP [51].
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The Gαi/o class
The Gαi/o class contains several families of Gαi , Gαt, Gαo, one Gαz, and one GαGus protein
family. Gαi can inhibit Adenylyl Cyclase, which results in inhibition of the production of cAMP
from ATP [52]. The Gαt and GαGus activate the Phosphodiesterase, which degrades cAMP to
AMP, when coupled to Rhodopsin and Taste receptors respectively. Gαi can inhibit the voltage-
dependent Ca2+channels and activate Cl- and K+ channels.
Upon the dissociation of Gαi/o from Gβγ subunits, Phospholipase C (PLC) could be acti-
vated. Phospholipase C hydrolyzes phosphatidylinositol 4,5-biphosphate (PIP2) to diacylglycerol
(DAG) and inositol triphosphate (IP3). Diacylglycerol acts as a second messenger and activates
the Protein Kinase C (PKC). IP3 binds to its receptors on the endoplasmic reticulum causing
the increase of intracellular [Ca2+] levels that triggers currently unknown signaling pathways,
which could cause cell chemotaxis [53].
The Gαq class
There are five families of Gαq proteins and all of them activate the Phospholipase C. The signaling
of GPCRs that couple to Gαq results in the increase of intracellular [Ca2+] that has an effect on
DAG-PKC interaction, which is crucial for activating downstream effectors [54].
Gα12,13 class
The Gα12,13 class proteins activate the GTPases of the Rho family. They are related to cytoskele-
ton functions, smooth muscle contractions and neuronal morphogenesis [55]. The activation of
Rho-GEF requires not only Gα12,13 but also PKC-mediated phosphorylation of Rho-GEF [56].
1.3.1.2. The Gβγ dimer
Five different genes encode the Gβ subunits, whereas Gγ subunits are encoded by 11 different
genes [57]. Due to alternative splicing there are 6 Gβ members, while Gγ type has 12 members.
Their molecular mass range from 35 to 37 kDa for Gβ, and 6 to 8 kDa for Gγ. The Gβ and Gγ
subunits form a functional heterodimer, which is a stable structural unit. Most of the Gβ subunits
can interact with different Gγ subunits, though not all of the possible dimer combinations occur.
The existing Gβγ dimer combinations are specific for the tissue or cell type.
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Figure 1.14.: Structure of Bos taurus Gβγ dimer.
PBD code: 1GOT [42].
All Gβ subunits contain seven WD-40 repeats, a Tryptophan-Aspartic acid (WD) sequence that
repeats about every 40 amino acids and forms small antiparallel β strands that mediates protein-
protein interaction (Figure 1.14) [47]. Crystal structures of the Gβγ dimer and Gαβγ trimer
demonstrated that these seven WD-40 repeats of the Gβ subunit folds into a seven-bladed β-
propeller structure. The N-terminal part of the Gβ subunit forms an α-helix structure [58].
The Gγ subunit folds into two α-helices; the N-terminal helix forms a coiled-coil with the N-
terminal α-helix of Gβ subunit, while the C-terminal helix makes extensive contacts with the
base of the Gβ subunit seven-bladed β-propeller structure.
Several posttranslational modifications of Gβ have been characterized. The N-terminus of Gβ
subunit undergoes the removal of the methionine at position 1, followed by N-acetylation of
serine at position 2 [59]. Phosphorylation of Gβ1 histidine 266 by nucleoside diphosphate kinase
(NDPK) was predicted as a mechanism of G protein activation [60].
G protein localization at the cytoplasmic face of the plasma membrane of the cells is critical
for the signaling [61]. This sub-cellular localization is facilitated due to Gγ subunit lipidation
[62, 63]. The Gγ subunit post-translational modifications at the N- and C-terminus, such as C-
terminal processing, the absence of prenylation, the N-terminal processing and phosphorylation,
are critical for the G protein function[64]. All these post-translational modifications bring more
diversity into the G protein heterotrimers and specificity for the signal transduction.
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Unlike the conformationally flexible Gα subunit, the Gβγ heterodimer does not undergo confor-
mational change when it dissociates from the G-protein heterotrimer. The Gβγ heterodimer is
able to interact with many effectors and also contribute to signal transduction. However, Gβγ
association with Gα prevents Gβγ from activating its effectors. Table 1.2 identifies the main
effectors of these proteins.
Class Family Effector
Gβ β1 to β6 Phospholipase C and A2 (+)
Gγ γ1 to γ12
Adenylyl cyclase I (-), II and IV (+),
GIRK (+), Ca2+ channels (-), MAPK
(+), Na+ channels (+), c-Jun
NH(2)-terminal kinase (+), PI3 kinase
(+), PKC and PKD (+)
Table 1.2.: Gβγ subunit classes and their effectors.
(+) Activation, (-) Inhibition.
Activated Gα and Gβγ proteins bind to various effectors that transmit the signal to different
second messengers. Many effectors are regulated by both Gα and Gβγ subunits. Initially the
Gβγ complex was considered as a passive partner of the Gα subunit. However, now it is clear
that Gβγ subunit can regulate various effectors. The Gβγ complex mediated signaling includes
regulation of ion channels such as G protein regulated inward rectifier potassium channel (GIRK)
and Voltage-Dependent Ca2+ Channels (VDCC).
In addition to the ion channels, the Gβγ complex was shown to be a positive regulator of a large
number of effectors including Adenylyl Cyclase, phospholipase C-β (PLC-β), phospholipase A
(PLA), phosphoinositide-3-kinase (PI3K), Protein Kinase C (PKC), Protein Kinase D (PKD)
and β-Adrenergic Receptor kinase [38].
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1.3.2. G protein independent signaling
For many years it was considered that G protein activation is a necessary step in all signal trans-
duction pathways induced by GPCRs. Growing number of receptor binding protein discoveries
suggested that there are alternative signaling mechanisms (Figure 1.15). Some of these GPCR
binding proteins have properties of signaling molecules with enzymatic activity; others appear to
act as adaptor proteins that can promote kinase binding to the receptor. Such mechanisms allow
direct cross-talk with other transduction pathways without GPCR interaction with G proteins.
Figure 1.15.: G protein independent signaling.
Following agonist binding, GPCRs can associate with members of diverse families of
intracellular proteins, including polyproline-binding proteins such as those containing SH3
domains (SH3), β-arrestins, G Protein–coupled Receptor Kinases (GRK), small GTP-binding
proteins (g), SH2 domain–containing proteins (SH2) and PDZ domain–containing proteins
(PDZ). All these interactions allow GPCRs to initiate multiple intracellular signaling pathways.
GRKs and Arrestins
Ligand activated GPCR, in addition to heterotrimeric G protein activation, is phosphorylated
by a family of specific G protein coupled receptor kinases (GRKs) (Figure 1.16) [65]. This
phosphorylation allows the cytosolic proteins known as β-arrestin to interact with the GPCR.
Usually arrestins bind to the third intracellular loop and the C-terminal part of the GPCRs, the
same region as G proteins. The association of arrestins with GPCRs does not simply uncouple
receptors from G protein pathways (signaling to effector proteins), but rather induces a switch in
receptor signaling from classical G protein mediated pathways to a process termed desensitization
described thereafter.
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Figure 1.16.: The signaling mediated by GRKs and Arrestins.
Adapted from[66].
GRK and β-arrestins play additional roles in GPCR regulation and signaling. The agonist-
induced interaction of β-arrestin with the phosphorylated GPCR allows the β-arrestin mediated
recruitment of clatrin, thus triggering receptor internalization, dephosphorylation and recycling
(Figure 1.16) [67]. In addition β-arrestin can interact with the cytosolic tyrosine kinase c-Src
and promote its recruitment to the receptor signaling complex, suggesting a key role for GRK
and β-arrestin function in modulation of mitogen-activated protein kinase (MAPK) cascades by
GPCRs.
The β-arrestin activates the GPCR-stimulated Mitogen-Activated Protein (MAP) kinase. This
pathway was analyzed in a study of the β2AR [68].
SH2 domain-containing signaling proteins
GPCRs and SH2 domain based signaling complexes act similarly as receptor tyrosin kinases and
GRKs [69]. Following stimulation with Angiotensin II the heptahelical Angiotensin AT1 receptor
activates JAK2 tyrosine kinase. This mechanism involves Src mediated tyrosine phosphorylation
of the AT1 receptor[70].
Small GTP binding proteins
GPCRmediates regulation of small GTP binding proteins such as Ras, Rab, Rho and ARF, which
can activate the phospholipase D. It was demonstrated that GPCR activated phospholipase D
is not blocked by the inhibitors of the heterotrimeric G protein pathways, which confirms that
this activation is independent of G proteins [71].
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PDZ domain containing proteins
GPCRs can also interact with the PDZ domain containing proteins. These PDZ domains gener-
ally bind to the C-terminal motif (S/T-x-L) of target proteins [72, 73].
Polyproline binding proteins
Some GPCRs exhibit polyproline regions on their third intracellular loop or C-terminal tails.
These polyproline regions are known to mediate binding of conserved protein domains such
as SH3 domains, WW domains (two highly conserved tryptophans) and EVH (Enabled/VASP
homology) domains [74, 75, 76, 77].
1.3.3. Desensitization
Desensitization reduces receptor activity and plays a role in signal duration, intensity and quality.
Desensitization is initiated by phosphorylation of Serine and/or Threonine residues in the third
intracellular loop and C-terminus of the receptor. Two types of desensitization are known:
heterologous and homologous [78]. Both types are the result of receptor phosphorylation.
1.3.3.1. Homologous desensitization
Homologous desensitization is specific for agonist-occupied GPCR. The conformational change
in GPCR caused by the agonist binding further allows GRK to interact with the receptor. Serine
and Threonine in the intracellular loop and the C-terminal part of the GPCR are phosphorylated
by GRK. This mechanism was demonstrated for the Rhodopsin and β2AR [79, 80]. Agonist
activated and GRK phosphorylated GPCR binds to β-arrestin, which serves to inhibit G protein
coupling. This way the active state of GPCR is terminated, and may also direct the receptor to
clathrin-coated pits for internalization.
1.3.3.2. Heterologous desensitization
Heterologous desensitization is much less selective than the homologous desensitization. This
mechanism uses kinases (PKA, PKC) that are activated by second messengers that phosphorylate
all receptors present in the membrane without discriminating the active and inactive states.
Consequently, a receptor can be activated by its ligand and cause a desensitization of another
GPCR present in the same cell [81].
Just as GRK, the PKA and the PKC catalyse the phosphorylation of Ser/Thr residues that are
located at the intracellular loops and the C-terminus of GPCR. The following process is similar to
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that of GRK: the presence of phosphate groups recruits β-arrestin that prevents communication
between GPCR and heterotrimeric G proteins.
1.3.4. Internalization
Receptor desensitization, initiated by phosphorylation of the receptor by PKA, PKC or GRKs,
can be subsequently followed by receptor internalization.
Upon internalization, receptors can be dephosphorylated and returned to the plasma membrane,
fuzed with larger endosomes and slowly recycled, or degraded in lysosomes. Internalization may
regulate receptor desensitization and contribute to a positive regulation of receptor signaling
[82, 83, 84].
1.4. Dimerization of GPCRs
Even though classical models predict that GPCRs function as monomers, several recent studies
suggest that GPCRs exist as dimers or even oligomers. Homodimers or heterodimers can be
formed between members of the GPCR family [85].
GPCR dimerization has functional consequences on each step of the life cycle of the receptor
including ligand binding, signal transduction and internalization.
There are two GPCR dimerization processes that occur either in the endoplasmic reticulum or
at the cell surface. In the endoplasmic reticulum the receptors are gathered together as dimers
or multimers and then transported to the cell surface. Otherwise, receptors are synthesized as
momomers and then transported to the cell surface where they assemble into dimers/oligomers
[23].
Dimeric receptors possess several properties that monomers do not have [86, 87, 88].
Targeting membrane expression and internalization
Heteromerization is involved in receptor maturation, folding and expression at the cell surface
by modulating its targeting from the endoplasmic reticulum or internalization.
In some cases dimerization has a role in receptor maturation and allows the correct transport
of GPCRs from endoplasmic reticulum (ER) to the cell surface. Oligomer formation at the ER
masks specific retention signals or hydrophobic patches of the momomers. For the metabotropic
γ-aminobutyric acid b (GABAb) receptor dimerization is essential for its function [23, 89, 90].
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This receptor consists of an obligate heterodimer of the GABAbR1 and GABAbR2 subunits.
Each of the subunits belongs to the Glutamate family. When expressed alone the GABAbR1 is
retained in the ER whereas GABAbR2 subunit is expressed at the cell surface and couples to the
G proteins but does not bind agonist [91]. When both subunits are co-expressed, the heterodimer
is formed allowing proper targeting of a functional GABA heterodimer to the plasma membrane
[92, 93, 94].
In other cases early heterodimerization between wild type and mutant receptors leads to their
retention in ER. In case of naturally occurring mutations this could have pathophysiological con-
sequences. GPCR dimerization in an early secretory pathway was shown for CCR5 chemokine
receptor. CCR5Δ32 is a natural genetic mutation where there is an internal 32-nucleotide dele-
tion within the CCR5 open reading frame [95]. When expressed alone the CCR5Δ32 is retained
in the ER while CCR5 reaches the cell surface. When CCR5 and CCR5Δ32 were co-expressed in
the same cell a significant reduced cell surface expression of wild type CCR5 was observed, sug-
gesting that in the case of dimerization, CCR5Δ32 act as a dominant negative inhibitor of CCR5
expression. CCR5/CCR5Δ32 heterodimerization contributes to the delayed onset of AIDS in
HIV-infected patients with a CCR5/CCR5∆32 genotype [95].
Ligand binding
Ligand binding to an allosteric site is able to induce receptor conformational change. It can pro-
mote or inhibit the dimerization. In case of heterodimerization, one monomer can induce changes
in the active conformation of another monomer, leading to novel pharmacological properties of
the receptors.
In some cases heterodimerization could lead to the creation of new binding sites. Two functional
opioid receptors κ and δ form a heterodimer κ-δ, which results in the generation of a novel ligand
binding site and functional properties [96]. This also occurs with μ- and δ-opioid receptors
[97]. This phenomenon has a pharmacological importance: it provides new opportunities for
the development of more selective compounds that would target specific heterodimers without
affecting the individual monomers [10].
In some cases ligand binding regulates dimerization at the plasma membrane. Ligand binding to
the chemokine receptors CCR2b, CCR5 and CXCR4 promotes receptors homodimer formation
[98, 99, 100].
Signal transduction
G protein coupling could be promoted or attenuated by receptor heterodimerization (Figure 1.17)
[101].
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Figure 1.17.: GPCR heteromerization role signaling.
R1: receptor 1, R2: receptor 2, L1: ligand 1, L2: ligand 2, G1: G protein 1, G2: G protein 2,
G3: G protein 3.
In some cases, this regulation by receptor heterodimerization can open new signaling pathways
to a new G protein coupling or a switch to the recruitment of other signaling protein such as
β-arrestin.
Heterodimerization has also been proposed to promote changes in the selectivity of some GPCRs
towards the different G-protein subfamilies. In cells that co-express CCR5 and CCR2 chemokine
receptors, heterodimers are formed, which activates different signaling pathways such as Gαq/11
association and delayed activation of phosphatidyl inositol 3-kinase (PI3K), while monomeric
receptors couple to Gαi [102].
Recently, it was shown that serotonin type 4 receptor (5-HT4R) homodimer activates G protein
twice as much comparing to receptor monomer activation [103]. In case of leukotriene B4 receptor
(BLT2), it was shown that dimer formation reduced the signaling ability [104].
1.5. GPCRs as pharmaceutical targets
GPCRs remain the target of many drug design programs due to their central role in most of
physiological systems. Approximately 30% of all approved drugs target GPCRs, highlighting the
clinical importance of this protein family (Figure 1.18).
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Figure 1.18.: Schematic representation of actual drug targets in the pharmaceutical market.
Adapted from [105].
Mutations in GPCRs can have dramatic impacts on cell signaling and it might cause various
diseases. Perturbation of their activity can result in a multitude of diseases, including obesity,
diabetes, congestive heart failure, hormone-dependent cancers, infertility, etc. Table 1.3 lists
human diseases, for which the responsible GPCR has been determined and drugs created.
Disease GPCR
Cardiovascular βAR, αAR
Obesity MC4, 5HT6, CB1
Diabetes CB1, AT1
Cancer CCR5, CXCR4
Asthma βAR, Adenosine A2A
Schizophrenia 5HT2A, Dopamine D2
Parkinson’s Dopamine D2, Adenosine A2A
HIV CCR5, CXCR4
Table 1.3.: Disease associated GPCRs.
Among the top 10 best selling drugs (2008 and 2009 ratings) there are four that target GPCRs, i.e.
Plavix (Atherosclerosis), Advair (Asthma), Diovan (Hypertension) and Abilify (Schizophrenia)
(Table 1.4).
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Nr Name Company Indications 2008
US
$bln
2009
US
$bln
1 Lipitor Pfizer, Astellas High cholesterol 13.35 12.5
2 Plavix BMS & Sanofi-Aventis Atherosclerosis 9.4 9.39
3 Enbrel Amgen, Pfizer, Takeda Arthritis, Psorias 7.7 8.0
4 Advair GSK Asthma 7.65 7.76
5 Remicade J & J, Merck Arthritis 6.2 6.9
6 Diovan Novatis Hypertension 5.7 6.0
7 Avastin Roche Cancer 4.8 5.9
8 Rituxan Roche Arthritis 5.4 5.8
9 Abilify Otsuka, BMS Schizophrenia 4.8 5.6
10 Humira Abbott Arthritis 4.5 5.5
Table 1.4.: The list of top 10 blockbuster drugs.
Plavix works by irreversibly inhibiting a receptor called P2Y12, an adenosine diphosphate
(ADP) chemoreceptor on platelet cell membranes. Advair - is a Beta2-adrenergic agonist
which also acts on cholinergic M2 receptors and alpha-1 adrenoreceptors. Diovan is a specific
and selective type-1 angiotensin II receptor (AT1) antagonist which blocks the blood pressure
increasing effects of angiotensin II via the renin-angiotensin-aldosterone system (RAAS).
Abilify possesses affinity for and acts on the following receptors: Dopamine receptor D2,
5-HT7 receptor and histamine receptor.
In the past years, traditional GPCR drug design was focused on targeting the orthosteric-binding
site of the receptor. This approach addressed a classical orthosteric ligand development that
directly activated or blocked the targeted receptor. However, the disadvantages of this approach
were soon faced, mostly because of the high homology between receptor subtypes, the selective
targeting of orthosteric sites were hindered [106]. New approaches emerged based on small
molecules that target topographically distinct allosteric sites on GPCRs [107, 108, 109]. The
binding events evoke conformational changes in the receptors while still allowing the simultaneous
binding of orthosteric ligands. Allosteric drugs present better selectivity of action. However, the
most challenging steps of the new GCPR targeting drug candidate development and validation
remain for the future [110].
Heteromeric GPCR complexes having unique biochemical and functional properties provide im-
portant new targets for drug discovery [10, 111, 112, 113].
1.6. Solved GPCR structures
One of the first bottlenecks for structural studies of GPCRs is to obtain sufficient amounts of
proteins. The natural low abundance of GPCRs limits their purification in biochemically relevant
amounts. To overcome this problem, various heterologous expression systems were developed.
Eukaryotic expression systems present the advantage of direct folding of the GPCRs in the
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cell membranes. Yeast [114, 115, 116, 117], insect [118, 119] and mammalian [120, 117] cell
expression systems were developed. Proteins produced in eukaryotic expression systems undergo
post-translational modifications. Nevertheless, expressed proteins not always were stable and
needed engineering to improve stability and crystallizability [121, 122, 123].
Bovine rhodopsine was the first GPCR whose X-ray structure was solved in 2000 [15], which was
crystallized in mixed micelles. This was the only GPCR structure with no sequence modifications,
as the receptor was obtained from a natural source.
Another seven years of extensive research and technology developments were needed to obtain
the high-resolution structure of the human β2AR [124, 123]. Several problems that prevented
β2AR structure solving were indicated. First of all, the large and flexible ICL3 and C-terminus
caused problems for crystallization. T4-lysozyme (T4L), a well structured protein, replaced the
third intracellular loop to stabilize helices V and VI and to increase the polar surface to facilitate
crystallization process (Figure 1.19) [123]. The engineered protein was crystallized in two lipidic
environments: bicelles and lipidic cubic phase. Only the crystals grown in lipidic cubic phase led
to a diffraction data set, from which the structure was solved by molecular replacement using
T4 lysozyme as a model.
However ICL3 is functionally important for G protein activation, therefore the β2AR-T4L protein
did not couple to GαS [123].
Figure 1.19.: Structure of human β2AR.
The large flexible third intracellular loop between TM5 and TM6 was replaced by lysozyme to
constrain helices V and VI [123].
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Until the end of 2011, several GPCR of the Rhodopsin-like class were crystallized using a similar
approach (in lipidic cubic phase environments) and structures were solved for the following (Table
1.5): β1AR [125], A2A Adenosine Receptor (A2AAR) [126], chemokine CXCR4 [127], Dopamine
D3 receptor (D3R) [128], and Histamine H1 Receptor (H1R) [129].
Table 1.5.: Solved GPCRs structures by the end of 2011.
Apart from the structure of the Rhodopsin, all other GPCR structures have truncated/modified
N- or C- termini. The sequences were further engineered to thermostabilize the proteins.
A large diversity in the ligand-binding pockets was observed when comparing the different GPCR
structures: they greatly vary in shape, size and electrostatic properties. GPCR subtypes that
bind to the same endogenous ligand have a greater degree of binding pocket conservation. The
β1AR and the β2AR crystal structures represent 100% conserved contact residues for different
antagonists [130].
In most crystal structures analyzed, the GPCR molecules pack in non-functional antiparallel
orientations. Only CXCR4 crystals were packed in parallel arrangement [127]. All five different
crystal-packing forms of CXCR4 complexes with peptide or small-molecule antagonist suggested
that CXCR4 dimer is functionally relevant.
GPCRs agonist bound form corresponds to the active state but it spontaneously relaxes into
an inactive form in the absence of stabilization via G protein binding. To diminish protein
dynamics, GPCRs were therefore crystallized in inactive conformation, and finally bound to
agonist, antagonist, or inverse agonist. So far, there are only three GPCR structures solved in
an activated form [131, 132, 133].
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Recently the crystal structure of the active ternary complex composed of agonist-occupied
monomeric β2AR and nucleotide-free G protein heterotrimer was solved [132]. Although this
construct contains sequence of the T4 lyzozyme between helices 5 and 6 it is still able to intercat
with the GαS protein. This provides the first high-resolution structural information for GPCR
signaling across the membrane (Figure 1.20).
Figure 1.20.: Structure of GPCR in complex with G proteins.
The receptor is colored red, Gα blue, Gβ green and Gγ orange (PDB entry 3SN6).
Comparing the active and inactive β2AR structures, the differences found are in the TM5 and
TM6, as in the inactive conformation structure the T4L was inserted between the cytoplasmic
ends of TM5 and TM6. Another difference was observed in the second intracellular loop (IL2),
which forms an α-helix in the β2AR-Gs complex.
Since crystallography can only provide one structure at a time, active or inactive conformation,
the mechanism by which GPCRs transition between inactive and active states remains unclear.
It was suggested that GPCRs could adopt multiple conformational states in response to the
binding of different ligands. Using molecular dynamics (MD) simulations a detailed activation
mechanism for β2AR was proposed and is presented in the Figure 1.21.
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Figure 1.21.: The β2AR activation mechanism.
(A) An agonist bound to an inactive receptor. (B) The activation process begins on the
receptor intracellular side with an outward motion of helix 6 bringing the receptor to an
intermediate state. Here, the connector and the ligand-binding site are in equilibrium between
inactive and active conformations; the bound agonist stabilizes the active conformation. (C) A
G protein may bind to the intermediate state, favoring the final step on the activation pathway:
conformational change in the NPxxY motif (helix 7) [134].
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2. The model proteins
2.1. Chemokine receptors
There have been 23 chemokine receptors identified in humans. They form a structurally distinct
subfamily among the class A GPCR and signal through coupling with Gi class of G proteins.
Their major shared biological function is leukocyte trafficking. After the interaction with specific
chemokine ligands, chemokine receptors trigger an intracellular calcium ion flux. This causes
directional cell migration called chemotaxis.
2.1.1. Chemotaxis
Chemotaxis is a directional movement of the cells in response to a chemokine gradient towards
chemoattractant agents (Figure 2.1). Establishment of chemokine concentration gradients on
endothelial layers and in the surrounding tissue provides directional cues to guide cell movement.
Figure 2.1.: Gradient sensing and chemotaxis.
Chemotaxis is the result of three separate steps: chemosensing, polarization and locomotion [135].
Depending on the cell type and the microenvironment, migration can involve single unattached
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cells or multicellular groups [136]. Besides immune cells such as granulocyte, monocyte and
lymphocyte there are other type of cells that are mobile such as fibroblasts and endothelial
cells. Chemotaxis has a high significance in early embryogenesis, as it is involved in organogen-
esis. Under pathological conditions chemotaxis can cause tumor growth, cancer metastasis and
inflammatory diseases, such as asthma, arthritis and atherosclerosis [137].
2.1.2. Leukocyte extravasation
Leukocyte extravasation from the blood into the tissues is a regulated multistep process involving
series of coordinated interactions between leukocytes and endothelial cells. Several families of
molecular regulators, such as selectins, integrins, and chemokines control different aspects of this
process (Figure 2.2).
Figure 2.2.: Leukocyte entry into site of inflammation.
Adapted from [138].
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At sites of inflammation and infection, leukocytes and cytokine-activated endothelial cells secrets
the chemokines. Chemokines establish a local concentration gradient surrounding the inflamma-
tory stimulus by being retained on cell-surface heparan sulfate proteoglycans. Selectins facilitate
the movement of leukocytes, called rolling, along the surface of endothelial cells. In this manner
the leukocyte surface GPCRs are brought into contact with chemokines retained on cell-surface
heparan sulfate proteoglycans. Chemokine/GPCR interaction leads to subsequent clustering of
integrins inside lipid rafts and leukocyte activation. Activated integrin interaction with intracellu-
lar adhesion molecules displayed at the surface of the endothelium cells forms strong interactions
that immobilize the rolling leukocyte at the site of inflammation. Additional signaling events
cause the reorganization of the cytoskeleton resulting in the spreading of one edge of the leuko-
cyte. This edge inserts itself between endothelium cells and the leukocyte migrates through the
blood vessel wall into the inflamed tissue. Rolling, activation, adhesion and transendothelium
migration are the four steps of the process called leukocyte extravasation [138].
Because of high local chemokine concentration the recruited leukocytes activated by proinflam-
matory cytokines may become desensitized to further chemokine signaling. The Duffy Antigen
Receptor for Chemokines (DARC), a non-signaling erythrocyte chemokine receptor, controls the
inflammation process [139]. DARC functions as a sink, removing chemokines from the circulation
and consequently helping to maintain a chemokine gradient.
Once leukocytes have entered the target tissue they can perform various immune activities, such
as pathogen elimination and tissue repair [140]. Remarkably, this extravasation process occurs
with little or no damage to the endothelium cells [141].
2.1.3. Classification of chemokine receptors
According to the chemokines they bind, chemokine receptors are classified into four groups:
CCR, CXCR, CR and CX3R (Table 2.1) (Chapter 2.2.1). The family also includes several decoy
receptors, the Duffy antigen receptor for chemokine (DARC), D6 and CCX-CKR, which are
involved in chemokine clearance at inflammation sites.
Chemokine decoy receptors topology is identical to classical chemokine receptors. They are
also called “silent” chemokine receptors. Chemokine decoy receptors are unable to couple to G
proteins and therefore there is no ligand-induced signaling pathway through these receptors [142].
Chemokine decoy receptors are neither capable to mediate chemotaxis. Instead they efficiently
internalize their cognate chemokine ligands. These receptors are involved in controlling the local
levels of chemokines.
2.1.4. Characterization of chemokine receptors
Chemokine receptors share from 25 to 80% amino acid identity; their sequence length vary from
340 to 370 amino acids [143]. The short extracellular N-terminal domain is acidic and might
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Receptor Ligand (high affinity)
CCR1 MIP-1α, δ, RANTES, MCP-1, MCP-3, MPIF-1,HCC-1, 2, 4
CCR2 MCP-1, 3, 4, 5
CCR3 Eotaxin 1, 2, 3, MCP-2, 3, 4, RANTES, MIP-1δ
CCR4 MIP-1, RANTES, TARC, MDC
CCR5 MIP1α, MIP1β, RANTES
CCR6 MIP-3α
CCR7 MIP-3β, 6Ckine
CCR8 I-309, TARC, MIP1β
CCR9 MIP1α, MIP1β, MCP-1, 3, 5
CCR10 CTACK
CCR11 MCP-1-4, Eotaxin
CXCR1 IL8, GROα, β, χ, ENA-78, GCP-2
CXCR2 IL8, GROα, β, χ, NAP-2, ENA-78, GCP-2
CXCR3 IP-10, MIG, I-TAC
CXCR4 SDF1α, β
CXCR5 BCA-1
CXCR6 SR-PSOX
CXCR7
CX3CR1 Fractalkine
XCR1 Lymphoatractin SCM-1β
DARC IL-8, GRO-α, RANTES, MCP-1, MCP-3, MCP-4,Eotaxin
D6
CCX-CKR
Table 2.1.: Human chemokine receptors
be sulfated on tyrosine residues and contain N-linked glycosylation sites. The third intracellular
loop is short and basic. The intracellular C-terminus contains serine and threonine residues that
act as phosphorylation sites for receptor regulation. Extracellular loops 1 and 2 are linked by
highly conserved disulphide bond. The second intracellular loop contains the conserved motif
DRYLAIVHA or a variation of it.
2.1.5. Receptor dimerization
It is known that several chemokine receptors can homo- or heterodimerize: CCR2, CCR5,
CXCR1, CXCR2, CXCR4 and Duffy antigen receptor for chemokine (DARC) [144]. Fluorescence
Resonance Energy Transfer (FRET), Co-immunoprecipitation, and Bioluminescence Resonance
Energy Transfer (BRET) techniques demonstrated that such multimers exist in cells naturally
co-expressing these chemokine receptors.
It is hard to establish general rules for the chemokine receptor multimerization. However receptor
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dimerization can be triggered by different events.
Ligand binding induced dimerization
In vivo studies showed that at lower chemokine concentration CCR2 and CCR5 undergo ligand-
mediated heterodimerization that results in activation of different signaling pathways such as
Gq/11 association, and delays activation of phosphatidyl inositol 3-kinase. The consequences of
such change are a pertussis toxin resistant Ca2+ flux and triggering of cell adhesion rather than
chemotaxis [102].
Dimerization upon co-expression
Dimers can be formed during biosynthesis prior to arriving at the cell surface as shown for
CXCR1/CXCR2 heterodimers [145].
At physiological concentrations the CCR5 exist as constitutive oligomers that are formed early
after biosynthesis, in the endoplasmic reticulum as described earlier in Chapter 1.4 [146, 95].
Signaling modulation upon dimerization
CXCR4 and the δ-opioid receptor (DOR) are both expressed on the surface of monocytes and
other immune cells. In the presence of both receptors ligands they form heterodimers. The
formation of the CXCR4/DOR heterodimer prevents each of them from signaling [147, 148].
Although the functional importance of dimerization remains incompletely characterized many
experiments suggest that receptor dimerization has important in vivo pharmacological effects.
2.1.6. Chemokine receptors of interest
2.1.6.1. CCR5
CCR5 (CC chemokine receptor 5) is predominantly expressed on macrophages, dendritic cells,
brain microglial cells and memory T-cells [149]. CCR5 plays a role in inflammatory responses to
infection, though its exact role in normal immune function is unclear [150].
In 1996, several groups described a 32-base-pair deletion within the coding region of the CCR5,
which results in a frame shift and generates a non-functional receptor [151, 152, 153]. It has been
hypothesized that CCR5-Δ32 allele was favored by natural selection either during the bubonic
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plague or smallpox in the Middle Ages [154] or, occurred even before, as the frequency of CCR5-
Δ32 in the Bronze Age is similar to that seen today [155]. The CCR5-Δ32 mutation occurs at
high frequency in European Caucasians but is rare among African, Native American, and East
Asian populations [154].
The CCR5-Δ32 mutation prevents the entry of CCR5 tropic strain of Human Immunodeficiency
virus (HIV). Two copies of this allele provide strong protection against HIV infection. Homozy-
gous individuals have nearly complete resistance to HIV-1 infection despite repeated exposure
[156, 157]. Individuals with the Δ32 allele of CCR5 are healthy, suggesting that CCR5 is largely
dispensable. However, CCR5 plays a role in mediating resistance to West Nile virus infection
in humans, as CCR5-Δ32 individuals are enriched in cohorts of West Nile virus symptomatic
patients, indicating that all CCR5 functions may not be compensated by other receptors [158].
CCR5 consists of 352 amino acid residues. It has multiple natural chemokine ligands, including
Macrophage Inflammatory Protein 1 α (MIP1α), MIP1β, RANTES and monocyte chemotactic
protein 2 (MCP-2). Among these ligands, RANTES and MIP-1α can bind to other CC chemokine
receptors, while MIP-1β is known to be specific to CCR5 [159].
Maraviroc (UK-427,857) was identified as a small-molecule ligand [160]. Maraviroc is a selective
CCR5 antagonist with potent anti-HIV-1 activity; it is a HIV entry inhibitor. Maraviroc has
been approved for the treatment of patients infected with only CCR5-tropic viruses [160, 161].
Combining site-directed mutagenesis and homology modeling using solved GPCR structures a
CCR5 topology model (Figure 2.3) with ligand binding sites was proposed [162].
Figure 2.3.: Snake-like plot of human CCR5 sequence.
Residues surrounding the proposed hydrophobic binding pocket for small molecule CCR5
inhibitors are highlighted with a black circles [162].
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Signal transduction through CCR5 is known to play important roles in both physiological and
pathological processes, including inflammation and hematopoiesis [163].
2.1.6.2. CXCR4
CXCR4, a CXC chemokine receptor 4, is expressed on brain, lung, colon, heart, kidney, and
liver cells [164]. CXCR4 is widely expressed on T-lymphocytes, B-lymphocytes, monocytes,
macrophages, neutrophils, eosinophils [149, 164]. CXCR4 is also expressed on astrocytes, neu-
ronal cells, and smooth muscle progenitors [164]. CXCR4 plays a significant role in development
of metastatic diseases, particularly in directing tumor cells towards the specific sites of metastases
[165, 164].
CXCR4 consists of 352 amino acid residues. Unlike the other chemokine receptors that have
a number of distinct ligands, CXCR4 has only one endogenous natural ligand known as SDF1
[166]. However, CXCR4 can also be recognized by an antagonistic ligand, vMIP-II, encoded by
the Kaposi’s sarcoma-associated herpes virus [167].
CXCR4 or SDF1 gene knockout mice result in impaired hematopoiesis exhibited as a defect in
either trafficking of hematopoietic stem cells (HSC) from the fetal liver to the embryonic bone
marrow, or in heart and brain development, and vascularization. Thus, CXCR4 and SDF-1
knockouts are embryonic lethal [168, 169, 170, 171, 172].
CXCR4 structure
The three dimensional structure of the chemokine receptor CXCR4 recently has been solved
[127]. The authors used approaches already used to solve other GPCR structures. The flexible
C-terminal part was truncated from residue 320 or 326.
Previous studies performed on the β2-Adrenergic Receptor demonstrated that the removal of the
poorly structured third intracellular loop (IL3) would favor crystallization [123]. This truncation
would diminish the movement of the transmembrane helices but would also reduce the polar
surface area important to form protein-protein contacts in the crystal. Therefore this loop was
replaced by the well-structured T4 lysozyme (T4L) to increase the polar surface and to constrain
the transmembrane helices.
Previous studies with β2-Adrenergic Receptor showed that engineering of the TM4-TM3-TM5
interface might provide a general strategy for the stabilization of other receptors [173]. There-
fore, the thermostabilizing mutation L125W was introduced in CXCR4 to increase the yield of
functionally folded receptor.
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All these modifications resulted in several CXCR4 constructs with small variations. The prepared
constructs differed in: the precise T4L junction; the position of the C-terminal truncation; addi-
tional T240P mutation (in one construct). Stabilized constructs were expressed in baculovirus-
infected Spodoptera frugiperda (Sf9) insect cells and were selected for structural studies on the
basis of thermal stability, monodispersity and lipid matrix diffusion.
Prepared constructs required further stabilization with ligands to facilitate crystallization in
lipidic cubic phase. Five independent crystal structures of CXCR4 were solved in inactive an-
tagonist small molecule IT1t and cyclic peptide CVX15 bound conformation [127].
Architecture of CXCR4
The solved structure includes 293 residues (27 to 319) of the 352 total residues of CXCR4 and
residues 2 to 161 of T4L (Figure 2.4).
Figure 2.4.: Solved CXCR4 structure.
The CXCR4 helices are shown in colors where T4L appears in gray. PBD code: 3OE9 [127].
The overall fold of CXCR4 is similar to the other previously solved GPCR structures. The
extracellular interface of CXCR4 consists in 34 N-terminal residues. The Extracellular loop 1
(EL1) is from residues 100 to 104 (4 residues in total) and links helices II and III. The EL2, the
largest extracellular loop, contains 18 residues (from 174 to 192 residues) and links helices IV
and V. The EL3 is 6 residues long (from 267 to 273 residues) and links helices VI and VII.
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The structure shows that both conserved disulphide bonds at the extracellular side of CXCR4
constrain EL2 and the N-terminal segment and shape the entrance to the ligand-binding pocket.
The intracellular side of CXCR4 contains intracellular loop 1 (IL1) from residue 65 to 71, which
links helices I and II. The IL2 contains four residues (140 to 144) linking helices III and IV. The
IL3 contains five residues (225 to 230) and links helices V and VI.
Structural alignment of CXCR4 with other GPCR high-resolution structures indicates that the
intracellular part of CXCR4 is more conserved than the extracellular part.
Comparison with other GPCR
Comparing the CXCR4 structure with other solved GPCR structures showed that the intracel-
lular part of the CXCR4 helix VII is one turn shorter, ending just after the GPCR conserved
NPxxY motif. All five CXCR4 solved structures lacked the short helix VIII that is considered
as a regular structural element for all class A GPCRs (Figure 2.5).
Figure 2.5.: CXCR4 transmembrane helices comparison with other GPCR structures.
CXCR4 (blue); b2AR (PDB ID: 2RH1; yellow); A2AAR (PDB ID: 3EML; green); and
rhodopsin (PDB ID: 1U19; pink) [127].
CXCR4 lacks a putative palmitoylation site at the end of helix VIII, which anchors the C-terminal
part of many GPCRs to the lipid membrane [127].
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Structures of CXCR4 bound to an antagonist small molecule IT1t and a cyclic peptide CVX15
ligand-binding sites considerably overlap. Comparing the ligand binding sites of CXCR4 to other
GPCRs highlights the structural plasticity of GPCR binding sites [130].
Figure 2.6.: Diversity of ligand binding pocket shapes in GPCR crystal structures.
(a) The Adenosine A2AAR is bound to the antagonist ZM241385 (PDB ID 3EML). (b) The
Adrenergic β1AR antagonists cyanopindolol (PDB ID 2VT4). (c) The Adrenergic β2AR is
bound to an antagonists carazolol (PDB ID 2RH1). (d) The chemokine CXCR4 receptor is
bound to a small molecule IT1t (PDB ID 3ODU). (e) The chemokine CXCR4 receptor is
bound to a cyclic peptide CVX15 (PDB ID 3OE0). (f) The Dopamine D3R is bound to an
antagonist eticlopride (PDB ID 3PBL). (g) The Histamine H1R is bound to the antagonist
Doxepin where a PO43– ion modulates the ligand access to the pocket (PDB ID 3RZE). (h)
The Rhodopsin is bound to its agonist retinal (PDB ID 1GZM). All pockets are shown in the
same orientation. Adapted from [130].
Compared with previous GPCR structures the ligand-binding cavity of the CXCR4 is larger,
more open and located closer to the extracellular surface (Figure 2.6) [130].
CXCR4/SDF-1α binding model
Chemokine activity is initiated by the agonist-chemokine binding to the GPCR. A two-step model
has been suggested for the receptor activation. The first step corresponds to the chemokine
specific recognition and its binding to the receptor. The first binding site is located in the
exposed area of the loop between the second and third cysteine residues of the chemokine. This
site considered as a low affinity region of interaction and binds to the extracellular N-terminus
of the receptor. This is followed by chemokine conformational change due to the flexible N-
terminus. The second binding site is the N-terminal part of the chemokine which specifically
interacts with the receptor and that leads to receptor activation [174].
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NMR studies provided structural evidence for the two-step CXCR4/SDF1α binding model (Fig-
ure 2.7) [175].
Figure 2.7.: Schematic diagram of the two-step mechanism for the CXCR4/SDF1α interaction.
Adapted from [175].
The 1st step interaction occurs between the SDF1α N-loop, β-sheet and 50-s loop and the CXCR4
extracellular region. This interaction facilitates the rapid binding and efficient anchoring of
SDF1α on the extracellular side of CXCR4. Consequently, the 2nd step interaction between the
N- terminus of the SDF1α and the CXCR4 transmembrane region is formed. The SDF1α N-
terminus triggers the conformational changes in the CXCR4 transmembrane region to induce
G-protein signaling [175].
The solved structures of CXCR4 provide new clues about the interactions between CXCR4 and
SDF1α. The crystal structures of CXCR4 suggest the possibility of a three-step interaction
between CXCR4 and its ligand. The first step would be the electrostatic interaction of the body
of the chemokine with the complementary surface of CXCR4. The second step would be the
insertion of the N-terminal of chemokine into the cavity defined by the TM helices and some
extracellular domains. The third step would be the folding of the N-terminus of CXCR4 across
the top of the docked chemokine [163].
Although CXCR4 structure has been solved the CXCR4/SDF1α complex stoichiometry is still
speculative. Due to the oligomeric nature of CXCR4 and the complementary electrostatic sur-
faces of the ligand and receptor, SDF1α could bind to the receptor as a 1:1, 1:2, or 2:2 (lig-
and:receptor) complex (Figure 2.8). No information on the orientation of SDF1α with respect to
CXCR4 is implied from the models presented in the Figure 2.8.
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Figure 2.8.: Stoichiometry of possible CXCR4-SDF-1α complexes.
Adapted from [127].
Additional experiments will still be necessary to fully define the relevance and functional impli-
cations of different chemokine: receptor stoichiometries.
2.1.6.3. Chemokine receptors and human health
CCR5 and CXCR4 are specifically implicated in HIV-1 infection [176, 177, 178] and cancer
metastasis [179, 180, 181, 182].
Human immunodeficiency virus
For some years it has been known that chemokines such as RANTES, MIP1α, MIP1β have
the ability to block HIV replication in laboratory experiments. This is explained by the fact
that chemokines compete with HIV to attach to chemokine receptors and also trigger receptor
internalization and its clearance from the cell surface. Chemokine receptors represent thus an
attractive therapeutic target to block HIV infection.
CXCR4 and CCR5 are the major HIV-1 co-receptors that mediate virus entry into CD4+ cells.
There are two main HIV-1 strains: T-cell-tropic (X4) and macrophage M-tropic (R5) which uses
CXCR4 and CCR5 as their co-receptors, respectively [183, 184, 185]. In the early HIV infection
the CCR5 tropic strains represent the major virus phenotype [183, 186]. CCR5-using viruses
(R5 viruses) are transmitted from person to person and are dominant in the early and chronic
phases of HIV-1 infection [177]. The emergence of CXCR4 using viruses is correlated with a
faster CD4+ T-lymphocyte depletion and rapid disease progression toward AIDS [187].
Therefore, HIV-1 tropism refers to the ability of the virus to establish infection in alternative
CD4+ cell types, and is influenced by co-receptor usage. M-tropic viruses can infect primary
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CD4+ T cells and macrophages and principally use CCR5; T-cell tropic viruses can infect CD4+
T cells and T-cell lines via CXCR4; and dual-tropic viruses can infect the three different cell
types and can use CCR5 and/or CXCR4 [177, 188, 189].
Chemokine receptors constitute an important target for the development of anti-HIV therapies.
This idea was strongly supported by the fact that Caucasian individuals with a homozygous
32 bp deletion in the CCR5 gene are relatively resistant against HIV-1 infection [153]. The
SDF1α and RANTES cooperate to strongly (93%) inhibit the viral replication of the dual-tropic
(R5/X4) HIV-1 strain [176]. The HIV co-receptor antagonists AMD3100 (CXCR4 antagonist)
and maraviroc (CCR5 antagonist) showed antiviral efficacy against a wide variety of X4 and R5
strains, respectively [190, 160].
Figure 2.9 shows the chemokine receptors as co-receptors for HIV entry into cells and chemokine
inhibition of HIV entry.
Figure 2.9.: Chemokine inhibition of HIV entry.
Adapted from [138].
The molecular interaction between HIV-1 glycoprotein 120 (gp120), in its trimeric conformation,
and the CD4 (primary receptor) on the host cell surface represents the first step of the HIV
infection cycle. Upon this interaction, the co-receptor-binding site on gp120 is exposed, enabling
the binding to chemokine coreceptors expressed on the surface of CD4+ lymphocytes [191]. To
gain entry into cells M-tropic HIV-1 uses principally CCR5 and T-tropic HIV-1 uses the CXCR4
for the most cases. Macrophage inflammatory proteins MIP1α, MIP1β and RANTES are the
chemokine ligands for CCR5, which block M-tropic HIV-1 from entering target cells. SDF1α is
a ligand for CXCR4 and blocks T-tropic HIV-1 from entering target cells.
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The initial binding of HIV gp120 to CD4 triggers a conformational change in gp120 that exposes
the V3 loop and permits subsequent interaction with the co-receptor (the chemokine receptor).
The interaction of CD4-bound gp120 with co-receptor induces further conformational changes
and exposes the N-terminus of the transmembrane glycoprotein gp41, which contains a fusion
peptide that embeds into the host cell membrane. The HIV gp41 ectodomain forms an extended
coiled coil conformation and a six-helix bundle structure, which promotes the juxtaposition of
the viral and target cell membranes. This results in an energetically stable structure, facilitating
fusion between the viral and cellular membranes and release of the viral core into the cell [192,
193].
The binding of the gp120-CD4 complex to chemokine coreceptors not only mediates HIV entry
but also activates intracellular signaling cascades; mimicking chemokine signaling induced by
binding to cognate receptors [194, 195].
The co-receptors post-translational modifications on N-terminal and EC loops may mediate the
efficient binding to the HIV gp120. In general, extracellular domains may undergo N-linked or
O-linked glycosylation and tyrosine sulfation, while modifications of intracellular loops include
palmitoylation, phosphorylation, and ubiquitination [196, 197, 198, 199].
Cancer and metastases
Apart from their role in organogenesis and cell migration, chemokines and their receptors are
involved in various pathological mechanisms, such as development of tumors and metastases
[200]. Indeed, tumor cells usually modify the expression of their chemokine receptors. While
some chemokine receptor expression is reduced or inhibited, others are over-expressed.
The migration of metastatic cells is not random but is determined by the receptors they express
and therefore the type of cancer they come from [201]. CXCR4 is the most common chemokine
receptor expressed in human tumors such as breast cancer, colorectal cancer, and ovarian cancer,
and SDF1α is highly expressed at sites of metastasis including lung, bone marrow, lymph nodes,
and liver [202, 203]. SDF1α is indeed a powerful potent chemoattractant and is expressed in
many tissues. An interaction between CXCR4 and its ligand SDF1α plays an important role in
the directional regulation of hematopoiesis, migration of hematopoietic cells, angiogenesis, and
migration of metastatic tumor cells [204]. Moreover, SDF1α promotes the survival and growth
of tumor cells and induces the secretion of cytokines [205].
RANTES and CCR5 are over-expressed in case of melanoma metastases which metastasizes to
regional lymph nodes, subcutis, and brains [182]. RANTES⁄CCR5 enhanced the metastatic
behavior of breast cancer cells [206] and are required for lung cancer metastasis [207]. The
change of RANTES/CCR5 expression pattern may be highly relevant for cancer metastases in
general [182].
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Currently, the involvement of chemokines and their receptors in the development of lympho-
proliferative diseases is an important subject of research. Its understanding will lead to new
therapeutic interest for the fight against human leukemia and cancer in general.
2.2. Chemokines
Chemokines (CHEMOtactic cytoKINES) are small-secreted proteins that belong to the family
of cytokines and have important functions in intracellular communication. Chemokines regu-
late biological processes such as proliferation, apoptosis, angiogenesis, lymphoid organ develop-
ment, hematopoiesis, T-cell differentiation and phagocyte activation. However the main role
of chemokines is to activate and control the migration of leukocytes in hematopoiesis and in
innate and adaptive immunity. Chemokines play a key role in many disease processes including
inflammation, autoimmune diseases, infectious diseases (such as HIV infection) and cancer.
The superfamily of human chemokines contains about 46 members that bind to 20 GPCRs
and three decoy receptors. Many chemokines bind multiple receptors and most receptors bind
multiple chemokines, suggesting the possibility of functional redundancy.
Chemokines are small and positively charged proteins that vary in size from 6 to 14 kDa. The
sequence identity between chemokines varies from less than 20% to over 90%. Nevertheless,
chemokines from different subfamilies adopt essentially the same monomer fold. Each monomer
has a flexible N-terminal domain, a three-stranded antiparallel β-sheet region, and a C-terminal
α-helix (Figure 2.10) [208, 209].
Figure 2.10.: Schematic representation of chemokine three dimensional structure.
Most chemokines have four cysteine residues in highly conserved positions that form two disulfide
bridges, one between the first and third cysteine residues, and the other between the second and
fourth cysteine residues [210].
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2.2.1. Chemokine classification
The discovery of chemokine has been rapid and somehow chaotic. Therefore, several groups
reported the same molecule under different names, contributing to a significant confusion in the
field. A new classification system has been adopted in 2000 [143].
Depending on the number of amino acids present between the first two cysteines of the N-terminal
domain, chemokines are classified into four classes: CC, CXC, CX3C, and C (where X stands for
any amino acid) (Figure 2.11). Modeling studies suggest that the three-dimensional structure
of chemokines can only accommodate 0, 1, or 3 amino acids between the first two cysteins,
explaining the absence of a CX2C chemokine class [210].
Figure 2.11.: Schematic representation of chemokine classes.
2.2.1.1. CC chemokines
The CC chemokines have two neighboring cysteines, near the amino terminus. There are about 27
members of this family reported in mammals (Table 2.2). CC chemokines induce the migration
of monocytes and other cell types such as lymphocytes, NK cells and dendritic cells but not
neutrophils.
Examples of CC chemokines include the monocyte chemoattractant protein-1 (MCP-1 or CCL2),
which stimulates monocytes to leave the bloodstream and enter the surrounding tissue to become
tissue macrophages. RANTES or CCL5 attracts cells such as T cells, eosinophils and basophils
that express the receptor CCR5.
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Name Other name(s) Receptor
CCL1 I-309, TCA-3 CCR8
CCL2 MCP-1 CCR2
CCL3 MIP-1α, LD78α CCR1
CCL4 MIP-1β CCR1, CCR5
CCL5 RANTES CCR5
CCL6 C10, MRP-2 CCR1
CCL7 MARC, MCP-3 CCR2
CCL8 MCP-2 CCR1, CCR2B, CCR5
CCL9/
CCL10
MRP-2, CCF18, MIP-1 CCR1
CCL11 Eotaxin CCR2, CCR3, CCR5
CCL12 MCP-5 CCR2
CCL13 MCP-4, NCC-1, Ckβ10 CCR2, CCR3, CCR5
CCL14 HCC-1, MCIF, Ckß1, NCC-2, CCL CCR1
CCL15 Leukotactin-1, MIP-5, HCC-2,
NCC-3
CCR1, CCR3
CCL16 LEC, HCC-4, LMC, Ckβ12 CCR1, CCR2, CCR5,
CCR8
CCL17 TARC, dendrokine, ABCD-2 CCR4
CCL18 PARC, DC-CK1, AMAC-1, Ck7,
MIP-4
Unknown
CCL19 ELC, Exodus-3, Ck11, MIP3β CCR7
CCL20 LARC, Exodus-1, Ckβ4, MIP3α CCR6
CCL21 SLC, 6Ckine, Exodus-2, Ckß9,
TCA-4
CCR7
CCL22 MDC, DC/β-CK CCR4
CCL23 MPIF-1, Ckß8, MIP-3, MPIF-1 CCR1
CCL24 Eotaxin-2, MPIF-2, Ckß6 CCR3
CCL25 TECK, Ckß15 CCR9
CCL26 Eotaxin-3, MIP-4a, IMAC, TSC-1 CCR3
CCL27 CTACK, ILC, Eskine, PESKY,
skinkine
CCR10
CCL28 MEC CCR3, CCR10
Table 2.2.: CC chemokines and their main receptors.
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2.2.1.2. CXC chemokines
In the CXC subfamily the two N-terminal cysteines are separated by one amino acid (Table 2.3).
CXC chemokines are potent chemoattractants and activators of neutrophils but not monocytes.
Name Other name(s) Receptor
CXCL1 Gro-α, GRO1, NAP-3, KC CXCR2
CXCL2 Gro-ß, GRO2, MIP-2a CXCR2
CXCL3 Gro-γ, GRO3, MIP-2ß CXCR2
CXCL4 PF-4 CXCR3B
CXCL5 ENA-78 CXCR2
CXCL6 GCP-2 CXCR1, CXCR2
CXCL7 NAP-2, CTAPIII, ß-Ta, PEP CXCR2
CXCL8 IL-8, NAP-1, MDNCF, GCP-1 CXCR1, CXCR2
CXCL9 MIG, CRG-10 CXCR3
CXCL10 IP-10, CRG-2 CXCR3
CXCL11 I-TAC, ß-R1, IP-9 CXCR3, CXCR7
CXCL12 SDF-1α/β, PBSF CXCR4, CXCR7
CXCL13 BCA-1, BLC CXCR5
CXCL14 BRAK, Bolekine Unknown
CXCL15 Lungkine, WECHE Unknown
CXCL16 SRPSOX CXCR6
CXCL17 DMC, VCC-1 Unknown
Table 2.3.: CXC chemokines and their receptors
CXCL12 (or SDF1α) together with its receptor CXCR4 plays a central role in the interactions
of hematopoietic stem cells, lymphocytes, and developing neutrophils in the marrow [211].
The CXC subfamily is further subdivided into two categories depending on the presence or
absence of an ELR motif (glutamate-leucine-arginine) upstream of the first cysteine residue.
ELR-CXC chemokines (CXCL1, CXCL2, CXCL3, CXCL5 and CXCL8) specifically recruit neu-
trophils into inflamed tissues in a multi-step process by rolling, adhesion and transmigration
[212, 213]. One characteristic of ELR-CXC chemokines (CXCL4, CXCL9 and CXCL10) is their
ability to promote angiogenesis [214, 215]. In contrast, non-ELR CXC chemokines inhibit the
angiogenesis induced by ELR-CXC chemokines [216].
2.2.1.3. CX3C chemokines
The CX3C chemokines have three amino acids between the first two cysteine residues (Table
2.4). The only member of this family is CX3CL1 - previously called fractalkine. This chemokine
totally differs from the others, as it is the only membrane bound chemokine [217].
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Name Other name(s) Receptor
CX3CL1 Fractalkine, Neurotactin, ABCD-3 CX3CR1
Table 2.4.: CX3C chemokine and its receptor.
2.2.1.4. C chemokines
The C class chemokines lack the first and third conserved cysteines (Table 2.5). This family has
two members called XCL1 (lymphoatractin-α) and XCL2 (lymphoatractin-β) [218].
Name Other name(s) Receptor
XCL1 Lymphotactin α, SCM-1α, ATAC XCR1
XCL2 Lymphotactin β, SCM-1β XCR1
Table 2.5.: C chemokines and their receptors.
According to the nomenclature: CCL1 stands for the ligand 1 of the CC-family of chemokines,
and CCR1 for its respective receptor.
This structural classification is now used as a reference nomenclature but some common names
are still widely used, such as RANTES (CCL5), SDF1α (CXCL12), MCP-1 (CCL2), etc...
2.2.2. Functional chemokine classification
Based on their expression patterns and functions chemokines have been divided into two groups:
inflammatory chemokines and homeostatic chemokines [219, 220, 215].
Inflammatory chemokines, are produced by the immune system cells such as leukocytes or related
cells such as epithelial and endothelial cells, fibroblasts and others. Inflammatory chemokines
can be activated after contact with a pathogen. They participate in the development of the
immune and inflammatory reactions [220].
Chemokines that are constitutively expressed in specific tissues or cells in discrete locations in the
absence of apparent activating stimuli have been classified as homeostatic chemokines. Home-
ostatic chemokines are constitutively expressed in the lymphoid organs and in non-lymphoid
organs such as skin and mucous membranes. The functions of the homeostatic chemokines
are more diverse than those of the inflammatory chemokines. They are involved in cell migra-
tion. Homeostatic chemokines regulate lymphocyte trafficking and localization of lymphocytes
[221, 222].
However, the division between inflammatory and homeostatic chemokines is not absolute, certain
chemokines belong to both families.
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2.2.3. Chemokine 3D structure
The 3D structure of many chemokines has been solved by Nuclear magnetic resonance (NMR)
spectroscopy and/or crystallography.
Despite their functional diversity the structural fold of CXC and CC chemokine monomers is
very conserved (Figure 2.12) [208].
(a) SDF1α (b) RANTES
Figure 2.12.: 3D structures of SDF1α and RANTES monomers.
PDB codes: 1VMC for SDF1α [223] and 1EQT for RANTES [224].
Both monomers have unstructured N-terminal part which forms a long loop. The main sec-
ondary structure elements comprise three antiparallel β sheets and a C-terminal α helix. The
two characteristic disulphide bridges define and stabilize the overall architecture of chemokines.
2.2.4. Oligomerization
It has been demonstrated that chemokines bind and signal through their receptors as monomers
[225, 226] nevertheless the ability of chemokines to oligomerize is important for in vivo function
[227]. NMR studies showed that chemokines can dimerize [228, 225]. All chemokines oligomerize
into dimers [209], and some form tetramers [229] or higher molecular mass oligomers [208, 230].
Although each chemokine has its own set of unique properties there are some general mechanisms
of oligomerization.
Despite having similar monomer folds, CXC and CC dimers associate differently [209].
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(a) CXC dimer. (b) CC dimer.
Figure 2.13.: 3D structures of chemokine dimers.
The 3D structures are: (a) SDF1α, PDB code 2J7Z; (b) RANTES, PDB code 1EQT [231, 224].
The more globular CXC-type dimer is formed by extension of the three-stranded β-sheet from
each monomer into a six-stranded β-sheet, on top of which run the two C-terminal antiparallel
α-helices (Figure 2.13a). The CC chemokines form elongated end-to-end type dimers. Their
contacts are formed between their N-terminus, which are unstructured in the monomer, but
form a β-sheet in the dimer (Figure 2.13b). The two C-terminal helices run almost perpendicular
to each other on opposite sides of the molecule.
CXC chemokine dimerization is independent of pH and salt concentration. CC chemokine dimer
is stable at very low pH and is also independent of salt concentration [232].
Chemokines bind to glycosaminoglycans (GAGs) on the cell surface which increases their local
concentration. Chemokines binding to GAGs facilitate their accumulation in localized areas, al-
lowing them to function as directional cues for migrating cells [233]. GAGs also induce chemokine
oligomerization [234]. Reciprocally, oligomerization plays an important role in chemokine-GAG
interaction, which is necessary for some in vivo chemokine activity. It has been shown that
oligomerization-deficient and GAG-binding-deficient chemokine variants result in impaired mi-
gration in vivo [233].
Chemokine oligomerization and the ability to bind GAG represent essential structural features
for their ability to recruit leukocytes in vivo [233]. Several analyses show that some, but not all
chemokines either bind as dimers or dimerize after binding to GAG on endothelial cells [235],
which is necessary for their function [236].
In addition to cell migration, oligomeric forms of chemokines may also be involved in other
processes such as cellular activation associated with inflammatory responses.
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Heterodimerization
Heterodimerization has been observed for both CXC and CC chemokines. Homodimers of
chemokines can be substituted by heterodimers if the arrangement of individual residues at the
monomer-monomer interface is energetically and sterically more favorable than in homodimer
[228].
The change of chemokine concentration could result in chemokine homodimerization / het-
erodimerization at a particular site [228]. It is known that different quaternary states of chemokines
play different biological roles. Heterodimerization dramatically modulates the biological activities
of chemokines. For example, the presence of angiogenic CXCL8 in solution with anti-angiogenic
CXCL4 induces the formation of the CXCL8-CXCL4 heterodimer which increases the anti-
proliferative activity of CXCL4 against endothelial cells [230]. In the case of RANTES–CXCL4-
heterodimerization, the RANTES-induced monocyte arrest on atherosclerotic or inflamed en-
dothelium is enhanced by CXCL4 [237, 238].
2.2.5. Biological activity of chemokines
Chemokines play a key role in numerous biological processes, from organogenesis and leukocyte
trafficking to host immune response to infection [239]. Chemokine-dependent signaling is nec-
essary for inflammation, hematopoiesis, angiogenesis and tumors. In addition, chemokines can
control HIV-1 infection [239].
Chemokine interaction with receptor
Biological activity of chemokines is mediated by their receptors. Chemokine activity is initiated
by the chemokine binding to its specific receptor the GPCR. The activation of the GPCR was
previously described in Chapter 1.3. Like other GPCRs, some chemokine receptors initiate their
ligand-induced signaling cascade by receptor dimerization (Figure 2.14).
Ligand binding to chemokine receptor activates signaling cascade events represented in Figure
2.14, and results in diverse physiological processes including gene expression, cell polarization
and chemotaxis [240, 239, 241].
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Figure 2.14.: Schematic model representing chemokine receptor activated signaling pathways.
Adapted from [241].
It was suggested that chemokine receptor dimerization and JAK/STAT pathway activation is
common for CC and CXC class chemokine receptors [241]. This is the case for CCR5 and CXCR4,
both of which induce activation of different JAK/STAT family members. In the absence of JAK
activation, chemokine signaling through chemokine receptors does not occur. This was confirmed
by the observation that G protein–mediated signaling events are blocked by JAK kinase inhibitors
[242].
Chemokine interaction with glycosaminoglycans
In addition to GPCR, chemokines also interact with glycosaminoglycans (GAGs) of the hep-
arin/heparan sulfate family. GAGs serve to present chemokine to their receptors expressed on
leukocytes. This chemokine-GAG interaction avoids chemokine dilution within lymph or blood
vessels.
Chemokine interaction with cellular or extracellular matrix GAGs is important for their biological
activity. GAGs are highly sulfated oligosaccharides characterized by high degree of structural
heterogeneity. Chemokines interact with GAGs via typical BBXB heparin-binding motif (where
B stands for a basic residue and X for a hydropathic residue) [243].
Chemokines control the selective migration of leukocytes in immune surveillance, inflammation
and atherogenesis [244, 245]. This involves not only the directed migration of leukocytes along
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chemokine gradients within the extracellular matrix but also the arrest of circulating leukocytes
on activated endothelium under flow (Chapter 2.1.2).
The immobilization of chemokines to endothelium via binding to glycosaminoglycans (GAGs)
has been implicated in triggering leukocyte arrest, as well as transmigration in flow [246, 247].
Chemokine binding to GAGs is essential for presentation of chemokines on endothelial layers and
in vivo leukocyte migration [236, 248]. This interaction is not required for in vitro chemotactic
activity.
2.2.6. Chemokines of interest
2.2.6.1. RANTES
The chemokine RANTES (Regulated on Activation, Normal T cell Expressed and Secreted) is
8-kDa protein that belongs to the CC chemokine class and is also called CCL5.
RANTES is a proinflammatory chemokine secreted by both endothelial cells and activated leuko-
cytes to attract leukocytes to sites of inflammation. RANTES is chemotactic for T cells,
eosinophils and basophils. Together with other cytokines such as Interleukin-2 (IL-2) and
Interferon-gamma (IFN-γ) that are produced by T cells, RANTES induces the proliferation
and activation of natural-killer (NK) cells [249, 250].
RANTES expression has been associated with more then 100 human diseases such as transplant
rejection, atherosclerosis, arthritis, airway inflammatory disorders, and cancer [251, 252, 253].
RANTES is one of the most potent natural chemokine inhibitor of M-tropic HIV-1 infection
[254]. High concentration can also act as a stimulator, enhancing viral infection. Indeed, in the
early stage of the HIV infection the virus uses CCR5 for entry, high RANTES concentrations
shift the virus to use the CXCR4 for entry and towards AIDS development [255, 256].
RANTES is the most effective antiviral CCR5 binding chemokine and is being investigated as
a potential anti HIV agent. However, an in vivo use of RANTES is impaired by the proin-
flammatory properties of this chemokine triggered upon receptor binding and subsequent signal
transduction. These potential difficulties encourage the search for modified RANTES analogues
or small peptide derivatives that are not implicated in the signal transduction.
RANTES has been shown to interact with CCR3 [257, 258], CCR5 [258, 259, 260], and CCR1
[258, 260]. Apart from the chemokine receptors it was shown that RANTES activates another
GPCR class receptor - GPR75 [261].
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N-terminal modifications
It was reported that the extension of recombinant human RANTES by a single residue at the N-
terminus (Met-RANTES) is sufficient to produce a potent and selective antagonist [262]. Series
of Met-RANTES analogs were created (Table 2.6).
Chemokine N-terminal
sequence
Properties Signaling Ref.
RANTES
wild-type
SPYSSDTTPCC- Antiviral properties,
Ca2+mobilization,
Chemotactic activity
Yes [263,
264,
265,
266,
267,
174,
262]
Met-RANTES MSPYSSDTTPCC- Antiviral activity No [262]
L-RANTES L-SPYSSDTTPCC- Antiviral activity reduced,
Ca2+-mobilization,
Chemotactic activity
Decreased [268]
C1.C5 RANTES CPYSCDTTPCC- Antiviral activity reduced,
Ca2+-mobilization,
Chemotactic activity
Decreased [268]
RANTES 3-68 --YSSDTTPCC- Antiviral activity, No
chemotactic and
Ca2+-mobilization activity
Controversial [265,
266]
RANTES 9-68 --------PCC- Antiviral activity, No
chemotactic and
Ca2+-mobilization activity
No [269]
AOP-RANTES AOP-SPYSSDTTPCC- Antiviral activity reduced,
Chemotactic activity
reduced, Ca2+-mobilization,
Inhibit the recycling of
internalized CCR5
Yes [270]
NNY-RANTES NNY-SPYSSDTTPCC- Antiviral activity, Inhibit
the recycling of internalized
CCR5
[271]
PSC-RANTES PSC-SPYSSDTTPCC- Antiviral activity, Induce
internalization, Inhibit the
re-expression of the receptor
Yes [272]
5P12-RANTES GPPLMATQS-RANTES Antiviral activity, Inhibit
the re-expression of the
receptor
No [273]
5P14-RANTES GPPLMSLQV-RANTES Antiviral activity No [273]
6P4-RANTES GPPGDIVLA-RANTES Antiviral activity, Inhibit
the re-expression of the
receptor
No [273]
Table 2.6.: N-terminal RANTES modifications.
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Engineered versions in particular PSC-, AOP- RANTES lead to significantly stronger inhibition
of HIV-1 replication [270, 268].
Figure 2.15.: Substitution of the first three residues of RANTES dramatically changes the pro-
tein’s ability to prevent entry of HIV into cells.
L-RANTES bears an additional hydrophobic amino acid (Leu) at the N-terminus. AOP-RANTES
(aminooxypentane-RANTES) is a rationally designed analogue of Met-RANTES. NNY-RANTES
(Nα-nonanoyl-RANTES) is a further-optimized molecule based on AOP-RANTES [271]. PSC-
RANTES (L-Thia-Pro2,L-α-cyclohexyl-Gly3-NNY-RANTES) is a further optimized analogue
[272].
PSC-RANTES is a highly potent inhibitor of CCR5-dependant HIV entry in vitro [274, 275].
PSC-RANTES required a chemical synthesis step during production. PSC-RANTES analogs
that contain only natural amino acids were also produced. Three mutants 5P12-RANTES,
5P14-RANTES, and 6P4-RANTES, were identified with anti-HIV properties [273].
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RANTES aggregation
Recombinant human RANTES tends to oligomerize and even to form large aggregates. To
characterize the pH effect on RANTES oligomerization a titration from pH 5.0 to pH 2.5 was
performed. The results demonstrated that RANTES is extensively aggregated in solution above
pH 4.0 and at pH 3.7 the protein is mostly dimeric [276].
Latter the tetrameric E26A and the dimeric E66A RANTES mutants have been described [277].
The biology of RANTES aggregation has been investigated using RANTES and disaggregated
variants, enabling comparison of aggregated, tetrameric, and dimeric RANTES forms [277].
RANTES aggregation may be responsible for a proportion of its proinflammatory activity. The
relative inability of RANTES E66S to stimulate the protein tyrosine kinase pathway and to
activate leukocyte suggests that dimeric RANTES is noninflammatory. Disaggregated RANTES
will be a valuable tool to explore the biology of RANTES action in human immunodeficiency
virus infection and in inflammatory disease.
Combining complementary data from multiple techniques such as available crystal structures of
dimers, solution NMR data, SAXS data, and hydroxyl radical foot-printing MS an oligomeriza-
tion model of RANTES has been generated (Figure 2.16) [278].
Figure 2.16.: Octameric structure of RANTES.
Basic regions are shown in blue. Positive charges form an elongated RANTES surface. Adapted
from [278].
It has been shown that RANTES is able to oligomerize without significantly changing its dimeric
structure (Figure 2.17b). While other CC class chemokines such as MCP-1 and IP-10 have
globular tetrameric structure (Figure 2.17a) [279, 280], RANTES forms an elongated tetramer,
where its interacting dimer units form a long linear polymeric chain containing an even number
of monomer units.
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(a) MIP1α tetramer. (b) RANTES tetramer. Residues E26 and E66 shown in red.
Figure 2.17.: Comparison of MIP1α tetramer with RANTES tetramer .
A single dimer unit from each tetramer is arranged in identical orientation. PDB code: MIP1α
- 2X69, RANTES - 2L9H. Adapted from [278].
Figure 2.18.: The model of tetrameric RANTES binding GAG.
Graphical Abstract [278].
RANTES forms linear oligomeric complexes, allowing extended interactions with glycosamino-
glycan (GAG) chains (Figure 2.18). The basic residues on the surface of RANTES oligomer are
arranged linearly and form GAGs binding sites.
Signaling
Numerous elements of the RANTES signaling cascade have been characterized, but the whole
process remains poorly understood [281]. It has been shown that depending on the affinity and
protein concentration RANTES act via two different signal transduction pathways in T cells
[282].
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At relatively low concentrations of RANTES it activates the high affinity GPCR signaling
through Gi protein mediating chemotaxis, transient calcium mobilization, and suppression of
HIV infection.
The other signaling pathway at high concentrations of RANTES involves protein tyrosine kinase
(PTK) activation pathway resulting in a prolonged mobilization of calcium [283, 284]. This
RANTES induced stimulation leads to T cell activation, including proliferation of T cells, induc-
tion of interleukin-2 (IL-2) expression and increases in expression of cell surface molecules such
as the IL-2 receptor (CD25) [282, 283]. This G protein independent CCR5 activation can induce
apoptosis [277, 285].
The existence of two different signaling pathways suggests that oligomeric RANTES activates
different signaling pathways than those induced by monomeric RANTES [277, 285]. Aggre-
gated RANTES activates human T cells, monocytes, and neutrophils. Disaggregated, dimeric
RANTES has lost its cellular activating activity, rendering it noninflammatory and does not en-
hance HIV infection [256]. In vivo study showed that engineered, non-oligomerizing chemokine
are less effective in recruiting cells along a chemokine gradient [233].
Depending on the N-terminal RANTES modification CCR5 undergoes different recycling path-
ways (Figure 2.19).
Figure 2.19.: Trafficking routes of CCR5 upon different RANTES treatment.
Adapted from [286].
After interaction with the natural chemokine RANTES the receptor follows internalization and
is located in Recycling Endosomes (RE) before re-accumulating in the plasma membrane. Af-
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ter binding to CCR5 the chemically modified aminooxypentane AOP-RANTES the receptor
is cycling back from the cell surface to the RE. The receptor exposed to Nα-(n-nonanoyl)-des-
Ser1-[l-thioproline2, l-α-cyclo-hexyl-glycine3] PSC-RANTES becomes trapped in the Trans-Golgi
Network (TGN). The receptor interaction with Met-RANTES bypasses the RE and then receptor
accumulates in the TGN [286].
2.2.6.2. SDF1α
SDF1 is an acronym for Stromal cell-Derived Factor 1, also called CXCL12. It belongs to the
large family of chemokines that initiate the migration of effector cells.
There are six human SDF1 isoforms, SDF1α, SDF1β, SDF1γ, SDF1δ, SDF1ε, and SDF1Φ [287].
SDF1α and SDF1β were generated through alternative splicing; SDF1β has an additional 4 amino
acids at the C-terminus. The other SDF1 isoforms (γ to Φ) are also splice variants. They all share
the same first three exons, but the fourth exon is different. SDF1α/β share similar expression
patterns and tissue distribution; their highest expression levels are in liver, pancreas and spleen.
The human SDF1γ is only expressed in the heart. All human SDF1 isoforms can stimulate cell
migration once bound to CXCR4.
For a long time it was thought that SDF1 was the only ligand for CXCR4 and that CXCR4 was
the only receptor for SDF1. Even though SDF1α preferentially binds to CXCR4 it was shown
that SDF1α also binds to and signals through the orphan receptor RDC1 in T-lymphocytes [288].
In vitro studies showed that SDF1α exist in equilibrium between monomeric and dimeric forms.
It was shown that the N-terminal 38 residue of CXCR4 promotes SDF1α dimerization [289]
by contacting specific sulfotyrosine recognition sites on both sides of the dimer interface [290].
A stable SDF1α dimer was created by double mutation (L36C/A65C) where introduced Cys
residues formed a pair of symmetric intermolecular disulphide bounds [290]. This disulphide
bridge stabilized dimer enabled the resolution of the SDF-1α and N-terminus of CXCR4 complex
by NMR.
In vitro studies of SDF1α interaction with GAGs demonstrated that SDF1α binds selectively
to heparan sulphate (HS) and heparin [291]. Electrostatic calculations showed that the SDF1α
dimer association allows the formation of a crest constituted by the positively charged Lys-27,
Arg-41, Lys-24, and Lys-43, creating a possible binding site for the negatively charged heparin
(Figure 2.20) [292].
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Figure 2.20.: SDF1α dimer.
The surface of the SDF1α dimer color-coded according to the electrostatic potential, blue -
negative regions and red - positive regions [292].
Several SDF1α mutants were created to identify the amino acids involved in heparin binding. It
was shown that a double mutant K24S/K27S was unable to bind heparin. Single mutants K24S
and K27S strongly diminished the binding, indicating that both K24 and K27 are involved in the
complex formation. However, the binding of these mutants to the heparin increased at higher
concentrations [292].
A 3D model of the interaction between SDF1α and heparin was proposed (Figure 2.21) [293].
Figure 2.21.: Model of SDF1α and heparin complex.
SDF1α dimer in complex with a heparin-derived dodecasaccharide. The basic amino acids
involved in the complex are shown in blue, the proline residue at position 2 is shown in red,
and the heparin oligosaccharide is represented as sticks [293].
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It was suggested that the N-terminal lysine residue of the SDF-1α interaction with the ex-
tended dodecasaccharide terminal sugar residues protects the chemokine from cleavage by the
CD26/dipeptidyl peptidase IV (DPP IV) a serine protease, which mediates the selective removal
of the N-terminal dipeptide of SDF1α [293]. Heparin and HS specifically prevent the processing
of SDF1α. Chemokine mutants that do not bind the HS are cleaved by DPP IV. Processed
chemokines lose their biological activity [294]. Therefore, chemokine/GAGs interaction medi-
ates a control mechanism of selective protease cleavage events that directly affect the chemokine
activity [293].
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3. Biochemistry of membrane proteins
GPCRs are integral membrane proteins and their handling obeys “classical” membrane biochem-
istry rules.
3.1. Solubilizing membrane proteins
Biological membranes are generally rich in proteins. In order to study in vitro structure and func-
tion of membrane proteins it is necessary to extract the proteins from their native environment,
the membrane.
The hydrophobic domains of membrane proteins make them difficult to manipulate once they
have been extracted. Usually membrane proteins tent to precipitate and/or form insoluble ag-
gregates. They have to be handled in an environment that resembles the native membrane.
Hydrophobic interactions play a major role in defining the native tertiary structure of the pro-
teins. In water-soluble proteins, hydrophobic domains are folded-in together and protected from
aqueous environment. In membrane proteins, some hydrophobic domains are exposed to the
aqueous environment and therefore are surrounded by a mixture of lipids and other components.
Membrane proteins are usually extracted from cell membranes and maintained soluble in aqueous
solution thanks to surfactants. The most common used surfactants are detergents. The selection
of detergents suitable for the solubilization and purification of a specific membrane protein is a
critical step in the purification of membrane proteins.
However, detergents can destabilize the protein. The structure and function of membrane protein
can depend on associated lipids and cofactors, which are often lost upon detergent extraction.
That leads to protein destabilization and frequently to aggregation. Many membrane proteins
require specific types of phospholipids to maintain active function. This is a hard task to achieve
while working with the detergents. Liposome preparation was used for these cases to incorpo-
rate membrane proteins. However, they are heterogeneous in size and difficult to prepare with
precisely controlled size and stoichiometry. Membrane proteins when extracted with detergents
are in monomeric state, while in the native membrane they are often in oligomeric state. That
is another frequent protein destabilization problem, which leads to the loss of protein function.
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Membrane proteins solubilized in detergents tend to form mixed detergent-protein-lipid micelles.
Free micelles often co-concentrate with the protein and that can interfere with many techniques
such as absorbance and light scattering.
3.2. Detergents
3.2.1. General introduction
Detergents are small, amphipatic molecules classified as surfactants. Detergents have similar
dual properties as lipid molecules; they have hydrophobic tail and hydrophilic head. Detergents
vary in both nature of the hydrophilic head groups (sugar-based, phospholipid like) and length
and composition of hydrophobic alkyl tails. Many different detergents with various combinations
of hydrophobic and hydrophilic groups are available. It is crucial to choose the right detergent
while working with membrane proteins.
Detergents at low concentration in solution exist as monomers. However, at a specific concentra-
tion called the Critical Micelle Concentration (CMC) the detergent molecules form micelles due
to hydrophobic interaction of the alkyl chains. The CMC is a function of the specific detergent
and is varying according to the composition of the solvent. The CMC is related to the length
of the alkyl chain of the molecule: the longer alkyl chain the smaller CMC value. At concentra-
tions below the CMC the detergent is a monomer in solution. At the concentration equal to the
CMC, the detergent spontaneously aggregates into a micelle. At the concentration above the
CMC, there is equilibrium between monomers and an increasing concentration of micelles [295].
In order to effectively solubilize membrane proteins detergents must be used at concentrations
above their CMC [296].
At the CMC, detergent start to disrupt the interactions between membrane protein and the lipid
bilayer. Detergents solubilize membrane proteins by mimicking the lipid bilayer environment.
The hydrophobic protein regions are covered by detergents and hydrophilic regions are exposed
to the water environment. Depending on the concentration of detergent used it is possible to
obtain a mix of protein-lipids-detergent or just protein-detergent.
The CMC varies with the salt concentration and temperature. These features are important to
bear in mind while working with MPs.
3.2.2. Detergent classification
According to the nature of the hydrophilic head group, detergents can be classified as ionic,
nonionic and zwitterionic.
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Ionic detergents contain a head with a net charge (either negative or positive). Ionic detergents
contain either a hydrocarbon (alkyl) straight chain or a more complicated rigid steroid structure.
Ionic detergents are rather denaturing; they strongly bind to membrane proteins. Due to the
charged nature of their head groups, the CMC, the micellar structure and behavior will be
strongly dependent on solution parameters such as ionic strength and pH.
Non-ionic detergents contain uncharged, hydrophilic head groups that consist on either poly-
oxyethylene moieties or glycosidic groups. In general, non-ionic detergents are better suited for
breaking lipid-lipid and lipid-protein interactions than protein-protein interactions. Nonionic
detergents are less aggressive and allow the isolation of MP in a native state.
Zwitterionic detergents are unique in that they offer combined properties of ionic and non-ionic
detergents; they do not show any net charges. Like non-ionic detergents they do not possess a
net charge, they lack conductivity and electrophoretic mobility, and do not bind to ion exchange
resins and are relatively mild for membrane proteins. They are suitable for the extraction of
membrane proteins and can be used in the subsequent purification and crystallization steps.
3.2.3. Physical properties of detergents
The difference between detergents and biological lipids is that detergents tend to assemble into
relatively small, well-defined micelles when biological lipids form extended structures typical of
lipid bilayers. The reason is geometric. In the membrane, the polar and apolar moieties of
lipids occupy comparable areas, as lipid molecules look more or less cylindrical: the combination
of many molecules forms a flat monolayer, two of which form the membrane. In detergents,
the apolar part is less bulky than the polar one, which bends the interface, generating spheres,
ellipsoids, or cylinders, called micelles.
For the detergent interaction with proteins the head group has a strong influence, while the length
of the alkyl chain affects the CMC and aggregation number. For detergents with the same alkyl
chain length, those with bigger polar head groups tend to be milder. For example, OM (n-octy-
beta-D-maltopyranoside) is milder than OG (octyl-beta-D-glucopyranoside). Detergents with
longer hydrophobic tails will be milder than the ones with shorter tails provided that they have
the same polar head. For instance, NG (nonyl-beta-D-glucopyranoside) is milder than OG but
harcher than DG (n-decyl-beta-D-glucopyranoside). The solubility of detergents decreases as the
alkyl tails gets longer [296].
3.2.4. Extraction/solubilization from membranes
For the extraction and solubilization of membrane proteins a key concept is the Critical Solu-
bilization Concentration (CSC). The CSC is the minimal detergent concentration required to
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disrupt a membrane system into a predominantly micellar dispersion. The CSC depends on the
starting conditions such as the lipid concentration, the membrane system and the detergent.
Selective solubilization of proteins at detergent concentrations below the CSC can be a very
effective purification strategy.
Figure 3.1.: Solubilization of membranes by detergents.
Adapted from [296].
In many cases the membrane preparation is completely solubilized when the target protein is
fully extracted from the membrane (Figure 3.1 and Figure 3.2).
Figure 3.2.: Schematic representation of the solubilization process.
Free detergent monomers (A) associate to form detergent micelles (B) at concentrations above
the CMC. When added to a membrane preparation (C), the micelles extract membrane
proteins from the lipid bilayer yielding a solution containing detergent/protein complexes, free
lipid-detergent micelles and detergent monomers (D) [297].
The temperature factor is very important and should be controlled depending on the requirements
of the protein solubilization. The lipid concentration in the starting membrane suspension is the
most critical parameter to control and to ensure batch-to-batch reproducibility during detergent
solubilization [298, 299, 300].
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3.2.5. Protein denaturation and aggregation
Sometimes the detergent may not be able to fully mask the transmembrane regions of a pro-
tein. This typically results in the aggregation and precipitation of the protein. In some cases
the precipitate may be resolubilized by the addition of more detergent, or of a more effective
detergent. In most cases, protein aggregation is irreversible leading to non-specific interactions
between surfaces that are normally buried in the folded protein.
Despite the large number of detergents that are commercially available, no single ‘‘universal
detergent’’ is ideally suited to all biochemical applications. As a result, the choice of detergent
is one of the most fundamental decisions that must be made in developing a new protocol for a
given membrane protein.
3.2.6. Commonly used detergents
In general, membrane proteins are more stable in detergents with long alkyl chains such as
dodecyl-β-D maltoside (DDM) than those with shorter chains such as octylglucoside (OG). Alkyl-
glucosides, such as n-dodecyl-β-D maltoside (DDM), are increasingly used in membrane protein
solubilization as many proteins can be readily solubilized in a functional state in DDM but with
retention of functional properties [301].
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Table 3.1.: Structures and properties of detergents commonly used to solubilize membrane pro-
teins.
The most commonly used detergents to study membrane proteins are: N,N-dimethyldodecylamine-
N-oxide (LDAO), n-octyl-β-D-glucopyranoside (OG), octyltetraoxyethylene (C8E4), n-decyl-β-
D-maltopyranoside (DM) and n-dodecyl-β-D-maltopyranoside (DDM), sodium dodecyl sulfate
(SDS), dodecyl phosphocholine (DPC) and CHAPS (Table 3.1) [296].
3.3. Nanodiscs
The Nanodisc is a non-covalent assembly of phospholipids and a genetically engineered Membrane
Scaffold Protein (MSP) [302]. MSP is derived from human serum apolipoprotein AI [303]. The
phospholipids associate as a bilayer while two molecules of MSP wrap around the edges of
the disc-like structure in a belt-like configuration. The MSP sequence is a highly engineered
synthetic gene, optimized for Escherichia coli expression and can contain various affinity tags
(6xHis, FLAG, Cys, etc.) [304]. There are different MSP sequence lengths that allow controlling
the overall nanodisc size [305]. When prepared properly, nanodiscs are uniform in size allowing
a native local environment for a chosen membrane protein in vitro study.
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The membrane in nanodiscs can be composed of different mixtures of phospholipid types as
well as other components such as cholesterol. Nanodiscs are the ideal model for membrane
protein system with defined size and phospholipid composition [303]. Membrane proteins which
function depends on association with cellular lipids, co-factors and additives could be addressed
in nanodiscs [306].
The work carried out by Leitz and co-workers illustrates the use of nanodisc for GPCRs [307].
Figure 3.3.: Schematic representation of β2AR assembled in Nanodisc.
Adapted from [307].
Purified and solubilized in detergent the β2AR monomers assembled into Nanodiscs (Figure 3.3).
Receptor functionality was confirmed by a ligand binding assay and a functional receptor/G
protein complex formation [307].
3.4. Fluorinated Surfactants
New types of surfactants have been designed to keep membrane proteins soluble.
Fluorinated Surfactants were designed based on the observation that alkanes and perfluorinated
alkanes while being hydrophobic are poorly miscible [308, 309]. Chemically the fluorinated
surfactants looks similar to classical detergents with a hydrophobic tail containing fluorine atoms;
they are both hydrophobic and lipophobic [310]. The first Fluorinated Surfactant successfully
tested was C6F13C2H4- S-poly-Tris-(hydroxymethyl) aminomethane (F-TAC) (Figure 3.4) [311,
312].
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Figure 3.4.: Chemical structure of Fluorinated Surfactant.
For F-TAC the R=F, in case of HF-TAC the R=C2H5 [308].
Fluorinated Surfactants alone cannot extract membrane proteins from their membranes. The
micellar phase of Fluorinated Surfactants is a poor solvent for lipids and other stabilizing hy-
drophobic co-factors [308, 313]. Classical detergents used for membrane protein solubilization
can be substituted by Fluorinated Surfactants [311]. Fluorinated Surfactants are less aggressive
and less efficient than detergents at disrupting protein/protein interactions.
However, perfluorinated chains have little affinity for the hydrogenated transmembrane surface of
membrane proteins and are inefficient at keeping them from aggregating. To improve interactions
with the protein, a hydrogenated tip was grafted at the end of the fluorinated tail, yielding
hemifluorinated surfactants (HFSs) [308, 310].
It was shown that three membrane proteins: bacteriorhodopsin, the transmembrane domain of
OmpA and the cytochrome b6f complex remained soluble when transferred in (H)F-TAC. The
bacteriorhodopsin and the b6f, were stable when stored in (H)F-TAC, as compared to storage in
equivalent concentrations of detergent [311, 312].
Fluorinated Surfactants were used for membrane proteins cell-free synthesis [314, 315] and for
their thermodynamic studies [316].
3.5. Amphipols
Amphipols (APol) are small amphipatic polymers. They are highly flexible and remain solu-
ble despite the presence of multiple hydrophobic chains. They can stabilize and keep soluble
membrane proteins in aqueous solutions without detergent (Figure 3.5) [317].
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Figure 3.5.: Membrane protein trapped in APols.
Cartoon by P.L. Porté.
APols are poorly dissociating surfactants; therefore they are not efficient at solubilizing biological
membranes [318, 319]. Usually, membrane proteins are first extracted and purified in buffer
containing detergent and then transferred to buffer with APols [317].
Membrane proteins trapped in APols have been implemented in functional and/or ligand binding
studies. APols have successfully been used for both β-barrels and α-helical membrane proteins
studies. Examples of β-barrel membrane proteins functionally solubilized in APols includes
OmpF [320], while the α-helical proteins includes the bacteriorhodopsin (BR) [321, 322], the
calcium ATPase [318, 323], the nicotinic acetylcholine receptor (nAChR) [324, 325], followed
by several GPCRs trapped in APols which maintained their functionality: rhodopsin [320], the
leukotriene receptors 1 and 2 (BLT1 and BLT2) [326], the 5HT4(a) serotonin receptor, the CB1
cannabinoid receptor 1, the GHSR-1a ghrelin receptor [326, 327, 328] and the chemokine receptor
CCR5 described in this thesis manuscript.
3.5.1. Amphipol A8-35
The first designed and most extensively studied APol is the A8-35 (Figure 3.6) [317, 329, 330].
The A8-35 contains a polyacrylate chain of about 70 residues, in which around 17 carboxylates
are grafted at random position with octylamine and around 28 carboxylates with isopropylamine.
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Figure 3.6.: A8-35
Amphipol A8-35 where x, y, and z corresponds to 35, 25, and 40%, respectively [329, 313].
The average MW of A8-35 molecule is 9-10 kDa. A8-35 is highly water-soluble and in aqueous
solutions forms well defined, small, globular particles [330]. A8-35 self-assembles into well-defined
clusters consisting of four 9-10 kDa macromolecules [321, 330].
Extensive study of the A8-35 led to the discovery of some APol limitations which are important
while working with membrane proteins. The solubility of A8-35 depends on the presence of
ionized carboxylates, it is highly sensitive to their protonation, as well as to the presence of
multivalent cations, in particular of Ca2+ ions [318, 331, 330, 329, 323].
To overcome some limitations of A8-35 such as precipitation at pH below 7.0 and in the presence
of divalent cations series of new APols have been synthesized including SAPols, PC-APols and
NAPols [332, 331, 323].
3.5.2. Non-ionic Amphipol (NAPol)
NAPols are nonionic β-D-glucose-based amphipols. Previously the glucose-based NAPols were
synthesized by free-radical co-telomerization of hydrophilic and amphiphilic monomers [333].
Even though it was expected that the hydroxyl groups will provide a good solubility, however,
these NAPols had rather poor solubility, which limited their use in biochemistry approaches
[333]. Therefore, the strategy of the synthesis was firstly improved by employing the homo-
telomerization of a glucosylated acrylamide monomer carrying two hydroxyl groups, onto which
undecyl alkyl chains are subsequently grafted through a urethane bond [334, 335]. These gluco-
sylated NAPols were tested using two model membrane proteins: bacteriorhodopsin (BR) and
OmpA [334]. It was demonstrated that there was no difference in stability whether the BR was
trapped into A8-35 or in NAPol.
The further improvement was achieved by creating new NAPols through free-radical homo-
telomerization of an acrylamide-based monomer comprising of C11 alkyl chain and two glucose
moieties, using a thiol as a transfer reagent (Figure 3.7) [336]. The advantage of this new strategy
is that there are less batch-to-batch variations. In this way only one type of monomer undergoes
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free-radical polymerization. Thus the reproducibility was improved allowing the larger-scale
synthesis [337].
Figure 3.7.: NAPol.
Where n ranges from 9 to 90[336].
New glucosylated NAPols are highly water-soluble molecules. In aqueous buffers they form small,
compact, globular particles. The average molecular weight of the NAPols varies from 8 to 63
kDa [336]. NAPol, which is an electrically neutral surfactant, is less aggressive while working
with membrane proteins. Membrane proteins trapped in NAPols are suitable for applications,
such as NMR, where the overall size of the particles is important [334].
Recently, the studies of the outer membrane protein X from E. coli (OmpX), BR and the ghrelin
G protein-coupled receptor GHS-R1a stabilized in NAPols were extended to further applications
to membrane protein folding, cell-free synthesis and Solution Nuclear Magnetic Resonance [337].
3.5.3. Sulfonated Amphipol
Addressing the A8-35 incompatibility with calcium ions and pH sensitivity the Sulfonated Am-
phipols (SAPols) were designed (Figure 3.8). SAPols are anionic at any pH, with an average
molecular mass of about 11 kDa [323, 332].
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Figure 3.8.: SAPol.
SAPol where x, y, and z corresponds to 35, 25, and 40%, respectively[323, 313]
The ability of SAPols to keep membrane proteins soluble in aqueous solution was tested us-
ing two membrane proteins an α-helical membrane protein from Halobacterium salinarum the
bacteriorhodopsin (BR) and the transmembrane β-barrel domain (tOmpA) of Escherichia coli
outer membrane protein A [338, 321, 332]. Tested tOmpA/SAPol complex remained soluble and
monodisperse at tested pH 6.5 as regards the dispersity of protein/SAPol complexes [332].
SAPols are insensitive to the presence of multivalent cations. The sarcoplasmic reticulum Ca2+−
ATPase trapped in A8-35 was stabilized but inactive, trapped in SAPol it remained stable and
fully functional [323].
3.5.4. Phosphorylcholine-based Amphipol
New neutral amphipols were developed bearing phosphorylcholine-based (PC) units (Figure 3.9).
Figure 3.9.: PC-APol.
[331]
The phosphorylcholine groups ensure PC-amphipol solubility. This type of polar group is highly
soluble over a wide range of conditions, including low pH and the presence of divalent ions. In
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addition, the phosphorylcholine group is a good mimic of the polar moiety of phosphatidylcholine,
which represents a large proportion of membrane lipids in eukaryotic organisms [331].
3.5.5. Labeled Amphipols
APols can be labeled during their chemical synthesis. So far, labeling was applied only to A8-
35 and A8-75 (which differs from A8-35 by the absence of isopropyl grafts) [317]. Isotopically
labeled APols include 14C-labeled A8-75 and 3H-labeled A8-35, which have been used to follow
the distribution of the polymers during fractionation experiments and to quantify their binding
to membrane proteins [321, 320, 339].
A A8-35 version where the short-chain parent polymer chain was hydrogenated and isopropy-
lamine and octyl groups were perdeuteriated [329] has been heavily used for SANS, AUC and
NMR experiments [326, 340, 321, 330, 329, 341].
3.5.6. Biotinylated Amphipols
A biotinylated version of A8-35 termed BAPol (Figure 3.10) has been used for the immobilization
of APol trapped membrane proteins onto solid supports coated with streptavidin (SA) [325].
This allows the study of immobilized membrane proteins for ligand-binding experiments such as
Surface Plasmon Resonance (SPR).
Figure 3.10.: BAPol.
Where w = 0.7% - 1.4%, x = 30% - 35%, y = 21% - 25%, z = 36% - 41% [325].
Membrane proteins trapped in BAPol are stabilized and functionalized for specific immobilization
onto surfaces
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3.5.7. Fluorescent Amphipols
A fluorescently labeled version of A8-35 has been synthesized (FAPol) in order to study the size
and dispersity of membrane proteins and APols complexes and understand the dynamics of their
interactions (Figure 3.11) [338].
Figure 3.11.: FAPol.
Where x=35%, y=23.5% and z=34% [338].
First of all the A8-35 carrying a reactive arm (UAPol, non-fluorescent precursor of fluorescent
amphipol) was synthesized to which any desirable label could be bound. The subsequent binding
of NBD (7-nitrobenz-2-oxa-1, 3- diazol-4-yl) yielded a fluorescent amphipol (FAPol) (Figure
3.11).
NBD was chosen as the fluorophore for its low absorbance at 280 nm. Using FRET it could be
excited through tryptophans which are acting as donors. As NBD is weakly hydrophobic it is a
good reporter for the APol backbone.
Upon being trapped with such APols, any membrane protein become noncovalently but per-
manently functionalized, without having to be genetically or chemically modified [338]. FAPols
have been used in FRET experiments [338].
3.6. Applications for amphipols
Initially developed for membrane protein solubilization and stabilization in the recent years some
applications for amphipols have been developed. Membrane proteins trapped in amphipols have
been studied by size exclusion chromatography, equilibrium and sedimentation velocity analytical
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ultracentrifugation (AUC), dynamic and static light scattering, small angle X-ray scattering
(SAXS), Small Angle Neutron Scattering (SANS), Förster Resonance Energy Transfer (FRET)
and solution NMR Inelastic Neutron Scattering (INS) [313, 328].
Folding membrane proteins to their native state
Targeting the over-expression of membrane proteins towards E. coli inclusion bodies allows large
amounts of protein production. However, folding those inactive membrane proteins into their
native state is difficult. Several GPCRs were successfully folded in vitro using detergents, deter-
gent/lipid mixtures or lipid vesicles.
Some GPCRs have been produced in E. coli as inclusion bodies, purified and solubilized in
detergents such as SDS [342, 327, 104]. Receptors folding in amphipols were achieved by supple-
menting the SDS solution with either A8-35 or A8-35–lipid mixture. The SDS was removed by
precipitation with KCl followed by dialysis (Figure 3.12) [322].
Figure 3.12.: Schematic representation of GPCR folding and functional assay.
Adapted from [327].
The amount of ligand-binding competent receptor obtained after folding the SDS-unfolded re-
ceptors in fos-choline-16/asolectin (D + L), A8-35 (AP), and A8-35 plus asolectin (AP + L)
was compared for four GPCRs: leukotriene BLT1, serotonin 5-HT4(a), leukotriene BLT2, and
cannabinoid CB1 receptors (Figure 3.13).
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(a) (b)
Figure 3.13.: Amphipol assessed GPCRs folding.
(A) Comparing the folding of leukotriene BLT1 receptor in fos-choline-16/asolectin (D+L) and
in A8-35 at increasing amphipol/protein ratios (AP), and in A8-35 in the presence of asolectin
(1:5:1 protein/amphipol/asolectin weight ratio; AP+L). (B) Folding of serotonin 5-HT4(a),
leukotriene BLT2, and cannabinoid CB1 receptors in detergents or A8-35 and lipids. Adapted
from [327].
In case of leukotriene BLT1 receptor the use of A8-35 increased the amount of functional recep-
tor comparing to folding in detergent. The receptor/amphipol ratio is important as using not
enough or too much amphipol can dramatically decrease the amount of functional receptor. The
addition of lipids to the amphipol mix increased the receptor-folding yield to 65-70 %. The most
advantageous use of A8-35 versus detergents is shown in Figure 3.13b. After folding in detergent
only 5% of leukotriene BLT2 receptor was able to bind its ligand, while using A8-35 with or
without lipids 60-75% of functional receptor was obtained. Results obtained with cannabinoid
CB1 receptor were even more interesting since functional refolding could only be obtained with
amphipols.
Besides folding in amphipols enhanced receptor thermostability (Figure 3.14).
(a) (b)
Figure 3.14.: Stability of BLT1 trapped in A8-35.
The temperature (A) and time-dependent (B) stability of leukotriene BLT1 receptor folded in
amphipols (1:5 protein/amphipol weight ratio; AP), and amphipols plus lipids (1:0.2
amphipol/lipid weight ration; AP + L), compared to that of BLT1 folded in
fos-choline-16/asolectin mixed micelles (2:1, w/w; D + L) . Adapted from [327].
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BLT1 thermostability and time stability were tested using ligand-binding assay. In the Figure
3.14 shows that BLT1 folded in amphipols and in the amphipol/lipid mixture is able to bind the
ligand at higher temperature and retain its functionality over 20 days.
Cell-free Synthesis of Membrane Proteins
Not all APols are suitable for cell free synthesis. It has been reported that both A8-35 and SAPols
inhibit the synthesis of membrane proteins [315]. Great results were obtained when NAPol was
used for barteriorhodopsin synthesis. Using NAPol the yield of protein synthesis was higher and
more reproducible than that observed while using DDM [337]. Also the majority of the protein
remained soluble over several months in NAPols while in DDM it tended to precipitate[337]. The
use of NAPol for the cell-free synthesis could be applied to GPCRs.
Immobilizing Membrane Proteins onto Solid Supports for Ligand-Binding Studies
The immobilization of BAPol-trapped membrane proteins could be achieved on streptavidin-
coated chips or beads. Trapping membrane proteins with APols does not interfere with ligand
biding (Figure 3.15) [325].
Figure 3.15.: Immobilization of BAPol trapped membrane protein.
Membrane protein solubilized in detergent (1) is transferred to BAPol. The complex (2) is
applied to a support, which exposes a functional streptavidin group to which BAPol can
associate (3). Protein ligands are applied (4) and their interaction can be detected by any
convenient method. Adapted from [325].
This strategy of immobilization presents several advantages. Once the protein is successfully
folded in BAPols their association is irreversible as long as amphipols are not displaced by
another surfactant. Protein/amphipol complex resists to the extensive washes with surfactant-
free buffer therefore there is no need to supply the buffers with amphipols.
BAPol mediated immobilization should be more favorable to the ligand binding assays than
classical amine coupling. The latter one is non-specific and it cross link the proteins via their
NH2 groups leading to a random orientation of the proteins and could impair the access to the
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ligand-binding sites. Immobilization via BAPol should offer a more accessible ligand-binding site
and facilitate the interaction with the tested analyte.
Trapping a membrane protein with a functionalized APol therefore results in a permanently
functionalized complex. This way functionalized membrane proteins are suitable for the ligand
binding studies as the ligand binding site is exposed and accessible [325, 328, 308].
Other APol applications
Membrane proteins trapped in APols are suitable for many other applications.
Fragile membrane proteins and their super-complexes trapped in amphipols could be used for
electron microscopy studies [343, 344, 345].
APols could be used for the membrane protein delivery to pre-existing membranes. APols do no
lyse target membranes (lipid vesicles or black films, cell plasma membrane) and can therefore be
used to deliver to them hydrophobically charged proteins such as membrane proteins [328, 322,
346, 316].
Usually for membrane proteins the solution NMR conditions are highly aggressive. The A8-35
and sulfonated A8-35 - SAPol stabilize membrane proteins at higher temperatures. Another ad-
vantage is that A8-35 and SAPol are easier to deuterate than most detergents. A8-35 aggregates
at pH < 7, preventing the study of solution-exposed amide protons, while the pH insensitive
SAPol overcome that limitation [340, 326, 347, 348, 332, 349, 350, 341].
The mass spectrometry analysis of APol trapped membrane proteins along with weakly bound
partners could be useful to identify membrane protein bound lipids and co-factors, that tend to
dissociate in detergent solutions [322].
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Since its discovery in the XIXth century, for a long period of time, rhodopsin was the GPCR
the most studied by scientists. In the late XXth century other GPCRs were extensively studied
at the cellular level and their interaction with G proteins was discovered. Molecular studies
have been until recently hindered by the difficulty to express and purify GPCRs. Recently
the first GPCR structure from recombinant source has been obtained and now more than 30
structures of almost ten different GPCRs are known. Most of these GPCRs were produced
using insect cell expression system, which is an expensive system and is not affordable for many
laboratories. To allow expression the proteins were highly modified with many mutations and
insertions. The expressed GPCRs were so highly modified that they were far from the natural
proteins. Despite this breakthrough at the structural level, functionality was assessed only for a
few of those modified GPCRs. High amounts of purified, stable and functional receptor would
open the way to studies at the molecular level such as: receptor dimerization, stoichiometry of
receptor/ligand complex, interactions with intracellular proteins such as G proteins, β-arrestins
and others. Therefore, there is still need for alternative production protocol where GPCRs would
be expressed in high yield, functional and with minimal amount of modifications.
Corinne Vivès, in the team of Franck Fieschi has been already working on alternative expression
strategies for CCR5 and CXCR4. CXCR4 and CCR5 genes were optimized for E. coli expression
to avoid the limitation due to rare codons. To circumvent the toxicity linked to membrane protein
expression, the collaboration with the group of J.-L. Banères and B. Mouillac (Montpellier) led
to the design of fusion proteins targeting the expression to E. coli inclusion bodies [104]. With
this fusion and inclusion body strategy we could access to high yields of purified receptors.
The receptor production was already started to be developed and its folding was assessed with
detergents and amphipols. It was shown that only a small amount of receptor was maintained
soluble in detergent solution where only 4% of it was functional. Folding in amphipols gave
promising results, higher amount of receptor was solubilized, but its functionality was not yet
assessed. Therefore, the receptor folding using alternative methods to detergents, the amphipols,
developed by J.-L. Popot (Paris), will be attempted [317].
To assess the functionality of folded receptor we needed to produce their functional ligands.
Therefore, the first step of my work was to produce functional CXCR4 and CCR5 ligands:
SDF1α (specific for CXCR4) and RANTES (specific for CCR5). Once chemokines will be pro-
duced it is essential to confirm that they are functional. Collaboration with C. Moreau and
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M. Vivaudou (IBS, Grenoble) was established which allows us to test chemokine functionality
independent of receptor folding. Therefore, receptor binding and signaling will be assessed using
an electrophysiology recording strategy.
Once the production of functional ligand will be established, I will concentrate on the initial goal
of the project – on the functional GPCR production. I will produce CCR5 and CXCR4 using E.
coli inclusion body production strategy and their folding in amphipols will be assessed. Several
different amphipols will be tested as well as the presence of lipids will be investigated on the
receptor folding impact. Folded receptor functionality will be tested at the molecular level by
setting up an interaction with their ligands using Surface Plasmon Resonance (SPR) technique.
The access of high yields functional GPCRs and their ligands will open the ways for further
investigations at the molecular level and in solution studies of those GPCRs in complex with
their ligands to reply to remaining unanswered questions such as the complex stoichiometry.
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en français
Depuis sa découverte au 19ème siècle, et pendant une longue période, la rhodopsine était le
récepteur couplé aux protéines G (RCPG) le plus étudié par les scientifiques. Récemment,
d’autres RCPGs ont été étudiés au niveau cellulaire et leurs interactions avec les protéines G
ont été mises en évidence. Les études moléculaires ont été jusqu’à récemment entravées par
les difficultés à produire et purifier les RCPGs. Récemment, la première structure de RCPG
recombinant a été obtenue, et actuellement, plus de 30 structures de 10 RCPG différents sont
connues. La plupart de ces RCPGs ont été produits avec des systèmes d’expression utilisant
des cellules d’insectes, or ces systèmes sont onéreux et ne peuvent être utilisés par tous les
laboratoires. Pour permettre l’expression, les protéines sont modifiées de manière importante
avec un grand nombre de mutations et d’insertions. Les RCPGs produits sont ainsi parfois très
éloignés des protéines naturelles. Malgré cette avancée au niveau structural, la fonctionnalité a
été évaluée seulement pour quelques uns des RCPGs modifiés. Une grande quantité de récepteurs
purifiés, stables et fonctionnels pourrait permettre des études au niveau moléculaire comme la
dimérisation des récepteurs, la stœchiométrie du complexe récepteur/ligand, les interactions
avec les protéines intracellulaires comme les protéines G, les β-arrestins ou autres. Ainsi, il
est nécessaire de trouver des moyens de production alternatifs permettant d’obtenir des RCPG
fonctionnels en grande quantité, avec un minimum de modifications.
Les récepteurs de chimiokines sont des régulateurs essentiels de la migration des cellules dans le
cadre de la surveillance immunitaire, l’inflammation et le développement. Les RCPGs, CCR5
et CXCR4, sont spécifiquement impliqués dans de nombreux cancers et l’infection par le VIH-1.
L’entrée du VIH dans les cellules cibles nécessite l’interaction sequentielle de la protéine virale
gp120 avec CD4 (récepteur primaire) et un co-récepteur, CCR5 ou CXCR4 pour respectivement
les virus M- et T-tropique.
Depuis plusieurs années, il a été montré que les chimiokines RANTES et MIP1-α (ligands naturels
de CCR5) ont la possibilité de bloquer la réplication du VIH dans les expériences de laboratoire
[351]. Ceci s’explique par le fait que les chimiokines entre en compétition avec le VIH dans
la liaison au récepteur et aussi déclencher l’internalisation du récepteur et sa disparition de la
surface cellulaire. Les récepteurs de chimiokines représentent donc une cible thérapeutique pour
bloquer l’infection par le VIH.
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Corinne Vivès, dans l’équipe de Franck Fieschi travaille depuis plusieurs années sur une stratégie
alternative d’expression de CCR5 et CXCR4. Les codons rares des gènes CXCR4 et CCR5 ont
été optimisés afin de faciliter l’expression des protéines chez E. coli. Pour éviter la toxicité liée à
l’expression des protéines membranaires, une collaboration avec le groupe de J.-L. Banères et B.
Mouillac (Montpellier) a permis de concevoir des protéines de fusion permettant l’adressage vers
les corps d’inclusion d’ E. coli [104]. Grace à cette stratégie, nous avons pu obtenir un rendement
élevé de récepteurs purifiés. Le repliement de ces récepteurs obtenus en conditions dénaturantes
avait été avait testés avec des détergents et des amphipoles développés par J.-L. Popot (Paris).
Il avait été démontré que seulement une petite quantité des récepteurs était maintenu soluble
par les détergents et que seulement 4% de ces récepteurs étaient fonctionnels. Le repliement en
présence d’amphipoles donnait des résultats prometteurs, une plus grande quantité de récepteurs
était soluble, mais la fonctionnalité n’avait pas été évaluée. C’est sur ces approches alternatives
(repliement en amphipoles) que nous souhaitions nous concentrer [317].
Pour évaluer la fonctionnalité du récepteur replié, nous avions besoin de produire des ligands
fonctionnels. Ainsi, la première étape de mon travail a été de produire les ligands de CXCR4
et CCR5: SDF1α (ligand spécifique à CXCR4) et RANTES (Ligand spécifique à CCR5). Une
fois les chemokines produites, il était essentiel de confirmer leur fonctionnalité. Une collabora-
tion avec C. Moreau and M. Vivaudou (IBS, Grenoble) fut établie et nous a permis de tester la
fonctionnalité des chemokines indépendamment du repliement du récepteur. Ainsi, les interac-
tions et la signalisation du récepteur ont été évaluées en utilisant une stratégie d’enregistrement
électro-physiologique et chimiotactisme.
Un fois la production du ligand fonctionnel établie, je me suis concentrée sur le but premier du
projet, la production du RGPGs. J’ai produit les protéines CCR5 et CXCR4 (you did not pro-
duce CXCR4) en utilisant la production en corps d’inclusion chez E. coli et le repliement en am-
phipoles. Différents amphipols ont été testés et l’impact de la présence de lipides sur le repliement
a été évaluée. La fonctionnalité du récepteur replié a été testée en étudiant l’interaction avec les
ligands en utilisant la résonance des plasmons de surface.
L’accès à des rendements élevés de RCPG fonctionnels et de leurs ligands ouvrira la voie à de
futures études en solution de RCPG en complexe avec leur ligand, ce qui permettra de répondre
à des questions encore ouvertes telles que la stœchiométrie du complexe.
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6. Materials
6.1. Product lists
E. coli strain Company Reference
BL21(DE3) Novagene 70235-3
Rosetta2 (DE3) Novagene 71400-3
Top 10 Invitrogen C4040-03
XL 10 Gold Agilent 200315
Table 6.1.: Bacterial strains.
Product Company Reference
Quick change site-directed mutagenesis kit Stratagene 200519.5
Mass ruler DNA Ladder Mix Frementas SM0403
HiSpeed Plasmid Midi kit Qiagen 12643
QiaQuick gel extraction kit Qiagen 28704
QiaPrep Spin Mini-prep kit Qiagen 27106
Pfu turbo Stratagene 600250-52
Ultra Pure Agarose Invitrogen 15510-019
Rapid DNA Ligation kit Fermentas K1422
PCR Purification kit Qiagen 28106
PCR Master Mix Fermentas K0171
QuikChange XL Site-Directed Mutagenesis Kit, 30 rxn Agilent 200516
Table 6.2.: Products for Molecular Biology.
Product Company Reference
Ni-NTA superflow resin Qiagen 30430
Glutathione Sepharose High Performance Amersham 17527901
HiTrap Capto S 5ml GE Healthcare 17-5441-22
HiTrap Capto Q 5ml GE Healthcare 11-0013-02
Superdex 200 prep grade 150 ml GE Healthcare 17-1043-01
PD 10 (desalting) Columns GE Healthcare 17-0851-01
Amylose resin NEB Ozyme E80215
Ecno_Pac chromatography columns (empty) Biorad 732-1010
Strep Trap HP 5 ml GE Healthcare 28-9075-47
Table 6.3.: Columns and resins.
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Product Company Reference
Anti-His Antibody Amersham 27471001
Strep-Tactin horseradish peroxidase (HRP) conjugate IBA 2-1502-001
Monoclonal anti-polyhistidine peroxydase conjugate Sigma A7058-1VL
Anti-Rhodopsin, C-terminus, last 9 amino acids, clone Rho 1D4 Millipore MAB5356
Table 6.4.: Antibodies.
Product Company Reference
Amicon Ultra 4, 10 kDa Millipore UFC801024
Amicon Ultra 3K 15 ml Dutscher UFC900324
Dialysis Membrane 12-14,000 Spectrum Laboratories, Inc. 059026
Filter 0.2 μm Dutscher 146560
Membrane MCE 0.22 μm Dutscher 044121
Table 6.5.: Concentrators and membranes.
Product Company Reference
SDS 20% Euromedex 151-21-3
Acrylamide Euromedex EU0088-B
Unstained Protein Ladder Fermentas SM0661
Pre-stained Protein Ladder Fermentas SM0671
Immunoblot PVDF membrane Bio-Rad 162-0177
Trans-Blot Nitrocellulose membrane Bio-Rad 162-0097
SIGMAFAST™ 3,3´-Diaminobenzidine tablets Sigma D4168
Paper Blotting Whatman 3mm CHR 460 x 570 Dutscher 036347
Ammonium persulfate (APS) Sigma A3678
TEMED Euromedex 50406
Brilliant blue R Sigma B7920
Table 6.6.: Materials for gels.
Product Company Reference
Sensor Chip CM4 GE Healthcare BR-1005-39
Amine coupling kit GE Healthcare BR-1000-50
Sensor Chip SA GE Healthcare BR-1000-32
Sensor Chip NTA GE Healthcare BR-1004-07
HBS-N GE Healthcare BR-1003-69
Table 6.7.: SPR products.
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Product Company Reference
Ampicillin Euromedex EU0400-D
Choramphenicol Sigma C0378
LB Broth (Lennox) AthenaES 0102
LB agar Sigma L2897
Glucose Athenaes 0108
IPTG Euromedex EU0008c
Complete EDTA-free Roche 11873580001
Na2HPO4 Sigma S0876
NaH2PO4 Sigma S0751
Acetic acid Sigma 33209
Sodium acetate Euromedex EU0310
HABA Sigma HS126
DTT Fluka 43817
L-Glutathione reduced Sigma G4251
L-Glutathione oxidized Sigma G4376
DNase Euromedex 1307
Factor Xa protease Qiagen 33223
Thrombin Sigma T6884
Asolectin Sigma 11145
Tricine Sigma T0377
Triton X-100 Anatrace T1001
EDTA Euromedex EU0007
Tris-HCl Euromedex 26-128-3094-B
KCL Euromedex P017
Guanidine hydrochloride Euromedex EU0045
D-Desthiobiotin Sigma D-1411
Maltose Sigma M5885
HEPES Sigma H4034
NaCl Euromedex 1112-A
Imidazole Sigma 56749
NaOH Euromedex 2020
KH2PO4 Sigma P0662
K2HPO4 Sigma P5504
β-Mercaptoethanol Carl Roth GmbH + Co. KG 4227
CaCl2 Sigma C5080
Urea Sigma 51456
Ethanol Carlo Erba 528151
HCl 37% OM Group CAS-7647-01-0
Terbium Sigma 204560
RTS 100 E. coli HY Kit 5 PRIME 2401100
Table 6.8.: Biochemistry Products.
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7. Methods
7.1. Chemokine production
7.1.1. Molecular biology
7.1.1.1. MBP chemokine construct preparation
Optimized synthetic human chemokine genes encoding SDF1α, RANTES and RANTES-LT de-
signed for efficient production in E. coli cloned in standard pUC57 plasmids were ordered from
GeneCust (Evry, France) (sequences are listed in the Appendix 18). One construct contained an
additional double Lanthanoid Binding Tag (LT) in the C-terminal part of the protein [352].
The pUC57 plasmid containing SDF1α was digested using XbaI and BamHI enzymes. The
pUC57 plasmid containing RANTES was digested using BamHI enzyme. The pUC57 plasmid
containing RANTES-LT was digested with BamHI and SalI. The pMAL-c4x vector was digested
with BamHI, BamHI/XbaI and BamHI/SalI enzyme pairs. Digested chemokine sequences were
purified from the 1% agarose gel using Qiagen gel extraction kit. Each chemokine was ligated
into expression vector using Rapid DNA Ligation kit resulting in MBP-Xa-SDF1α-Strep, MBP-
Xa-RANTES-Strep and MBP-Xa-RANTES-LT-Strep. The Top 10 calcium-competent cells were
transformed with ligation reaction products. Mini-preps were prepared for each construct and
sequences were verified by sequencing (Beckman Coulter Genomics).
Factor Xa cleavage site was replaced by Prescission protease cleavage site by site directed mu-
tagenesis. New created constructs were named MBP-PrePro-RANTES-Strep, MBP-PrePro-
RANTES-LT-Strep and MBP-PrePro-SDF1α-Strep.
The double Lanthanoid Binding Tag was added to the SDF1α construct by multiple PCRs
(sequences of primers are listed in the Appendix 17). First, the LT sequence was amplified using
MBP-PrePro-RANTES-LT-Strep as a DNA template with a SDF-LT-fw and M13RV primers.
With the second PCR, the SDF sequence was amplified using MALE-Fw and SDF-LT-rv primers
and the MBP-PrePro-SDF-Strep clone as a DNA template. For the third PCR both results
from the previous two PCRs were mixed and used as a DNA template with the MALE-Fw and
M13RV primers. The product of the latter PCR (SDF1α-LT-Strep sequence) was digested with
HindIII and EcoRI enzymes and cloned into pMAL-c4x expression vector previously digested
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with the same enzyme pair. The new created construct was named MBP-PrePro-SDF1α-LT-
Strep (sequences are listed in the Appendix 18).
7.1.1.2. Constructs for the chemokine expression in E. coli inclusion bodies
The cDNA encoding chemokine sequences was amplified by PCR using MBP-chemokine con-
structs as templates with primers (see in Appendix 17) and sub-cloned into the pET-20b ex-
pression plasmid. Chemokine constructs were prepared with or without the LT. The SDF1α
clones contained C-terminal non-cleavable polyhistidine tag or Strep-Tag, which can be cleaved
by PreScission protease (SDF1α-His, SDF1α-LT-His, SDF1α-PrePro-Strep, SDF1α-LT-PrePro-
Strep).
SDF1α-His was prepared by PCR using pc4X-SDF as a template with primers SDF-NdeI and
SDF-XhoI. SDF1α-LT-His was prepared by PCR using pc4x-SDF-LT as a template with primers
SDF-NdeI and SDF-LT-XhoI.
Three RANTES constructs were prepared, where one had a C-terminal Strep-Tag (RANTES-
Strep), the second one was the same construct with LT (RANTES-LT-Strep) and the last con-
struct did not contained any tags (RANTES). All cloned DNA sequences were verified by se-
quencing (Beckman Coulter Genomics) (sequences are listed in the Appendix).
7.1.2. MBP-chemokine expression
The E. coli BL21 (DE3) calcium-competent cells were transformed with plasmids bearing chemokine
constructs and selected on ampicilin containing Luria Bertani (LB)-agar Petri dishes. A single
colony was isolated and a 10 ml pre-culture of Luria Bertani (LB) medium containing 100 μg/ml
ampicilin was prepared. One liter of LB medium containing 100 μg/ml ampicilin was inoculated
with 5 ml of overnight culture and grown at 37°C to an absorbance at 600 nm of 0.6 to 0.8.
The recombinant protein expression was induced by addition of IPTG to a final concentration of
1 mM for the MBP constructs, SDF1α-His, SDF1α-LT-His, SDF1α-Strep, SDF1α-LT-Strep and
RANTES-LT-Strep and 0.5 mM for RANTES and RANTES-Strep. Cells were further incubated
for 3 h at 37°C (SDF1α-His, SDF1α-Strep, RANTES-Strep, RANTES) or 16 h at 20°C (MBP
constructs, SDF1α-LT-His, SDF1α-LT-Strep, RANTES-LT-Strep). Cultures were harvested by
centrifugation for 30 min at 5 000 g using Sorvall Evolution RC Superspeed Centrifuge with
the rotor SLC6000 (Kendro laboratories). The purification of the recombinant proteins was
proceeded immediately or bacterial pellet were stored at -20°C.
7.1.3. MBP-chemokine purification
The bacterial pellet was resuspended in 50 ml of lysis buffer containing 100 mM Tris-HCl pH 8.0,
150 mM NaCl, 1 mM EDTA and supplemented with 1 tablet of Complete Protease Inhibitors.
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Bacterial pellet was disrupted twice using a Microfluidizer M-110P (Microfluidics international,
Newton, MA) at 10 000 psi. After ultracentrifugation for 45 min at 20 000 g, the supernatant
was filtered and loaded to the Strep-Trap column (5 ml) at 4°C previously equilibrated in 20
mM HEPES pH 8.0, 150 mM NaCl buffer. Recombinant protein was eluted with the same
buffer containing 2.5 mM desthiobiotin. Purified MBP-fusions were cleaved with the PreScission
protease (1.75 U protease/mg of fusion proteins) overnight at 4°C. Sample was centrifuged for
45 min at 20 000 g. To eliminate the GST tagged PreScission protease the supernatant was
loaded on the GST-Sepharose column equilibrated in the same 20 mM HEPES pH 8.0, 150 mM
NaCl buffer. The flow-through containing the protein of interest was collected and loaded to
an Amylose column to eliminate MBP proteins. Amylose column was previously equilibrated
in 20 mM HEPES pH 8.0, 150 mM NaCl buffer. The flow-through containing the protein of
interest was collected and concentrated up to a volume of less than 2 ml. Further chemokines
were purified on gel filtration Superdex 200 column in 20 mM HEPES pH 8.0, 150 mM NaCl
buffer. Proteins were concentrated using 3 kDa cut-off concentrator and stored at –80°C.
7.1.4. Chemokines purification from E. coli inclusion bodies
7.1.4.1. Preparation of inclusion bodies
Bacterial pellet were resuspended in 50 ml of 50 mM Tris-HCl pH 8.0 (buffer A) supplemented
with 1 tablet of Complete EDTA-free Protease Inhibitors and bacterial pellet was disrupted twice
using a Microfluidizer M-110P (Microfluidics international, Newton, MA) at 10 000 psi. After
centrifugation for 30 min at 20 000 g, inclusion bodies were pelleted and washed with buffer A
supplemented with 2 M Urea and 5 % Triton X-100, then with buffer A containing 2 M Urea
and finally with only buffer A.
7.1.4.2. SDF1α-His, SDF1α-Strep purification and refolding
Inclusion bodies were solubilised in 50 ml of 50 mM Tris-HCl pH 8.0 (buffer A) with 7.5 M
guanidine hydrochloride (GuHCl) and 20 mM DTT by incubating for 20 min at 50°C. Refolding
was performed by rapid dilution in buffer A up to 1 M GuHCl . The mixture was gently stirred
overnight at 4°C after addition of Complete protease inhibitors, diluted 4 times with buffer A
and loaded onto a 5 mL Capto S column equilibrated in 50 mM Tris-HCl pH 7.5. Chemokines
were then eluted with a linear NaCl gradient (0-1 M, length 25 ml), concentrated and further
purified on a gel filtration Superdex 200 column (Amersham Biosciences) previously equilibrated
in 20 mM Na2HPO4 pH 6.0. Purified proteins were analyzed by ion-spray mass spectrometry
and stored at –80°C.
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7.1.4.3. Rantes-Strep and RANTES purification and refolding
Inclusion bodies were solubilized in 50 mM Tris-HCl pH 8.0, 6 M GuHCl and 1 mM DTT
incubating 30 min at 60°C. Sample was centrifuged for 20 min at 29 434 g and dialyzed against
4 liters of 1% acetic acid for 3 hours at room temperature. Protein sample was centrifuged at
29 434 g for 30 min. The supernatant was filtered using 0.2 µm filter and concentrated. Protein
sample was then diluted up to 1 mg/ml final concentration in the 50 mM Tris-HCl pH 8.0, 6 M
GuHCl, 1 mM DTT buffer. Refolding was performed by 10 fold dilution of protein sample into
20 mM Tris-HCl pH 8.0, 0.01 mM oxidized glutathione, 0.1 mM reduced glutathione overnight
at 4°C with gentle stirring. Refolded protein was centrifuged for 20 min at 29 434 g and the pH
of the supernatant was adjusted to 4.5 with acetic acid. Sample was filtered using 0.2 µm filter
and loaded onto CaptoS column (GE Healthcare) previously equilibrated in 50 mM Na-Acetate
pH 4.5 buffer. Chemokines were then eluted with a linear NaCl gradient (0-2 M, length 25 ml).
Fractions containing chemokines were pooled, concentrated and further purified on a gel filtration
Superdex 200 column (Amersham Biosciences) previously equilibrated in 20 mM Na-Acetate pH
6.0, 150 mM NaCl. Purified proteins were concentrated using 3 kDa cut-off Amicon concentrator
and stored at –80°C until use.
7.1.4.4. SDF1α-LT-His, SDF1α-LT-Strep and RANTES-LT-Strep purification and
refolding
Inclusion bodies were solubilized by rotation on a wheel for 1 h at room temperature in 100 mM
Tris-HCl pH 8.0, 6 M Urea, 100 mM NaCl, 0.5 mM EDTA, 5 mM DTT buffer. Sample was
centrifuged at 29 434 g for 20 min. Refolding was achieved by drop-wise 100 fold dilution of the
supernatant in 100 mM Tris-HCl pH 8.0, 0.5 mM EDTA, 0.1 mM oxidized glutathione and 1
mM reduced glutathione buffer. The refolding solution was stirred overnight at 4°C. Sample was
centrifuged at 29 434 rpm for 20 min. Supernatant was loaded onto a 10 mL Q-Sepharose column
(Amersham Biosciences) previously equilibrated in 50 mM Tris-HCl pH 8.0. Chemokines were
eluted with a 0-100% linear 50 ml length gradient of 50 mM Tris-HCl pH 8.0, 1 M NaCl buffer.
Fractions containing the refolded chemokines were pooled, concentrated and further purified on
a gel filtration Superdex 200 column equilibrated in 50 mM Tris-HCl pH 8.0, 150 mM NaCl
buffer. Purified proteins were concentrated using 3 kDa cut-off Amicon Ultrafree and stored at
–80°C until further use.
7.2. Receptor production
7.2.1. Expression
The E. coli Rosetta2 (DE3) strain were transformed with the pET-21a-α5I-CCR5 expression
vector (sequence is listed in the Appendix 18) following the manufacturer’s (Novagen) instructions
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and grown overnight at 37°C on LB-agar plates containing 100 μg/ml ampicillin. An isolated
colony was picked from the plate and the bacteria were grown in 5 ml of LB broth containing 100
μg/ml ampicillin at 37°C overnight. This pre-culture was used to inoculate 100 ml of LB medium
containing 100 μg/ml ampicillin and 37 μg/ml chloramphenicol and grown overnight at 37°C. 15
ml of the pre-culture were used to inoculate 1 liter of LB medium supplemented with 100 μg/ml
ampicillin and 34 μg/ml chloramphenicol, and bacteria were grown at 37°C until the OD600 nm
reached 1. Then, 0.2 % glucose and 1 mM IPTG were added to the culture to induce expression
of the recombinant proteins. Bacteria were harvested 4 hours later, pelleted by centrifugation
for 15 min at 4 000 g using Sorvall Evolution RC Superspeed Centrifuge with the rotor SLC6000
(Kendro laboratories) and stored at – 80°C.
7.2.2. Extraction and purification
The cell pellet was thawed and resuspended in 30 ml of ice-cold lysis buffer containing 50 mM
NaH2PO4, 1 M Urea, 300 mM NaCl at pH 8.0 supplemented with 1 tablet of Complete Protease
Inhibitors and DNAse. Bacterial pellet was disrupted twice using a Microfluidizer M-110P (Mi-
crofluidics international, Newton, MA) at 10 000 psi. The lysates were centrifuged at 20 000 g
for 45 min. The lysis, sonication, and centrifugation steps were repeated. The resulting pellet
was suspended in 30 ml wash buffer containing 50 mM NaH2PO4 pH 8.0, 2 M Urea, 300 mM
NaCl. The lysates were centrifuged at 20 000 g for 45 min. The pellet wash step was repeated
twice.
Solubilization of inclusion bodies (IB) was carried out in 20 ml of solubilization buffer (10 mM
Tris-HCl, 6 M Urea, 100 mM NaH2PO4, 10% glycerol, 0.4 % SDS, 4 mM β-mercaptoethanol [pH
8.00]) overnight at room temperature on a rotating wheel. The solubilized sample was centrifuged
at 20 000 g for 45 min and the supernatant was collected.
The supernatant was incubated overnight at room temperature with 3 ml of Ni-NTA (Nickel-
nitrilotriacetic acid) superflow slurry equilibrated with solubilization buffer. The sample-resin
suspension was allowed to settle down into a 1 cm diameter empty column. The resin was
first washed with 30 ml of solubilization buffer and then with 30 ml of solubilization buffer
supplemented with 20 mM imidazole. The recombinant CCR5 fusions were eluted with 20 ml of
elution buffer (10 mM Tris-HCl, 6 M Urea, 100 mM NaH2PO4, 10% glycerol, 0.4 % SDS, 4 mM
β-mercaptoethanol and 500 mM imidazole [pH 8.00]). The eluted fractions were analyzed using
12% SDS-polyacrylamide gel and visualized by Coomassie blue staining.
Fractions containing CCR5 fusions were pooled and dialyzed overnight at room temperature using
a 12-14 kDa molecular weight cut-off membrane against 500 ml of 25 mM Tris-HCl, 150 mM
NaCl [pH 8.0]. Dialysis buffer was changed 4 times. After dialysis, the SDS concentration was
decreased enough to be compatible with thrombin cleavage. The protein sample was centrifuged.
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The optimal thrombin cleavage is achieved when the protein concentration is 0.3-0.5 mg/ml. 1
U of thrombin to 100 μg of protein was added to the protein sample and supplemented with 2.5
mM CaCl2. An optimized incubation time was determined. The reaction was stopped by adding
6 M Urea and 0.4% SDS and incubated for several hours.
The mixture was applied on the 3 ml of Ni-NTA (Nickel-nitrilotriacetic acid) superflow slurry
equilibrated with solubilization buffer and incubated overnight at room temperature. The
sample-resin suspension was allowed to settle down into a 1 cm diameter column. The resin
was washed with 30 ml of solubilization buffer. The recombinant CCR5 were eluted with 20 ml
of elution buffer (10 mM Tris-HCl, 6 M urea, 100 mM NaH2PO4, 10% glycerol, 0.4 % SDS, 4
mM β-mercaptoethanol and 500 mM imidazole [pH 8.00]). The eluted fractions were analyzed
using 12% SDS-polyacrylamide gel and visualized by Coomassie blue staining.
Fractions containing CCR5 were pooled and dialyzed overnight at room temperature using a
12-14 kDa molecular weight cut-off dialysis membrane (MWCO) against 50 mM Tris-HCl, 0.8 %
SDS [pH 8.0]. Dialysis buffer changed twice. At this stage the receptor sample is stable at room
temperature during several month.
7.2.3. Receptor folding in amphipols
It was observed that the receptor folding was working better when protein concentration was
0.3 - 0.5 mg/ml, therefore the receptor sample was diluted or concentrated accordingly. The
amphipols were prepared by dissolving their powder in H2O at final 100 mg/ml concentration.
The mix of lipids - asolectin was prepared at 10 mg/ml concentration in 50 mM Tris HCl, 0.8
%SDS [pH 8.0] buffer. The amphipols and lipids were added to the protein solution to reach a
protein:amphipol:lipid mass ration 1:5:1 for A8-35 and BAPol and 1:10:1 mass ration for NAPol
and were incubated at room temperature for one hour. Then SDS were precipitated by addition
of KCl to reach a final concentration equal to concentration of detergent with additional 150 mM
and was incubation for 30 min under vigorous stirring at room temperature. The formed KDS
crystals were removed by two centrifugations at 15 000 g for a 10 min, at room temperature.
Protein sample was dialyzed to remove residual dodecylsulphate against 100 times larger volume
of 30 mM Potassium phosphate (30 mM KH2PO4 + 30 mM K2HPO4), 150 KCl [pH 8.0] buffer.
7.3. Protein characterization methods
7.3.1. Transwell (Boyden Chamber) Cell Migration Assay
To study the characteristic movements of the cells along a chemical concentration gradient to-
wards the chemical stimulus, the Boyden chamber was used (Figure 7.1). It implies that cells
undergo directed motion in a chemokine gradient.
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The Boyden chamber is composed of two compartments separated by a filter membrane that cells
can easily pass through. The chemokines were located in the lower compartment and the cells
in the upper compartment. After an incubation, the amount of cells in the lower compartment
was determined.
Figure 7.1.: Schematic representation of Boyden/transwell chamber.
The human Jurkat T cell line was purchased from the American Type Culture Collection and
grown in RPMI 1640 medium (Invitrogen) supplemented with 10% fetal bovine serum (FBS)
at 37°C in 5% CO2. For the chemotaxis studies, Jurkat cells were stained with 5 mM calcein-
AM (Molecular Probes) in PBS - 1% BSA for 30 min at 37°C in 5% CO2. Stained cells were
washed twice with PBS buffer and resuspended at the density of 2 x 106 cells/ml in RPMI 1640
containing 20 mM HEPES and 1% human AB serum (Institut J. Boy, Reims). T cell migration
was evaluated using 5 μm pore polycarbonate filters in 96-well transwell chambers (Corning,
Sigma). 2 x 105 cells in 100 µl RPMI medium supplemented with 20 mM HEPES and 1%
human AB serum were added to the upper chamber of a transwell culture insert. The same
media (250 µl) with or without chemokine (range from 3 to 300 nM) were placed in the lower
chamber. Each condition was set up in triplicate. Chemotaxis proceeded for 3 hours at 37°C in
humidified air containing 5% CO2. Migration of calcein-stained cells through the filter to the
lower chamber wells was evaluated by fluorescence (485-525 nm) using a Victor fluorescent plate
reader (Perkin-Elmer).
7.3.2. Surface Plasmon Resonance (SPR) analysis
7.3.2.1. Materials
A Biacore 3000 machine, NTA Sensor Chip, SA Sensor Chip, CM4 Sensor chip, amine coupling
kit and HBS-N (10 mM Hepes, 150 mM NaCl [pH 7.4]) from GE-Healthcare were used. The 1D4
antibody (Anti-Rhodopsin, C-terminus, last 9 amino acids, clone Rho 1D4, Cat. Nr. MAB5356)
was purchased from Millipore.
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7.3.2.2. Immobilization of CCR5-His on NTA Sensor Chip
Experiments were performed using 30 mM KPhosphate, 150 mM KCl, 50 μM EDTA [pH 8.0] as
a running buffer and the flow rate was 5 μl/min.
For CCR5-His immobilization on NTA Sensor Chip receptor folded in A8-35/L, NAPol/L, and
BAPol/L was used. The two first flow cells (Fc1 and Fc2) of the NTA Sensor Chip, using extra
clean option, was washed with 5 μl injection of 175 mM EDTA and then with 5 μl injection of
10 mM NaOH, 200 mM NaCl solution. On the Fc2 Ni2+ was loaded by 5 μl injection of 30 mM
KPhosphate, 150 mM KCl, 500 μM NiCl2 buffer. The receptor was immobilized by several (two
or three) 20 μl injections or, for later experiments, by one 70 μl injection of CCR5/NAPol/L or
CCR5/BAPol/L, or CCR5/A8-35/L at 60 μg/ml concentration.
To reuse Ni-NTA surface, the coupled receptors were removed injecting 20 μl of running buffer
with 500 mM imidazole, followed by 10 μl injection of 25 mM EDTA, 50 mM Glycine NaOH,
0.15 % Triton X-100 [pH 12.0] buffer.
7.3.2.3. Chemokine interaction with the receptor on CCR5-His functionalized NTA Sensor
Chip
Firstly, chemokine interaction with receptor was tested at the flow rate of 20 μl/min by injecting
20 μl at 500 nM SDF1α-Strep or 500 nM RANTES-Strep.
For RANTES-Strep titration, a range of concentrations from 4 nM to 1000 nM was prepared
by 3 fold serial dilutions of 1 mM RANTES-Strep stock solution. RANTES-Strep titration
was performed at 20 μl/min flow rate injecting 20 μl of each RANTES-Strep concentration. The
injections were performed from the lowest to the highest concentration to minimize accumulation
of analyte on the receptor surface. No regeneration was done between analyte injections.
7.3.2.4. Immobilization of CCR5-His-C9 on CM4 Sensor Chip
Experiments were performed using HBS-N (10 mM HEPES, 150 mM NaCl [pH 7.4]) as a running
buffer and the flow rate was 5 μl/min.
7.3.2.4.1. 1D4 antibody pre-concentration test The 1D4 antibody (5 μg/ml) was prepared
in 10 mM Na Acetate buffer at pH 4.0, 4.5. 5.0 and 5.5. Then 5 μl of 1D4 antibody at each
buffer pH was injected onto the surface.
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7.3.2.4.2. 1D4 antibody immobilization on CM4 Sensor Chip The 1D4 antibody was im-
mobilized on a CM4 sensor chip using standard amine-coupling chemistry. The CM4 sensor
chip was activated by 50 μl injection of 0.2 M 1-ethyl-3-(3-diethylaminopropyl)-carbodiimide
(EDC)/0.05 M N-hydroxysuccinimide (NHS). The antibody was coupled on the surface with 35
μl injection of 1D4 antibody at 100 μg/ml concentration diluted in 10 mM Na Acetate [pH 4.5]
buffer. Remaining activated groups were blocked with 50 μl injection of 1 M Ethanolamine [pH
8.5].
7.3.2.4.3. CCR5-His-C9 capture The C9-tagged CCR5/NAPol/L was captured by 1D4 im-
mobilized on the surface of CM4 chip by 30 μl injection at 100 μg/ml concentration.
7.3.2.4.4. CCR5-His-C9 surface regeneration To remove the receptor from 1D4 surface the
buffer of 10 nM NaOH, 1% n-octyl-β-D-glucopyranoside was used.
7.3.2.5. Chemokine interaction with the receptor on CCR5-His-C9/1D4 functionalized
CM4 Sensor Chip
Experiments were performed using 50 mM HEPES, 150 mM NaCl [pH 7.0] as a running buffer
and the flow rate was 100 μl/min.
Chemokine RANTES-Strep and SDF1α-His were injected (90 μl) over the captured receptor at
200 nM concentration. The analyte injection was followed by a blank injection of buffer to
reference the surface. No regeneration was performed between analyte injections.
7.3.2.6. Immobilization of CCR5-His on SA Sensor Chip
For CCR5-His immobilization on SA Sensor Chip, receptor folded in BAPols/L was used. First,
the sensor chip was washed with 5 μl injection of 50 mM NaOH, 1M NaCl at the 5 μl/min flow
rate. On the Fc1, the reference surface, 55 μl of BAPol was injected at 60 μg/ml concentration.
On the Fc2 the 55 μl of CCR5/BAPol/L was injected at 60 μg/ml concentration.
7.3.2.7. Immobilization of RANTES-Strep on CM4 Sensor Chip
Experiments were performed using HBS-N (10 mM HEPES, 150 mM NaCl [pH 7.4]) as a running
buffer.
7.3.2.7.1. RANTES-Strep pre-concentration test The RANTES-Strep (7 μg/ml) was pre-
pared in 10 mM Na Acetate buffer at pH 4.0, 4.5. 5.0, 5.5 and 6.0. Then 5 μl of RANTES-Strep
in each buffer pH was injected at the flow rate of 5 μl/min.
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7.3.2.7.2. RANTES-Strep immobilization on CM4 Sensor Chip The RANTES-Strep was
immobilized on a CM4 sensor chip using standard amine-coupling chemistry. The CM4 sensor
chip was activated by 50 μl injection of 0.2 M EDC/0.05 M NHS mixture. The RANTES-Strep
was coupled to the surface with 35 μl injection of RANTES-Strep at 1.76 μg/ml concentration
diluted in 10 mM Na Acetate [pH 5.0] buffer. Remaining activated groups were blocked with 50
μl injection of 1 M Ethanolamine [pH 8.5]. The flow rate was 5 μl/min.
7.3.2.7.3. Chemokine interaction with amphipols Experiments were performed at 20 μl/min
and 100 μl/min flow rates. 10 μl of each amphipol (NAPol or A8-35) at 1.17 mg/ml and 0.234
mg/ml concentrations were injected over the captured RANTES-Strep. The surface was regen-
erated by 10 μl injection of 10 mM NaOH.
7.3.3. Electrospray mass spectrometry
Masses and purities of purified chemokines were confirmed using electrospray mass spectrometry.
Sample preparation Purified chemokines were prepared in 50 mM Tris, 150 mM NaCl [pH 8.0]
buffer. Two samples of each chemokine were prepared in volume of 10 μl at 200 μM concentration
and one sample additionally contained 100 mM of DTT. Then 10 μl of each protein sample were
diluted in 90 μl FA 0.1%; 100 μl of this dilution was desalted on line.
Methods All solvents were HPLC grade. HPLC (Agilent 1100 series) was coupled with elec-
trospray TOF mass spectrometer (Agilent, LC/MSD TOF). MacroTrap (Michrom) was used for
desalting with 0.03 % FA in water and for elution with 70 % solvent B (95% acetonitrile, 5%
water, 0.03 % FA).
7.4. Introduction to Lanthanoids1
Lanthanoid metals are elements from 57 to 71 in the periodic table of elements (Figure 7.2). They
are also called “Rare Earth” metals, not because of their rare natural abundance but because of
the difficulties encountered in their purification [353]. The informal chemical symbol Ln is used
in general discussions of lanthanoid chemistry.
1The current IUPAC recommendation is that the name lanthanoid be used rather than lanthanide, as the suffix
"-ide" is preferred for negative ions whereas the suffix "-oid" indicates similarity to one of the members of the
containing family of elements. However, lanthanide is still favored in most (90%) scientific articles.
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Figure 7.2.: Lanthanoid metals.
In our approach we used terbium to bind to Lanthanoid Binding Tag (see paragraph 9.2.1.1).
Many lanthanoid ions (including Tb3+) exhibit distinct luminescence emission spectra, due to
f − f electronic transitions (Figure 7.3).
Figure 7.3.: Emission spectrum of Tb3+ .
The origin of the peaks are highlighted in color.
Because f − f electronic dipole transitions are forbidden by parity rules (Laporte-forbiden), it
is much easier to excite Ln3+ ions via an organic fluorophore (Figure 7.4). First, an organic
fluorophore (in our case, the side-chain indole of tryptophan) is excited (A) by irradiation from
a source such as UV light, making an excited singlet. This singlet may release a photon and
fluoresce (B), or it may undergo intersystem-crossing and become an excited triplet. If the
triplet releases a photon, the process is known as phosphorescence (C), but it may instead
undergo another (non-radiative) exchange of energy with a nearby Tb3+ ion. The energy of
this now-excited Tb3+ may be lost by a non-radiative process, or the Tb3+ may luminesce (D),
giving rise to the spectrum in Figure 7.3. It should be noted that this process is formally known
as “luminescence”, and is referred as such throughout this work, because the ground state of
Tb3+ is not a singlet (having six unpaired f electrons) and therefore is neither fluorescence nor
phosphorescence.
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Figure 7.4.: Excitation of Tb3+ luminescence.
A. An organic fluorophore (the indole ring of tryptophan) is excited by UV light. B. The
excited state singlet may fluoresce. C. If the excited singlet undergoes intersystem crossing, the
excited triplet state may phosphoresce. D. Or, the energy may be transferred to the nearby
Tb3+ , which can luminesce.
The direct absorption of Ln3+ cations is very weak, and for this reason they have very low
molar absorption coefficients, which limits their practical use. In order to circumvent these low
extinction coefficients, the luminescent metal ion can be chelated to a chromophore-containing
group, which functions as an ’antenna,’ absorbing incident light, then transferring this excitation
to the metal ion, which can then deactivate by undergoing its typical luminescent emission (Figure
7.5).
Figure 7.5.: Antenna effect.
An illustration of the ’antenna’ effect, wherein incident excitation is first absorbed by a
chelating organic chromophore and then transferred to the metal.
While many lanthanoid ions are capable to luminesce, terbium is the only one that can be
sensitized by the side chain of the tryptophan. Although sensitizing Tb3+ via tryptophan at 280
nm is acceptable for most in vitro applications, such high-energy radiation would be damaging
to living cells.
Ubiquitin was the first protein with LT, for which the structure was determined (Figure 7.6)
[354].
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Figure 7.6.: LT tag bound terbium ions.
The side chains that chelate Tb3+ ion (dark green) are shown in clear green. Tryptophan
(shown in red) serve as antenna. The indole ring is excited at 280 nm, thereby sensitizing Tb3+
which emits at 544 nm. The structure was determined by NMR, the PDB code is 2OJR [354].
LT tagged proteins can be directly visualized in SDS polyacrylamide gels by UV illuminator
[352, 355]. The gel has to be soaked in buffer containing terbium prior to illumination with UV.
Lanthanoids and lanthanoid luminescence has an interesting application in the security measures
of banknotes. Luminescent europium chelates are responsible for the red color that shows up on
the Euro paper currency under UV light (Figure 7.7).
Figure 7.7.: The security measures on euro banknotes.
50 euro banknotes containing europium chelates that emit red luminescence under UV light.
7.4.1. Lanthanoid binding tag
Lanthanoid binding tags are short peptide sequences that tightly and selectively bind lanthanoid
ions and can sensitize terbium luminescence [352]. Increasing the number of bound lanthanoids
would improve the capabilities of these tags [352].
The similarity of trivalent lanthanoids to Ca2+ in ionic radius and oxophilicity has enabled their
direct incorporation into calcium-binding proteins. Using information about calcium-binding
loops, short polypeptides comprising 20 or fewer encoded amino acids that bind tightly and se-
lectively lanthanoids were designed, engineered and developed. Therefore, on the base of using a
structurally well-characterized single lanthanoid binding tag sequence, a double lanthanoid bind-
ing tag was designed. (Figure 7.8). It was shown that double lanthanoid binding tag improved
105
CHAPTER 7. METHODS
up to 3-fold luminescence intensity [352]. A lanthanoid binding sequence can be integrated as a
protein co-expression tag via molecular biology strategies.
Figure 7.8.: Double lanthanoid binding tag.
[352]
These tags have been used for many applications, such as luminescence-based visualization on gels
[355], as magnetic-field paramagnetic alignment agents in protein NMR experiments [356, 357],
in fluorescence microscopy [358], as partners in luminescence resonance energy transfer (LRET)
studies [359], and in the dissociation-enhanced lanthanoid fluorescent immunoassay (DELFIA)
technology for ligand screening assays [360].
7.4.1.1. Terbium titration
Titrations were recorded on Photon Technology International Quanta Master I fluorimeter using
1 cm path length quartz cuvette and slit widths of 2 and 4 nm. Tryptophan-sensitized Tb3+
luminescence was collected at room temperature by exciting the sample at 280 nm. The purified
SDF1α-LT-His protein (2 ml at 75 µM in Hepes 20 mM, NaCl 100 mM [pH 8.0]) was titrated by
adding ten 2 µl aliquots of 15 mM Tb3+. After each addition, the solution was mixed and the
fluorescence emission spectra was recorded between 450 and 550 nm.
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9. Chemokine production
This first part of the results will describe the engineering of various versions of two HIV co-
receptor ligands, RANTES (for CCR5) and SDF1α (for CXCR4). Those recombinant chemokines
constitute critical tools to assess the functionality of the folded receptor and later on will be
used to investigate receptor/ligand complex. The commercially available chemokines are very
expensive, therefore the production of recombinant chemokine receptors ligands was carried out
in E. coli. Choosing this way of chemokine production the advantage was taken to produce them
in a functionalized form bearing different tags for several purposes. Several modifications were
introduced including different tags such as Strep-Tag, His-Tag and Lanthanoid Binding Tag.
The Strep-Tag was introduced to form chemokine/receptor complex and to constitute affinity
chromatography. The Lanthanoid binding tag was introduced for luminescence experiments. In
order to set up a chemokine production strategy protocols already published in the literature
were examined. Two different approaches were considered.
The first method consisted in fusing the Maltose Binding Protein (MBP) to the N-terminal part
of the chemokines [361]. It has been shown that MBP fusion improves protein solubility, proper
folding, overall purification via affinity chromatography and protects against proteolysis [362,
363, 361]. In this article, DNA fragments encoding MBP, RANTES and SDF1α were amplified
by PCR and cloned into pET20b vector with a N-terminal hexahistidine tag for purification of
the recombinant proteins via immobilized metal affinity chromatography. The authors produced
MBP-RANTES and MBP-SDF1α chemokines in E. coli under variety of culture conditions. The
use of MBP-fusion for RANTES and SDF1α protein expression improved yields of soluble protein
under optimized culture conditions, using a relatively simple purification scheme. According to
the authors this MBP-fused chemokine strategy resulted in high-yield expression of functional
chemokines. It was stated that using a double fusion system comprising a His-tag and MBP-
fusion partner increased the purity of chemokines. Recombinant chemokine MBP-RANTES and
MBP-SDF1α binding activity to their receptor was confirmed by flow cytometry using EL-4 cells
expressing CCR5 and CXCR4 receptors on their surface [361].
The second approach consisted in chemokine production in E. coli inclusion bodies [364]. This
method requires cell lysis and inclusion body isolation followed by protein solubilization and
renaturation.
At the beginning of my PhD the first approach was looking more promising than the second one as
functional chemokines were directly produced, avoiding the delicate step of refolding. Besides,
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MBP fusion strategy was already reported to improve the expression of soluble recombinant
proteins in E. coli [365, 366, 367]. Moreover it was demonstrated that the purified MBP-fused
proteins were functional. Therefore, chemokines were first produced using this strategy.
9.1. Chemokines
9.2. MBP constructs
9.2.1. Molecular biology
The chemokine genes of RANTES, RANTES-LT and SDF1α were ordered as synthetic genes,
where all nucleotides were optimized for E. coli expression.
The frequency of usage of redundant codons differs in human and in bacteria. The disponibility
of the corresponding tRNA directly reflects this frequency. Therefore human genes that contain
some codons that are poorly used in E. coli may be inefficiently expressed. Rare codons can cause
premature termination of the synthesized protein or misincorporation of amino acids. Clusters
of rare codons stand a higher chance to create translation errors and reduce the expression level.
Working with synthetic genes solve this problem and codons that are more frequently used in E.
coli were introduced. Sequences of the constructs can be find in Annex 18 .
9.2.1.1. Features
Besides their optimized sequence each synthetic construct contained several features.
MBP Constructs contained a N-terminal fusion with the Maltose Binding Protein (MBP)
which is a fusion partner for better protein expression.
The Factor Xa cleavage site The Factor Xa cleavage (Xa) allowed the cleavage of the MBP
from the chemokine.
Strep tag The chemokine also had a C-terminal Strep tag (Strep), which facilitated the pu-
rification step and could allow the subsequent creation of an affinity column.
Thrombin cleavage site (T) Thrombin cleavage site allowed the cleavage of the Strep tag
from the purified chemokine.
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Lanthanoid binding tag (LT) Lanthanoid binding tags (LTs) are short polypeptide sequences
that were derived from calcium binding motifs [355]. These tags selectively bind lanthanoid ions
and can sensitize terbium (Tb3+) luminescence [352]. The size of the LT is minimal; therefore
the impact on the structure and function of the proteins to which they are fused should be
limited. A double lanthanoid binding tag was designed, which concatenates two lanthanoid
binding motifs. Comparing with other luminescent tags the lanthanoid binding to LT tag can
achieve up to 3-fold greater luminescence intensity [352]. The goal of this double lanthanoid
binding tag was to incorporate two Tb3+- binding sites within a contiguous sequence, potentially
conferring advantages in luminescence output, X-ray scattering power, and anisotropic magnetic
susceptibility, together with reduced mobility relative to the tagged protein due to the larger
mass [352].
The double lanthanoid binding tag (LT) was first introduced for RANTES construct and later on
added to SDF1α chemokine. The purpose of this tag in our case was to facilitate the tracking of
the chemokine by luminescence [355] and also, in the future, it could be used for a chemokine/co-
receptor complex structure solving [368] as well as for a time-resolved FRET strategy in cell lines
[369].
9.2.1.2. Cloning
The pMAL-c4X vector was chosen for the MBP fusion cloning for cytoplasmic protein expression.
The malE gene on pMAL-c4X vector has a deletion of the signal sequence, leading to cytoplasmic
expression of the fusion protein.
Figure 9.1.: Schematic representation of MBP-chemokine constructs.
The synthetic chemokine genes cloned into pMAL-c4X vector are schematized in Figure 9.1.
The final constructs contained a N-terminal MBP fusion followed by the Factor Xa site, which
enables the subsequent cleavage of the fusion protein. Constructs contained a C-terminal Strep
tag, which is cleavable by thrombin. One RANTES construct comprised an additional double
Lanthanoid binding Tag (LT).
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9.2.2. Expression
First of all, to determine the best expression conditions, small-scale expression tests were carried
out. The expression of the constructs MBP-Xa-SDF1α-Strep, MBP-Xa-RANTES-Strep and
MBP-Xa-RANTES-LT-Strep were performed. Expression, induced by IPTG addition (1 mM)
was tested at two different temperatures at 37°C for 4 hours and 20°C for overnight growth.
Three different growth medias were tested: LB, TB and auto-induction. Comparison of the
results (Figure 9.2) indicated that expression was similar in LB and TB media while very poor
in auto-induction media. In regards to the temperatures, MBP-Xa-SDF1α-Strep was similarly
poorly expressed in either conditions while MBP-Xa-RANTES-Strep expression was improved
at 20°C.
It was surprising to see that MBP-Xa-RANTES-LT-Strep was better expressed than the one
without the LT tag with the same tendency – better expression at 20°C.
(a) MBP-Xa-SDF1α-Strep (b) MBP-Xa-RANTES-Strep (c) MBP-Xa-RANTES-LT-Strep
Figure 9.2.: SDS-polyacrylamide gels showing expression of MBP-chemokine constructs.
(a) MBP-Xa-SDF1α-Strep (b) MBP-Xa-RANTES-Strep and (c) MBP-Xa-RANTES-LT-Strep
expression in different conditions. M - marker, T0 - sample before induction; LB - LB medium,
TB - TB medium, A - auto-induction medium indicates the culture medium ; 37°C and 20°C
indicates at which temperature cultures were grown after induction.
The next step consisted in examining the amount of soluble protein. Two constructs MBP-Xa-
RANTES-Strep and MBP-Xa-RANTES-LT-Strep grown in LB, medium at 20°C overnight were
compared. The bacterial cultures were harvested (sample corresponding to “total extract”) and
centrifuged. Bacterial pellets were resuspended in lysis buffer and sonicated. After ultracentrifu-
gation the supernatant containing the soluble proteins (supernatant) was separated from the
pellet, where cell membrane and inclusion bodies remained (pellet) (Figure 9.3).
The presence of the LT tag clearly enhanced the solubility of the protein since the MBP-Xa-
RANTES-Strep mostly remained in the pellet fraction while the MBP-Xa-RANTES-LT-Strep
was mostly soluble (Figure 9.3 b).
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(a) MBP-Xa-RANTES-Strep (b) MBP-Xa-RANTES-LT-Strep
Figure 9.3.: SDS-polyacrylamide gels representing solubility test of RANTES with and without
LT tag.
M - marker, T – total extract, S – supernatant, P –pellet.
Therefore, cultures for MBP chemokine fusion expression were carried out in conditions that
allowed soluble protein expression: in LB medium supplied with the relevant antibiotic, induced
with 1 mM of IPTG and incubated at 20°C overnight.
9.2.3. Purification
The purification was first attempted with MBP-Xa-RANTES-LT-Strep construct, which in the
small-scale expression test was better expressed, and where larger proportion of protein was
obtained in the soluble fraction. All the purifications described were performed form one liter of
bacterial culture.
9.2.3.1. MBP-Xa-RANTES-LT-Strep
A first step of the MBP-Xa-RANTES-LT-Strep chemokine purification was carried out on a
Strep-Trap column (Figure 9.4). The soluble fraction of the protein was applied to the column
equilibrated in the protein buffer.
Figure 9.4.: SDS-polyacrylamide gel showing MBP-Xa-RANTES-LT-Strep purification on Strep-
Trap column.
M - marker, FT - flow-through fractions, Elution - elution fractions from the Strep-Trap
column.
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The flow-through (FT) fraction still contained a lot of protein demonstrating that the column was
saturated. Protein was eluted from the column with a buffer containing desthiobiotin. Elution
fractions containing the MBP-Xa-RANTES-LT-Strep protein were pooled together, dialyzed and
Factor Xa digestion was performed to cleave off the MBP protein from the chemokine (Figure
9.5).
Figure 9.5.: SDS-polyacrylamide gel and Western blot showing MBP-Xa-RANTES-LT-Strep
Factor Xa digestion.
M – marker; T0 – non-digested protein; T3 – protein after 3 hours of digestion.
Digestion of MBP-Xa-RANTES-LT-Strep by Factor Xa analyzed on SDS-polyacrylamide gel re-
vealed three distinct bands that could correspond to RANTES-LT (Figure 9.5). The N-terminal
sequencing analysis of the 3 bands confirmed that the two upper bands started with the expected
amino acid sequence: ISEFS, while the lower band N-terminal sequence was AHIK which corre-
sponds to the sequence from RANTES 22nd amino acid. Western blotting using a Strep-Tactin
HRP indicated that the upper and the lower bands contained the Strep tag. Even though the
middle band was confirmed by the N-terminal sequencing having an expected amino sequence,
the C-terminus lacked the Strep tag and was not revealed by the Western blot. Therefore, we
can conclude that only the upper band corresponded to the full length RANTES-LT and that
there were two other Factor Xa cleavage sites resulting in two additional bands. Thus Factor Xa
was not optimal for the MBP cleavage and another cleavage site was required.
PreScission protease was directly tested on MBP-Xa-RANTES-LT-Strep construct in order to
determine if it could led to a non-specific cleavage (Figure 9.6).
Figure 9.6.: SDS-polyacrylamide gel showing MBP-Xa-RANTES-LT-Strep digestion test with
PreScission protease.
M - marker, T0 - non-digested sample, T1-4 - sample after 1, 2, 3, 4 hours digestion, o/n -
sample after overnight digestion.
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No non-specific cleavage was observed, therefore, Factor Xa cleavage site was replaced by PreScis-
sion protease site (PrePro) by site direct mutagenesis in all constructs resulting in MBP-PrePro-
RANTES-LT-Strep, MBP-PrePro-RANTES-Strep and MBP-PrePro-SDF1α-Strep.
9.2.3.2. MBP-PrePro-RANTES-LT-Strep Purification
The MBP-PrePro-RANTES-LT-Strep chemokine was expressed following the previously men-
tioned protocol. The amount of the expressed protein was examined on SDS-polyacrylamide gel
(Figure 9.7).
Figure 9.7.: SDS-polyacrylamide gel representing MBP-PrePro-RANTES-LT-Strep solubility
test.
M - marker, T – total extract, S – supernatant, P –pellet, the arrow indicates the expected
position of the protein.
Changing Factor Xa cleavage site to PreScission protease cleavage site improved the overall
protein solubility. Almost all expressed protein was soluble while the previous construct led to
a 50/50 soluble/insoluble protein ratio (Figure 9.3).
As before a first step of MBP-PrePro-RANTES-LT-Strep purification was carried out on a Strep-
Trap column (Figure 9.8a). Expression of the protein was so strong that the flow-through and
wash fractions contained quite a lot of protein. The used column was clearly saturated.
(a) (b)
Figure 9.8.: SDS-polyacrylamide gel representing MBP-PrePro-RANTES-LT-Strep purification.
(a) MBP-PrePro-RANTES-LT-Strep purification on Strep-Trap column. M - Marker, IN -
input sample, FT - flow-through sample, Wash - wash fractions, Elution - elution fractions from
the Strep-Trap column. (b) Purified MBP-PrePro-RANTES-LT-Strep digestion with
PreScission protease. T0 - non-digested sample, T1 - sample after 1 hour of digestion, o/n -
sample after overnight digestion with PreScission protease.
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The specificity of the PreScission protease digestion was verified on a small fraction of purified
MBP-PrePro-RANTES-LT-Strep (Figure 9.8b). After analyzing results on a SDS-polyacrylamide
gel the PreScission protease digestion was performed on the whole preparation. The PreScis-
sion protease contained a GST tag therefore it was removed by applying the whole digested
sample was applied to a GST resin: the cleaved MBP, chemokine and the non-cleaved protein
were collected in the flow-through fraction while the PreScission protease was retained by the
GST resin. With the next step, the non-digested protein and the MBP were removed by using
an amylose column. The MBP binds to the amylose resin: including the non-digested sample
(MBP-RANTES-LT-Strep) and the cleaved MBP, while the cleaved chemokine was collected in
the flow through fractions (Figure 9.9).
Figure 9.9.: SDS-polyacrylamide gel representing the RANTES-LT-Strep purification after di-
gestion with PreScission protease.
M - marker, 1 - non-digested sample, 2 - MBP-PrePro-RANTES-LT-Strep after overnight
digestion with PreScission protease, 3, 4, 5 - flow through fractions from GST column, 6, 7, 8, 9
- elution fractions from amylose column.
As the flow through fractions still contained a big amount of the MBP they were reloaded one
more time on the amylose column, to remove MBP contamination. RANTES-LT-Strep was
further purified by gel filtration column to characterize the oligomeric status of the protein
(Figure 9.10).
(a) (b)
Figure 9.10.: RANTES-LT-Strep elution profile on Superdex 200 column.
(a) RANTES-LT-Strep elution from Superdex 200 column, (b) SDS-polyacrylamide gel
representing 22-29 fractions from Superdex 200 column. M - marker.
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The gel filtration Superdex 200 column elution profile indicated that RANTES-LT-Strep elutes
with different oligomeric states: probably corresponding to monomers, dimers and mostly higher
oligomers (Figure 9.10).
At the end of the purification we obtained about 2.5 mg of dimer-monomer protein per one
liter of bacterial culture. The presence of two disulphide bridges, required for proper protein
folding was confirmed by Mass Spectroscopy analysis. The protein was analyzed in oxidized and
reduced conditions (in the presence of DTT). A 4 Da mass increase (from 13820 Da to 13824
Da) confirmed the presence of the two awaited disulphide bridges for these chemokines (Figure
9.11).
(a) (b)
Figure 9.11.: MALDI Spectrum of RANTES-LT-Strep.
(a) RANTES-LT-Strep sample corresponds to the 13820 Da mass, (b) RANTES-LT-Strep
sample with DTT was reduced and a 4 Da increase (13824 Da) confirmed the presence of two
disulfide bridges.
We wanted to characterize RANTES oligomerization and to examine if the produced RANTES
behaves similarly as it was previously described [370]. It was stated that at high protein con-
centration (1-10 μM) and low salt - 0.15 M sodium chloride concentration RANTES behaves
as a high molecular mass aggregate (100-200 kDa). The aggregation is reversible and protein
dilution as well as the presence of high sodium chloride concentration (0.5 M) reduce aggregation
of RANTES. Thus, in the presence of 0.5 M sodium chloride and at the same 1-10 μM protein
concentration, RANTES is a dimer.
Different protein concentrations (0,7 mg/ml and 1,4 mg/ml) and two salt concentrations (0.150 M
and 0.5 M of NaCl) were used to determine the influence of those two parameters on the oligomeric
state of RANTES-LT-Strep. The gel filtration elution profiles of those different conditions are
represented in Figure 9.12. In either case of low protein and low salt concentration or high protein
and high salt concentration RANTES-LT-Strep had a tendency to oligomerize or aggregate. Just
a small fraction of protein is in the dimer-monomer equilibrium fraction (Figure 9.12 A and B).
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In the presence of high salt concentration and low protein concentration the amount of oligomers
decreased and the dimer-monomer fraction increased (Figure 9.12 C).
Figure 9.12.: RANTES-LT-Strep oligomerization states monitored in gel filtration column.
A Superdex 200 column was used for all elution (a) RANTES-LT-Strep at 0.7 mg/ml
concentration elution profile in buffer containing 0.15 M NaCl. (b) RANTES-LT-Strep at 1.4
mg/ml concentration elution profile in buffer containing 0.5 M NaCl. (c) RANTES-LT-Strep at
0.7 mg/ml concentration elution profile in buffer containing 0.5 M NaCl.
To shift RANTES-LT-Strep towards dimer/monomer fractions an increase of salt concentration
was not enough as it was previously stated [370], in our case the protein concentration had to
be decreased as well.
9.2.3.3. MBP-PrePro-RANTES-Strep Purification
MBP-PrePro-RANTES-Strep was expressed and purified following the same strategy as MBP-
PrePro-RANTES-LT-Strep. Briefly the soluble fraction from one liter of bacterial culture was
applied to a Strep-Trap column. The elution fractions were pooled together and digested with
PreScission protease overnight. Unfortunately, removal of the MBP fusion led to total precipi-
tation of the protein.
9.2.3.4. MBP-PrePro-SDF1α-Strep Purification
MBP-PrePro-SDF1α-Strep was expressed and purified following the same strategy as MBP-
PrePro-RANTES-LT-Strep. Briefly the soluble fraction from one liter of bacterial culture was
applied to a Strep-Trap column. The elution fractions pooled together and digested with PreScis-
sion protease overnight. Once again, the digestion was complete but led to protein precipitation.
It was surprising and obvious from those experiments that besides enhancing the protein expres-
sion and the solubility of the fusion proteins, the LT tag was necessary to maintain the chemokine
soluble after MBP cleavage. Therefore, the LT tag was added to the SDF1α construct by PCR
resulting in MBP-PrePro-SDF1α-LT-Strep construct.
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9.2.3.5. MBP-PrePro-SDF1α-LT-Strep Purification
MBP-PrePro-SDF1α-LT-Strep was expressed and purified following the same strategy as MBP-
PrePro-RANTES-LT-Strep chemokine. A first step of purification was performed on a Strep
Tactin column. Elution fractions containing the fusion protein were pooled and PreScission
protease digestion was carried out (Figure 9.13).
Figure 9.13.: MBP-PrePro-SDF1α-LT-Strep digestion with PreScission protease.
M - marker, T0 - non-digested MBP-PrePro-SDF1α-LT-Strep, o/n - protein after overnight
digestion.
As described earlier, the digested sample was applied to the GST column to eliminate the GST
tagged PreScission protease. The flow through from the GST column, containing SDF1α-LT-
Strep, MBP and uncleaved proteins was applied to the amylose column where MBP and its
fusions were retained while the chemokine was collected in the flow through fraction. The flow
through from the amylose column was concentrated and applied to a Gel Filtration Superdex
200 column (Figure 9.14).
(a) (b)
Figure 9.14.: Purification of SDF1α-LT-Strep on Superdex 200 column.
(a) SDF1α-LT-Strep elution profile from Superdex 200 column. (b) SDS-polyacrylamide gel
corresponding to the underlined fractions from the Superdex 200 column. M - Marker, IN -
input sample to the Superdex 200 column, 10-35 - elution fraction numbers, the arrow indicates
SDF1α-LT-Strep.
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The SDF1α-LT-Strep fractions corresponding to the first peak were pooled and concentrated. At
the end of the purification we obtained 0.104 mg of SDF1α-LT-Strep from one liter of bacterial
culture.
The presence of two disulphide bridges, required for proper protein folding was confirmed by
Mass Spectroscopy analysis. The protein was analyzed in oxidized and reduced conditions (in
the presence of DTT). A 4 Da mass increase (from 13933 Da to 13937 Da) confirmed the presence
of the two awaited disulphide bridges for these chemokines.
9.2.4. Functional assays
9.2.4.1. Chemotaxis
Chemotaxis assays were performed in collaboration with Rabia Sadir (IBS, Grenoble).
In order to finally validate the functionality of our produced chemokines we examined the chemo-
tactic activity of purified SDF1α chemokines and therefore chemotaxis assay was performed. The
experiment was carried out using the Boyden chamber-based cell migration assay: a chamber of
two medium-filled compartments separated by a microporous membrane. Cells were placed in
the upper compartment and were allowed to migrate through the pores of the membrane into the
lower compartment, in which chemotactic agents were present. After an appropriate incubation
time, the number of cells that have migrated to the lower side of the membrane were determined.
Human Jurkat T cells expressing CXCR4 receptors on their surface were used.
As a control for this experiment we used a sample of SDF1α that Rabia Sadir was already
using in her experiments (prepared from E. coli inclusion bodies) and the functionality of this
chemokine was confirmed. Chemokine was added at different concentrations 0,3 nM; 3 nM; 30
nM; 100 nM and 300 nM. The control SDF1α induced chemotaxis of cells with a typically bimodal
concentration dependence dose response curve. The maximal response of the cells was obtained
for the control SDF1α chemokine at the concentration of 3 nM (Figure 9.15).
Figure 9.15.: Chemokine induced cell migration.
Control experiment. Mean numbers of migrated cells in triplicate wells are represented.
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Two proteins were tested in this assay: the non cleaved MBP-SDF1α-LT and after the SDF1α-LT
purified after MBP cleavage (Figure 9.16).
(a) (b)
Figure 9.16.: Chemotaxis assay of MBP-SDF1α-LT and SDF1α-LT.
Mean numbers of migrated cells in triplicate wells are represented.
Unfortunately neither MBP-SDF1α-LT nor SDF1α-LT induced cell migration (Figure 9.16). They
had no effect on cell migration within the tested concentration range.
As awaited and contrary to what was published [361] it appears that chemokines that still
contained the MBP fusion were not functional in a chemotaxis assay. As expected the MBP-
SDF1α-LT was not active, since the N-terminal of chemokines are known to be involved in the
interaction with the receptor. Although after MBP cleavage we expected to have a functional
chemokine. The disulphide bridge formation is not a conclusive proof of a correct folding; it is
necessary but not sufficient. Therefore, it was unexpected to see that SDF1α-LT did not induced
cell migration. At the time being the cells used for this chemotaxis assay were expressing only
the CXCR4 receptor and for that reason we could not test the functionality of the produced
RANTES.
The chemokine production strategy then was changed towards the inclusion body approach.
9.3. Expression in E. coli inclusion bodies
9.3.1. Molecular biology
The previous experiments indicated that the addition of the lanthanoid binding tag increased the
protein expression and solubility. Thus, for the expression in E. coli inclusion bodies chemokines
were prepared with and without the LT tag.
New constructs of chemokines were prepared by PCR. The synthetic genes encoding SDF1α
and RANTES were cloned into the pET-20b expression vectors. Various constructs of each
chemokines were designed for various purposes. On the C-terminal, SDF1α contained either a
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Hexahistidine Tag or a Strep-Tag. In another project developed in the group, we had observed
that the Strep-Tag could some how reduce the yield of production of another protein that re-
quired refolding. Therefore, for the chemokine production from the inclusion bodies additional
constructs were designed with a C-terminal His-tag. The two constructs were designed in two
versions with and without the LT tag, resulting in 4 constructs: SDF1α-His, SDF1α-LT-His,
SDF1α-Strep, SDF1α-LT-Strep. For RANTES three constructs were created, RANTES-Strep,
RANTES-LT-Strep and RANTES without of any tag. Those seven versions of chemokines are
schematically represented in Figure 9.17.
Figure 9.17.: Schematic representation of chemokine constructs for the expression in E. coli in-
clusion bodies.
The first constructs that were prepared were SDF1α-His and SDF1α-LT-His. Once the protocols
for the expression and purification were set up, the correct refolding was confirmed and chemo-
taxis assay showed that the produced chemokines were functional, only then, we carried out with
the remaining constructs.
9.3.2. Chemokine expression
The expression of the chemokines was attempted via expression in E. coli inclusion bodies [364].
The BL21 (DE3) competent bacteria cells were transformed with various plasmids. The protein
expression was carried out in one liter of LB medium with appropriate antibiotic at 37°C. When
the culture OD600 nm reached 0.6-0.8, cultures were induced with 1 mM of IPTG for SDF1α-
His and SDF1α-LT-His or 0.5 mM of IPTG for the other constructs. Bacterial culture for the
constructs without the LT tag were harvested after 3 hours growth at 37°C. Culture of the
constructs with the LT tag were harvested after overnight growth (16 h) at 20°C. Bacterial
pellets were resuspended in lysis buffer and lysed with a microfluidizer.
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After ultracentrifugation the supernatant containing the soluble proteins (supernatant) were
separated from the pellet, where the inclusion bodies remained (pellet) (Figure 9.18).
Figure 9.18.: SDS-polyacrylamide gel showing SDF1α-His and SDF1α-LT-His expression in E.
coli inclusion bodies.
M - marker, T – total extract, S – supernatant, P –pellet.
Once again it was observed that addition of the Lanthanoid binding tag tremendously increased
the amount of expressed proteins as well as their solubility.
9.3.3. SDF1α-His and SDF1α-LT-His purification
To solubilize inclusion bodies two conditions were tested for each construct: 7.5 M Guanidine
Hydrochloride (GuHCl) and 6 M Urea. The inclusion bodies of the SDF1α-His were solubilized
only in the presence of 7.5 M GuHCl and nothing was solubilized in the presence of 6 M Urea.
While for the SDF1α-LT-His, the inclusion bodies were solubilized by 6 M Urea but not by 7.5 M
GuHCl (Figure 9.19). Refolding took place overnight at 4°C in 50 mM Tris-HCl pH 8.0 buffer.
(a) (b)
Figure 9.19.: SDS-polyacrylamide gel showing solubilized inclusion bodies.
(a) SDF1α-His solubilized in 7.5 M GuHCl, (b) SDF1α-LT-His solubilized in 6 M Urea. M -
marker.
Chemokines have very basic pI, (9.75 for SDF1α-His) (Figure 9.17) and could therefore be pu-
rified over a cation exchange column. The addition of the Lanthanoid binding tag changed this
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chemokine property, the pI of the SDF1α-LT-His is 6.43. Therefore, the SDF1α-LT-His could be
purified on the anion exchange column. After refolding, SDF1α-His was applied to a Capto S
column and SDF1α-LT-His was therefore purified over a Q Sepharose column (Figure 9.20).
(a) SDF1α-His (b) SDF1α-LT-His
Figure 9.20.: Cation (a) and Anion (b) - exchange chromatography.
Fractions identified by the red line were analyzed on a SDS-polyacrylamide gel. M - marker
Fractions containing chemokines were pooled and concentrated prior injection to a Gel Filtration
Superdex 200 column (Figure 9.21).
(a) (b)
Figure 9.21.: Gel Filtration elution profiles of SDF1α-His and SDF1α-LT-His.
(a) SDF1α-His elution profile from Superdex 200 column. The protein samples from the main
peak were pooled and concentrated. The SDS-polyacrylamide gel indicates the purified
SDF1α-His. (b) SDF1α-LT-His elution profile from Superdex 200 column. The protein samples
from the peak were pooled and concentrated. The SDS-polyacrylamide gel indicates the
purified SDF1α-LT-His. M - marker, the red line indicate protein fractions which were pooled
and concentrated.
From one liter of bacterial culture 7.8 mg of pure SDF1α-His and 3 mg of pure SDF1α-LT-His
were obtained. The presence of two disulphide bridges, required for proper protein folding was
confirmed by Mass Spectroscopy analysis. The protein was analyzed in reducing (in the presence
of DTT) and non-reducing conditions. A 4 Da mass increase for SDF1α-His from 9160 Da to 9156
Da and for SDF1α-LT-His from 13023 to 13027 Da confirmed the presence of the two expected
disulphide bridges characteristic for these chemokines.
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9.3.4. SDF1α-Strep and SDF1α-LT-Strep purification
SDF1α-Strep and SDF1α-LT-Strep were purified form inclusion bodies using the strategy used
for SDF1α-His and SDF1α-LT-His. Details of purifications could be found in the Annex 15.1.
(a) (b)
Figure 9.22.: SDS-polyacrylamide gel showing purified SDF1α-Strep and SDF1α-LT-Strep.
(a) Sample of purified SDF1α-Strep. (b) Sample of purified SDF1α-LT-Strep.
The details of purification are placed in Annex 15.1. From one liter of bacterial culture 0.2 mg
of SDF1α-STREP and 3.2 mg of SDF1α-LT-Strep were obtained (Figure 9.22).
9.3.5. RANTES-Strep purification
Due to the known RANTES tendency to oligomerize the purification protocol used for SDF1α-
His was not optimal and was further improved by referring to some published protocol [371].
Inclusion bodies containing RANTES-Strep were solubilized in 6 M GuHCl, incubated for 30
minutes at 60°C and dialyzed against 1% acetic acid. Due to its very basic pI (9.00) and its
particular biochemistry RANTES-Strep resists to the harsh purification conditions while most of
other proteins precipitate. The protein sample was then centrifuged and diluted up to 1 mg/ml
final concentration in 50 mM Tris-HCl pH 8.0, 6 M GuHCl , 1 mM DTT buffer. Protein was
refolded overnight at 4°C in 20 mM Tris-HCl pH 8.8, 0.01 mM oxidized glutathione, 0.1 mM
reduced glutathione buffer. The refolded sample was centrifuged, the pH was adjusted to 4.5
and the protein was applied to a Capto S column (Figure 9.23a).
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(a) (b)
Figure 9.23.: RANTES-Strep purification on Capto S column.
(a) RANTES-Strep loading (first 50 ml) and elution from Capto S column, (b) Elution
fractions form both peaks were analyzed on a SDS-polyacrylamide gel. Fractions identified by
the green line on the chromatogram correspond to the indicated RANTES-Strep on the
SDS-polyacrylamide gel.
Elution fractions were analyzed on SDS-polyacrylamide gel (Figure 9.23b) which revealed that
RANTES-Strep was eluted in the second pick of the Capto S column. Fractions containing the
chemokine were pooled and concentrated prior injection to a Superdex 200 Gel Filtration column
(Figure 9.24).
Figure 9.24.: RANTES-Strep elution profile from the Superdex 200 column.
Elution pics were analyzed on a SDS-polyacrylamide gel. The fractions identified by the red
line on the chromatogram corresponds to the indicated RANTES-Strep in the
SDS-polyacrylamide gel.
The purest fractions containing RANTES-Strep were pooled and concentrated. From one liter
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of bacterial culture 0.2 mg of RANTES-Strep were obtained (Figure 9.25).
Figure 9.25.: SDS-polyacrylamide gel of purified RANTES-Strep.
9.3.6. RANTES purification
RANTES purification protocol was carried out as previously described for RANTES-Strep. From
one liter of bacterial culture 0.22 mg of RANTES were obtained (Figure 9.26).
Figure 9.26.: SDS-polyacrylamide gel of purified RANTES.
9.3.7. RANTES-LT-Strep purification
RANTES-LT-Strep was purified as previously described SDF1α-LT-His. Inclusion bodies con-
taining RANTES-LT-Strep were solubilized in 6M Urea and protein was refolded overnight at
4°C by a drop wise dilution in 20 mM Tris-HCl pH 8.8, 0.01 mM oxidized glutathione, 0.1 mM
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reduced glutathione buffer. The refolded sample was centrifuged and applied to a Q Sepharose
column (Figure 9.27a).
(a) Q Sepharose column (b) Superdex 200 column
Figure 9.27.: RANTES-LT-Strep purification on Q Sepharose (a) and Superdex 200 (b) columns.
Fractions identified by the red line were analyzed on a SDS-polyacrylamide gel. M - marker.
Elution fractions from Q Sepharose column containing the protein were pooled and centrifuged
prior injection to the Superdex 200 column. RANTES-LT-Strep eluted as oligomers (Figure
9.27b), fraction containing containing RANTES-LT-Strep were pooled and concentrated. From
one liter of bacterial culture 6.5 mg of RANTES-LT-Strep were obtained.
All purified chemokines are summarized in the Figure 9.28.
Figure 9.28.: SDS-polyacrylamide gel representing all purified chemokine constructs.
M - marker (kDa), * - mg/per liter of culture.
All prepared chemokine constructs were purified although not all of them were obtained in
similar quantities. Comparing the C-terminal tags of SDF1α it is clear that the refolding was
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working far better for His-tagged chemokines than for Strep-Tagged ones. The LT tag enable
a big improvement only for the Strep-Tagged constructs while it did not enhance so much His-
tagged constructs. For RANTES purification the LT tag allowed a tremendous (more than 30
times) improvement. The yield of RANTES and RANTES-Strep were very similar. RANTES
purification has just been produced once, contrary to the other chemokine construct productions
that were always obtained in similar amounts.
9.4. Chemotaxis
In order to examine the chemotactic activity of the purified chemokines a chemotaxis assay
was performed. The experiment was performed using the Boyden chamber-based cell migra-
tion assay. As before, a control SDF1α from Rabia Sadir was used. The functionality of this
control chemokine was first assessed (SDF1α-WT). As before, the chemokine was added at dif-
ferent concentrations ranging from 0.3 nM to 300 nM. Our “home made” chemokines SDF1α-His,
SDF1α-LT-His, SDF1α-Strep, SDF1α-LT-Strep, RANTES-Strep and RANTES-LT-Strep were
tested using the same concentration range from 0.3 nM to 300 nM (Figure 9.29).
Figure 9.29.: Chemotaxis assay of chemokines.
SDF1α-WT is a control experiment (green histograms). Mean numbers of migrated cells in
triplicate wells are represented.
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From this chemotaxis assays we can conclude that recombinant SDF1α-His, SDF1α-Strep and
RANTES-Strep chemokines are functional. The control SDF1α-WT and our “home made”
SDF1α-His induced chemotaxis of cells with a typically bimodal concentration dependence dose
response curve. Similar effect could be observed for the SDF1α-Strep. Surprisingly the SDF1α-
LT-His showed decreased activity but still followed the same typical bimodal concentration de-
pendence dose response curve. Though, it is hard to conclude if the slight activity of SDF1α-LT-
Strep at 30 nM concentration is significant. For some reason the SDF1α-LT-His showed some
activity while it is doubtful in the case of SDF1α-LT-Strep. RANTES-Strep induced cell migra-
tion but with a lower sensitivity than SDF1α, as the maximal responses of the cells were obtained
at 3 nM and 30 nM concentration, respectively. From the obtained results it is quite clear that
RANTES-LT-Strep was not active in this chemotaxis assay.
9.5. Luminescence titration
For terbium titration 2 ml of SDF1α-LT-His chemokine at 75 μM concentration were used.
Terbium luminescence was enhanced when metal-protein complex was excited at 280 nm. The
indole ring of the Trp present in the Lanthanoid binding tag serves as an antenna for the ter-
bium which then emits at 490 nm and 542 nm. The LT was developed to exclude water from
the lanthanide coordination sphere, since coordinated water molecules cause excited terbium to
undergo rapid, non-radiative energy transfer to the vibrational states of the water O-H bonds,
leading to a decrease in the luminescence intensity and lifetime. When terbium is in buffer (in
aqueous environment) the coordination of water leads to non-radiative decay of the lanthanide
excited state. Therefore no sharp picks are observed (Figure 9.30 blue graph). Upon peptide
binding (LT) to the terbium the water from the inner coordination sphere was excluded and
terbium was chelated. When terbium is bound to the protein, long luminescence lifetimes and
very sharp emission bands of the complexes were observed (Figure 9.30 red graph).
First the smallest concentration detectable in buffer of terbium was determined: a 2 μM concen-
tration was the smallest terbium concentration detectable (Figure 9.30 blue graph). Then the
same concentration of terbium was added to the protein solution (Figure 9.30 red graph). the
tremendous increase of the 2 emission peaks clearly indicate that the terbium is bound to the
LT.
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Figure 9.30.: Tryptophane-sensitized Tb3+ luminescence emission spectra of buffer and SDF1α-
LT-His during 2 μM terbium.
Blue graph - Tb3+ in the presence of buffer, red graph - Tb3+ in the presence of SDF1α-LT-His.
The terbium binding to the LT was assessed via direct luminescence titration (Figure 9.31).
Figure 9.31.: Tryptophane-sensitized Tb3+ luminescence emission spectra of SDF1α-LT-His in
the presence of terbium titration.
Titration performed on SDF1α-LT-His (monomer) using increasing concentrations, ranging from
15 μM to 150 μM, of terbium indicated an increase of luminescence at 490 nm and 542 nm. Those
results indicated that the Lanthanoid binding tag is well structured and thus functional, since it
can bind terbium.
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Figure 9.32.: Luminescence at 490 nm and 542 nm as a function of terbium concentration.
In order to determine at what terbium concentration both binding sites in the LT tag were fully
occupied the luminescence values from two wavelengths (of each major pick) were plotted (Figure
9.32). That graphic indicated that saturation of the double Lanthanoid binding tag is achieved
with two equivalents of terbium per protein as expected.
9.6. Development of an electrophysiology test of chemokine
triggered signal transduction
It is known that modifications of the N-terminal chemokine part drastically affect interaction with
their receptor. Nothing has been reported so far for C-terminal modifications. To characterize
receptor binding and signal transduction triggered by our recombinant chemokines we used the
approach set up by C. Moreau and M. Vivaudou (IBS, Grenoble).
Their strategy consists in the expression of the receptor in Xenopus oocytes (eukaryotic system)
by relatively simple mRNA transfection. Using the Two-Electrode Voltage Clamp method, the
ligand binding to the chemokine receptor triggers it activation and the subsequent activation of G
proteins that would affect ion channel gating. Real-time measurement of ion channel activation
allows the evaluation of biological chemokine activity both quantitatively and qualitatively.
The data corresponding to the characterization of engineered chemokines using an electrophysi-
ology approach are presented in the following preliminary version of a future manuscript.
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Introduction
The crucial interest in G protein coupled receptors
(GPCRs) does not need to be demonstrated any
more. The percentage – over 30 % - of drugs avail-
able in the actual pharmaceutical market that tar-
get GPCRs is sufficient to rank them as major bio-
logical topics Lagerström & Schiöth (2008). How-
ever, despite a very recent breakthrough in the res-
olution of GPCR structures (for a recent review see
Katritch et al. (2012)), the heavy sequence modi-
fications that were required to overcome expres-
sion, purification and crystallization bottlenecks
may have introduced bias to apprehend the bio-
logical functions of those proteins. The oligomeric
status of the class A receptor/ligand complex in
its native environment, for instance, has not yet
been answered by those structures. Besides, there
is still a strong need for “in solution” investigations
of the receptor or the receptor/ligand complex. Al-
though the membrane protein production remains
the most delicate aspect of such an approach, when
the ligand is also a protein, one prerequisite to such
studies is as well the set up of a solid and valid lig-
and production system. Once recombinant ligand
has been produced, and in particular if some mod-
ifications have been introduced in its sequence, its
functionality has to be assessed, and its receptor
binding and signaling capacities have to be eval-
uated prior any further receptor/ligand complex
formation. To investigate such molecular recog-
nition events and the consecutive ligand induced
signaling cascade, the reconstitution of an environ-
ment that resembles the native membrane is of-
ten required. Consequently, expression at the cell
membrane can be considered but is never straight-
forward as toxicity problems may be faced. Alter-
natively, reconstitution in proteoliposomes can be
requested. One prerequisite for some of those ex-
periments is the expression of large amount of pro-
teins, which could be a tight obstacle with those
receptors that are notoriously known to be reticent
to overexpression. Besides, most of the existing
methods to determine binding affinity are based
on the use of labeled ligands. One of the problems
to circumvent in that type of approach is to find
the ideal label that does not interfere with ligand
binding. Radioactivity can thus appear as a very
attractive approach as the introduction of radioac-
tive isotopes does not modify the binding proper-
ties but is unavoidably linked to the drawbacks in-
herent to radioactivity handling and disposal. One
alternative is the use of a fluorescent label Brid-
don et al. (2011), there, two difficulties have to
be faced: getting a sufficient signal/noise ratio,
and introducing the fluorophore to the ligand. Be-
sides, functional tests must ensure GPCR signal
transduction cascade. Ligand binding to GPCRs
triggers conformational changes within GPCR he-
lices, leading to a coupling with the heterotrimeric
G protein. The G protein a subunit undergoes
an exchange of GDP to GTP and dissociates from
the βγ subunits. Both elements can then inter-
act with downstream elements (adenylate cyclase,
ion channels. . . ) and modulate their activity. Be-
sides various secondary messengers (cAMP, IP3)
are produced by the effectors leading to the am-
plification of the signal. Most of the functional
assays on GPCRs are distal from the initial acti-
vation event as solely based on the determination
of concentration variation of those second messen-
gers. Those include the mesurement of agonist
stimulated radioactive GTP binding to the G pro-
tein Labrecque et al. (2009), the measurement of
intracellular Ca2+ flux, variation in cAMP con-
centration. . . Finally some cellular assays based
on GPCR induced cell morphology changes Pe-
ters et al. (2007) or on ligand triggered receptor
translocation Grånäs et al. (2005).
We present here the valuable diversion that
can be done from a conventional electrophysi-
ology approach to study the transduction path-
way generated by chemokine ligands binding to
their respective GPCRs. As regards of their key
roles in inflammatory processes and HIV pathol-
ogy, the two models that are considered in this
work (CXCL12/CXCR4 and CCL5/CCR5) do not
need to be further advertised as attractive drug
targets Sallusto et al. (2000); Wyatt & Sodroski
(1998). However, although they have been exten-
sively studied since the mid-nineties, crucial ques-
tions around their biology remain unanswered and
have not found any responses from the recently
published structure of CXCR4 Wu et al. (2010):
those include ligand/receptor complex stoichiom-
etry or the relevance of receptor oligomerisation.
Molecular investigation of those chemokines/ re-
ceptor interactions could be facilitated by the se-
quence engineering of the ligands. Affinity tags
could be added to facilitate purification (His tag),
ligand could be visualised by the incorporation
of fluorescent properties (addition of Lanthanoid
binding Tag), ligand anchorage to solid support
(chromatography matrix, Biacore chips. . . ) could
be enabled (addition of Strep Tag). However such
modifications could alter their functionality.
Abundant literature can be found concerning N-
terminus modifications of those chemokines that
have been reported to dramatically modified their
functionality including Examples of N-terminal
modified chemokines, designed and studied for
their potency as HIV inhibitors C1 C5 CCL5, Polo
et al. (2000), AOP CCL5, Mack et al. (1998),
NNY-CCL5, Sabbe et al. (2001), P2 CCL5, Jin
et al. (2010)... Therefore sequence engineering was
performed on the C-terminus of the chemokines.
In order to test the biological activity of our
broad range of differentially tagged recombinant
chemokines we exploited the ability of CXCL12
and CCL5, to trigger Gi/o protein activation af-
ter binding to their respective CXCR4 and CCR5
receptors. Once activated the heterotrimeric Gi/o
proteins separates and the Gβγ dimers open the G
protein-activated potassium channel Kir3.1* (Fig.
1A).
By co-injecting Kir3.1* mRNA with chemokine
receptors mRNA (Fig. 1B), we create an elec-
trophysiological reporter of the chemokine-induced
G protein activation. Using the Two-Electrode
Voltage-Clamp (TEVC) technique (Fig. 1C),
the current generated by all Kir3.1* channels ex-
pressed in the plasma membrane are easily record-
able. Moreover, the TEVC technique is appropri-
ate for the functional characterization of external
ligands, such as the chemokines.
Thus, the Kir3.1* functional assay offers the
possibility to easily evaluate the biological activity
of chemokines, qualitatively (receptor/channel ac-
tivation or not, reversibility of the activation) and
quantitatively (amplitude of activation, apparent
affinity). Besides it reflects a direct recording of
the ligand binding without too many secondary
messenger intermediates. No overexpression or pu-
rification procedure of the GPCR are required.
This article describes the expression and purifi-
cation of various chemokine constructs designed as
new tools to carry out chemokine receptor studies
and their functional validation using an electro-
physiology approach. This test non only states
the receptor binding capacity of the engineered
chemokines but also reports the consequences of
the modification on signal transduction.
Materials and methods
Engineering of expression vectors
Standard pUC57 plasmids containing optimized
synthetic human genes designed for the efficient
production of chemokines in E. coli were manu-
factured by GeneCust (Evry, France). After PCR
amplifications using suitable primers, cDNAs en-
coding the full-length chemokines were sub-cloned
into the pET-20b (Novagen) (chemokines expres-
Figure 1: Principle of the electrophysiological characterization of chemokine receptors.
A. Schematic representation of a plasma membrane containing the heterologously expressed chemokine
receptor and the G protein activated Kir3.1* channel. The channel Kir3.1 is mutated (*: F137S) to
form homomeric channels. Binding of specific chemokines induces receptor conformational changes
and subsequently the activation and scission of the heterotrimeric Go proteins. The Gβγ subunits
activates the Kir3.1* channels resulting in an increase of the inward current amplitude generated at
-50mV in symmetrical K+ concentration. B. Chemokine receptors and Kir3.1* channels are heterolo-
gously expressed in Xenopus laevis oocytes by mRNA micro-injection. After 2 days-incubation, purified
chemokines are electrophysiologically characterized. C. Schematic representation of the Two-Electrode
Voltage Clamp set-up. The oocyte is impaled by 2 glass pipettes containing 3M KCl and a Ag/AgCl
electrode. Electrical current recording is performed under continuous flow of buffer +/- ligands or
channel blockers. Change of solutions is controlled by a semi-automatic perfusion system. The used
TEVC bath has a potassium concentration similar to the intracellular K+ concentration. D. Repre-
sentative TEVC recording of Kir6.2 generated current at -50 mV. The basal current generated by the
channels in basal state is determined in the first minute and represented in blue line and bar. This
basal current is the reference (100%) for the normalization of ligand-induced effect represented in red
line and bar. Barium (Ba2+) is a generic blocker of K+ channels and positions the barium-sensitive
baseline.
sion in E. coli inclusion bodies) or pMAL-C4x
(New England Biolabs) (chemokines expression
with a N-terminal fused maltose binding protein)
expression plasmids (Fig. 2). For some constructs,
an additional double-lanthanide-binding tag Mar-
tin et al. (2007) was inserted in the C-terminal
part of the proteins. Depending on the construc-
tion, this tag is located before a PreScission pro-
tease site that can be used for the cleavage of the
C-terminal Strep-tag. The sequencing of each con-
struction listed in Fig. 2 was done by Cogenics
(Meylan, France).
Expression of recombinant chemokines
The E. coli BL21 (DE3) cells transformed with
the different expression vectors were grown at 37°C
in Luria Bertani medium supplemented with 100
μg.mL-1 of ampicillin until cultures reached an op-
tical density of 0.6 to 0.8 at 600 nm. Then, 1
mM isopropylthio-β-D-galactopyranoside (IPTG)
was added to the cultures in order to induce syn-
thesis of recombinant proteins. Cells were further
incubated for 3 h at 37°C (CXCL12-His, CXCL12-
Strep and CCL5-Strep) or 16 h at 20°C (MBP-
CXCL12-Strep, MBP-CCL5-Strep, CXCL12-LT-
His, CXCL12-LT-Strep and CCL5-LT-Strep), har-
vested and centrifuged for 30 min at 5 000 g.
MBP-CXCL12-Strep and MBP-CCL5-Strep
purification
Bacterial cells expressing the MBP-fused
chemokines were resuspended in buffer A
(100 mM Tris-HCl pH 8.0, 150 mM NaCl, 1
mM EDTA) containing 1 tablet of Complete
protease inhibitors (Roche) and disrupted as
described above. After centrifugation for 45 min
at 20 000 g, soluble MBP-chemokines present in
the supernatant were purified by an affinity chro-
matography using a StrepTactin column (5 mL,
Amersham Biosciences) previously equilibrated
in buffer A. After an extensive washing step,
recombinant chemokines were eluted with buffer
A supplemented with 2.5 mM of dethiobiotin.
After purification, the N-terminal MBP-domain
of the fusion proteins was cleaved after an
overnight incubation at room temperature with
the Pre-Scission protease (1.75 U protease/mg of
fusion proteins). Removal of the MBP moiety was
performed by purification over an amylose column
(BioLabs). The unbound fraction that contained
the chemokine was concentrated and run over a
Superdex 200 gel filtration column.
Inclusion bodies preparation
Bacterial cells expressing chemokines in inclusion
bodies were resuspended in 50 mM Tris-HCl pH
8.0 (buffer B) supplemented with 1 tablet of Com-
plete protease inhibitors (Roche). Each bacte-
rial pellet was disrupted twice using a Microflu-
idizer M-110P (Microfluidics international, New-
ton, MA) at 10 000 psi. After centrifugation for
30 min at 20 000 g, inclusion bodies were pelleted
and washed with buffer B supplemented with 2M
Urea and 5 % Triton X100, then with buffer B
containing 2M Urea and finally with the buffer B
alone.
CXCL12-His and CXCL12-Strep refolding and
purification
Inclusion bodies were solubilised for 20 min at
50°C in buffer B with 7.5 M GdmCl, 5 mM
EDTA and 20 mM DTT. Refolding was performed
by rapid dilution with buffer B down to 1 M
GdmCl. The mixture was gently stirred overnight
at 4°C after addition of Complete protease in-
hibitors (Roche), diluted 4 times with buffer B
and loaded onto a CaptoS column (5 mL, Amer-
sham Biosciences) equilibrated in 50 mM Tris-
HCl pH 7.5. Chemokines were then eluted with a
NaCl gradient (0-1 M), concentrated and further
Figure 2: Scheme of the expression pattern and theoretical parameters of the different engineered
chemokines.
Schematic representation of each chemokine construction are reported on the left. The numbers rep-
resent the position to the sequence in each construction. The theoretical molecular weight and iso-
electric point were determined with the Expasy ProtParam tool (http://web.expasy.org/protparam/).
The chemokine expression and refolding efficiency are also indicated. MBP: Maltose Binding Protein;
PP: PreScission protease site; STREP: Strep-Tag; HIS: His-Tag; LT: Lanthanoid binding tag; (-): low
refolding efficiency; (+): good expression level; (++): strong expression level; NT: Not tested.
purified on a Superdex 200 gel filtration column
(Amersham Biosciences) previously equilibrated
in 20 mM Na2HPO4 pH 6.0. Purified proteins
were analyzed by ion-spray mass spectrometry and
stored at –80°C until use.
CCL5-Strep refolding and purification
Inclusion bodies were solubilised for 30 min at
60°C in buffer B with 6 M GdmCl and 1 mM
DTT. After centrifugation for 30 min at 20,000 g,
the clear supernatant is dialyzed 4 hours at room
temperature against a 1% acetic acid in order to
remove impurities. The concentrated, clear super-
natant was diluted to obtain 1 mg/mL of protein
and refolding was achieved by dropwise dilution in
the adequate refolding buffer (20 mM Tris-HCl pH
8.0, 0.01 mM oxidized glutathione and 0.1 mM re-
duced glutathione). After an overnight incubation
at 4°C with mild stirring, the pH of the solution
was adjusted to 4.5 and subsequently loaded on
a CaptoS column (5 mL, Amersham Biosciences)
pre-equilibrated in 50 mMNa-Acetate pH 4.5. The
protein was then eluted with a NaCl gradient (0-
1 M), concentrated and further purified on a Su-
perdex 200 gel filtration column previously equili-
brated in 20 mM Na2HPO4 pH 6.0, 150 mM NaCl.
CXCL12-LT-His, CXCL12-LT-Strep and
CCL5-LT-Strep refolding and purification
Inclusion bodies were solubilised for 1 h at room
temperature in 100 mM Tris-HCl pH 8.0 (buffer
C) supplemented with 6 M Urea, 100 mM NaCl,
0.5 mM EDTA and 5 mM DTT. Refolding was
achieved by drop wise dilution into a volume 100
times that of the Urea solution of buffer C contain-
ing 0.5 mM EDTA, 0.2 mM oxidized glutathione
and 1 mM reduced glutathione. The respective re-
folding solution was stirred overnight at 4°C and
loaded onto a 10 mL Q-sepharose column (Amer-
sham Biosciences) pre-equilibrated in buffer B. A
linear gradient elution was performed over 100 mL
from 0 to 1 M sodium chloride in buffer B and the
fractions containing the refolded chemokines were
concentrated and further purified on a Superdex
200 gel filtration column equilibrated in buffer B
containing 150 mM NaCl. Purified proteins were
analyzed as described above.
Terbium titration and PAGE analysis
Titrations were recorded on Photon Technology
International Quanta Master I fluorimeter using
1 cm path length quartz cuvette and slit widths of
2 and 4 nm. Tryptophan-sensitized Tb3+ lumines-
cence was collected at room temperature by excit-
ing the sample at 280 nm. The purified CXCL12-
LT-His protein (2 mL at 75 μM in Hepes 20 mM
pH 8.0; NaCl 100 mM) was titrated by adding ten
2 μL aliquots of 15 mM Tb3+. After each addi-
tion, the solution was mixed and the luminescence
emission spectrum was recorded between 450 and
550 nm. For SDS-PAGE analysis, proteins were
loaded on two 15% polyacrylamide gels in denatur-
ing buffer, and subjected to electrophoresis at 220
V for 1 hour. After the migration, one gel is im-
mediately stained with a Blue Coomassie solution
whereas the other one is washed twice for 20 min-
utes in buffer D (100 mMNaCl, 10 mMHEPES pH
7.0), followed by an incubation of 1 hour in buffer
C containing 50 μM of TbCl3. Luminescent bands
were visualized on a UV-transilluminator (Gel Doc
2000, Bio-Rad).
Co-expression of receptors and channel in
Xenopus oocytes
Human CXCR4 and CCR5 genes were subcloned
in pGEMHE vector designed for protein overex-
pression in Xenopus oocytes like the Kir3.1F137S
(Kir3.1*) gene. Kir3.1 channels are physiologi-
cally associated with Kir3.4 subunits to form func-
tional G protein-activated channels. The muta-
tion Kir3.1F137S, noted Kir3.1*, allows the for-
mation of functional homotetramers simplifying
the system by abrogating one subunit. All con-
structs were linearized in 3’ terminus of the polyA
sequence and mRNAs synthesized using the T7
mMessage mMachine Kit (Ambion). mRNAs were
purified by standard phenol:chloroform extraction,
analysed on agarose gel and quantified by spec-
trophotometry.
Animal handling and experiments fully con-
formed with French regulations and were approved
by local governmental veterinary services (au-
thorization no. 38-08-10 from the Ministère de
l’Agriculture, Direction des Services Vétérinaires
to Michel Vivaudou). Oocytes were surgically re-
moved from Xenopus laevis and defolliculated by
2h incubations in 2 mg.ml-1 type 1A collagenase
solution at 19°C. Stage V and VI oocytes were
microinjected with 50 nl of RNase-free water con-
taining one or a mixture of the following quanti-
ties of RNA: β2-Kir6.2, 5 ng; Kir6.2ΔC36, 2 ng;
TMD0(SUR1)-F195, 1 ng. Microinjected oocytes
were incubated for >2 days at 19°C in Barth’s so-
lution (in mM: 1 KCl, 0.82 MgSO4, 88 NaCl, 2.4
NaHCO3, 0.41 CaCl2, 16 HEPES, pH 7.4) supple-
mented with 100 U.ml-1 penicillin, streptomycin
and gentamycin. All chemicals were purchased
from Sigma-Aldrich.
Electrophysiological recordings
Whole-cell currents were recorded with the two-
electrode voltage clamp (TEVC) technique using
a GeneClamp 500 amplifier (Molecular Devices).
Microelectrodes were filled with 3 M KCl and
oocytes were bathed in the following solution (in
mM): 91 KCl, 1.8 CaCl2, 1 MgCl2, 5 HEPES, 0.3
Niflumic acid (to block endogenous Cl- currents),
pH 7.4. The TEVC voltage protocol consisted
of 500-ms steps to 50, 0 and +50 mV - during
which current was measured - separated by 5 s at
a holding potential of 0 mV. The values shown in
the figures are those recorded at -50 mV. In our
TEVC configuration, chemokines are applied in a
constant flow over the impaled oocytes, and un-
der the conditions of -50 mV clamped-voltage and
high potassium concentration (96 mM), the cur-
rent generated by Kir3.1* is recorded in real-time
(Fig. 1D). By convention, the recorded current is
negative in our experimental conditions, and the
first seconds of recordings (Fig. 1D, blue line)
correspond to the basal current generated by the
channel in basal state (in absence of chemokines).
Application of agonists (such as chemokines) in-
creases the negative current amplitude (Fig. 1D,
red curve) and is consequently normalized using
the basal current as a reference (Fig. 1D, right-
side bar chart).
Data analysis
Basal current was measured while oocytes were in
standard bath solution during the first minute of
recording. Ba2+ (3 mM) was used as a generic
potassium-channel blocker to establish the amount
of exogenous current, designated as Ba2+-sensitive
current and calculated by subtracting from all
measured values the value measured at the end
of an experiment after application of 3 mM Ba2+.
All values of current reported here refer to Ba2+-
sensitive currents. Changes in Ba2+-sensitive cur-
rents by effectors were calculated with respect to
the value measured before application. Arrows in
the figures indicate the points at which the cur-
rent were measured on the current traces. For
the concentration-response data, obtained by se-
quential application of increasing agonist concen-
trations, changes in current were calculated only
with respect to the current before application of
the initial, lowest concentration.
Average values are presented as mean±s.e.m.
Non-linear least-square curve-fitting was carried
out with Origin 8 software (OriginLab) using a
standard Hill equation:
f(x)= Max
1+(EC50x )h
where x is the concentration of a ligand, Max
the asymptotical maximal effect, EC50 the con-
centration for half-maximal effect, and h the Hill
coefficient. The fits shown in the figures were per-
formed using average data. For statistical analy-
sis of parameters Max and EC50 (using Origin 8
software), individual dose-response data from each
oocyte tested were fitted using the above equa-
tion with h=1 to obtain a set of values of Max
and EC50 for each construct and ligand. Statisti-
cal significance for these parameters and for other
experimental data was established with unpaired
two-tailed Student t-tests and is indicated as p-
values in the text.
Results and discussion
Different versions of the two chemokines, CCL5
and CXCL12, were designed for diverse purposes;
they vary by the tags that have been appended.
Two different production approaches were consid-
ered.
Expression and purification of chemokines
Soluble expression of MBP fusions
The first production attempt was based on the
strategy adopted by Cho and co-workers Cho
et al. (2008) that promises high level of soluble
chemokine expression in E. coli thanks to a N-
terminal fusion with the Maltose Binding Pro-
tein MBP. Synthetic genes encoding for CXCL12
and CCL5, optimised for E.coli expression, were
designed to be cloned into the pMal 4x vectors.
The final constructs MBP-CCL5-Strep and MBP-
CXCL12–Strep displayed from Nterm to Cterm:
the MBP sequence, a prescission protease site
to enable the subsequent cleavage of the fusion
protein, the chemokine synthetic gene, a throm-
bin cleavage site and a C-terminal Strep Tag.
Similar constructs comprising an additional dou-
ble lanthanoid binding tag (LT) were also de-
signed: MBP-CCL5-LT-Strep and MBP-CXCL12-
LT-Strep. This tag specifically binds Terbium
(Tb) which fluorescent properties could be used
to track the chemokine. All those constructs are
represented in Fig. 2.
Protein expression was induced in E. coli BL21
(DE3) cells. After cell disruption, and removal of
cellular debris, the supernatant was purified over
a StrepTactin column. Although all MBP fusion
proteins were expressed with satisfactory yields, a
remarkable enhancement was provided by the ad-
dition of the LT tag. A yield of 7-8 mg / liter of
culture were obtained for MBP-CCL5-Strep and
MBP-CXCL12–Strep while the presence of the LT
boosted the quantities up to 70-80 mg/ liter of cul-
ture. The following cleavage of the fusion protein
led to the precipitation of the whole protein sam-
ple despite attempts to optimize the conditions.
Once again the LT tag dramatically affected the
protein behavior since its presence maintained the
chemokine perfectly soluble after cleavage. Re-
moval of the MBP moiety was performed by pu-
rification over an amylose column. The unbound
fraction that contained the chemokine was concen-
trated and run over a Superdex 200 gel filtration
column. The proteins eluted as a unique peak cor-
responding to oligomers but that happened to be
inactive in chemotaxis assays (data not shown).
Insoluble expression and refolding
Expression was then attempted via the approach
most commonly used for chemokine production:
an expression in E.coli under an insoluble form
in inclusion bodies [15]. For that purpose, the
synthetic genes encoding for CCL5 and CXCL12
Figure 3: CXCL12-LT-His terbium titration and SDS-PAGE analysis of purified chemokines.
A. SDS-PAGE analysis of the purified recombinant chemokines. Proteins were loaded onto 15% SDS-
PAGE polyacrylamide gels in denaturing buffer, subjected to electrophoresis at 220 V for 1 hour
and stained with a Blue Coomassie solution or treated with 50 μM of TbCl3. Luminescent bands
associated with the chemokines-LT constructs were visualized on a UV-transilluminator with contrast
enhancement. M: Protein mass ladder; lane 1: CXCL12-His; lane2: CXCL12-LT-His; lane 3: CXCL12-
Strep; lane 4: CXCL12-LT-Strep; lane 5: CCL5; lane 6: CCL5-Strep; lane 7: CCL5-LT-Strep. B.
Tryptophan-sensitized Tb3+ luminescence was collected as indicated in the materials and methods
section. Briefly, the purified CXCL12-LT-His protein (2 mL at 75 μM in 20 mM Hepes pH 8.0; 100
mM NaCl) was titrated by adding ten 2 μL aliquots of 15 mM Tb3+ (concentrations ranging from 15
μM to 150 μM). After each addition, the solution was mixed and the luminescence emission spectrum
was recorded between 450 and 550 nm. Inset: final terbium concentration after each metal addition
in the protein sample. Luminescence at 487 nm (blue graph) and 542 nm (red graph) as a function of
terbium concentration is also reported.
mentioned above were cloned into the pET-20b ex-
pression vector. Once again, various constructs
of each chemokines were designed for various pur-
poses. CXCL12 was C-terminally appended with
either a Hexahistidine Tag or a Strep-Tag. The
two constructs were declined under two versions
with or without an LT Tag, resulting in 4 con-
structs: CXCL12-His, CXCL12-LT-His, CXCL12-
Strep, CXCL12-LT-Strep. For CCL5 solely 3 con-
structs were created, CCL5-Strep, CCL5-LT-Strep
and CCL5 devoid of any tag. Those seven ver-
sions of chemokines are schematically represented
in Fig.2.
Protein expression was induced in BL21(DE3)
cells. Solubilization of inclusion bodies and the
subsequent purification steps completely differed
between the LT containing constructs and the oth-
ers. That is mainly explained by the great pI dis-
crepancy between those two sets of proteins, the
formers display an acidic pI (below 6.5) while the
latter are highly basics with pI values above 9
(see Fig.2). LT bearing proteins were thus sol-
ubilized in a 6M Urea buffer, while the others
were treated with 7.5 M Guanidine buffer. Sol-
ubilized inclusion bodies were loaded on a SDS-
PAGE gel (data not shown) and the amount of
overexpressed proteins was roughly appreciated
(Fig.2). One clear observation from this analysis
was the clear increase of expression triggered by
the LT addition. Indeed, for all constructs, the LT
form was far better expressed (CXCL12-His versus
CXCL12-LT-His, CXCL12-Strep versus CXCL12-
LT-His, CCL5-Strep versus CCL5-LT-Strep).
Refolding of the non-LT containing chemokines
was achieved by a 7.5 fold rapid dilution while
LT chemokines were refolded by drop wise dilution
into a large volume of refolding solution. Amazing
discrepancies were observed during the refolding.
Comparison of the same constructs with or with-
out LT Tag showed that while most of the protein
remained soluble in the constructs containing a LT
tag, apart from CXCL12-His which refolded very
well, all the proteins deprived of LT precipitated.
Another noticeable observation was the penalty
triggered by the Strep Tag. Indeed, comparison of
the refolding efficiencies of the CXCL12-His and
CXCL12-Strep constructs showed that the pres-
ence of the Strep Tag led to the precipitation of
a significant amount of protein. After refolding a
first step of purification over an ion-exchange chro-
matography was performed. The basic non-LT
containing chemokines, were retained by a Capto S
column, while their LT counterpart, with acidic pI
were purified over a Q-Sepharose column. After
concentration, the proteins were further purified
over a Superdex 200 gel filtration. CXCL12 pro-
teins eluted as a nice single monomer peak, while
CCL5, which is well known to oligomerize, eluted
as bigger complexes of higher molecular weight.
The structural integrity of the samples had to be
evaluated. First of all, ion-spray mass spectrom-
etry demonstrated that the oxidized proteins had
four mass units less than the reduced forms due
to the formation of the chemokine characteristic
two disulfide bridges. The purity of the prepared
protein can be appreciated on Fig 3A and is satis-
factory.
The enhancement of the fluorescence triggered
by addition of terbium to the CXCL12-LT-His sug-
gested the correct folding of the protein. Besides
terbium titration (see Fig. 3B) demonstrated that
a 2:1 molar ratio of Tb:protein was necessary to
saturate the sites and confirmed that the double
Lanthanoid binding tag was fully functionnal. The
fluorescent properties of the LT Tag are clearly il-
lustrated on Fig. 3B that displays the visualiza-
tion of the fluorescent chemokines on a SDS-PAGE
gel that was simply bathed into a terbium contain-
ing solution.
Figure 4: Functional characterization of tagged-CXCL12 chemokines.
A. Representative TEVC recordings performed on Xenopus oocytes co-expressing CXCR4 and Kir3.1*.
Different oocytes are used for each recording. The coloured arrows indicate the channel activations
induced by chemokine-binding on CXCR4 and subsequent Go protein activation. The chemokines
concentration is 1μM. B. Average current (+/- s.e.m.) normalized in reference to the basal current (=1)
and measured at the end of the ligand application represented by the arrows in the panel A. Numbers
below bars are the numbers of recordings. C. Dose-response curves of the indicated-chemokines.
Chemokine concentrations are applied gradually on the same oocyte and each point of the curves are
the mean +/- s.e.m. of different recordings from different oocytes.
Quantitative and qualitative functional
characterization of tagged chemokines
Tagged and purified CXCL12 chemokines at a
fixed concentration of 1 μM were applied on Xeno-
pus oocytes expressing CXCR4 and Kir3.1*. This
concentration far above the Kd (reported to be
of the low nM range) ensured to be in saturating
conditions and trigger a maximal response. Fig-
ure 4A reveals that all tagged CXCL12 are able to
activate Kir3.1*, meaning the binding of the mod-
ified chemokines on CXCR4 and the subsequent
activation of the Gi/o proteins. Statistical analysis
(Fig. 4B) show a similar amplitude of activation
between CXCL12 +/- LT tagged chemokines and a
slight but significant higher activation of CXCL12-
Strep than CXCL12-His.
The differences of ligand efficacy at 1 μM are
also confirmed by dose-response curves (Fig. 4C)
performed by increments of chemokine concentra-
tions. Interestingly, the dose-response curves re-
veal that while insertion of the LT-tag does not
significantly affect the CXCL12 efficacy at 1 μM,
it decreases the apparent affinity of CXCL12-LT-
Strep, but not CXCL12-LT-His. In an oppo-
site way, insertion of the LT tag in CXCL12-His,
does not alter the ligand affinity but increases
slightly the ligand efficacy (LT-His vs His). Thus,
analysing the tagged-CXCL12 effect only at the
saturating concentration (1 μM) (Fig. 4C) re-
veals that LT-tag does not modify significantly the
CXCL12 efficacy (Emax: Strep vs LT-Strep and
His vs LT-His), but LT-tag clearly decreases the
apparent affinity for Strep-tagged CXCL12 (EC50
LT-Strep>Strep).
Another change induced by the LT-tag is the
apparition of “reversibility”. Reversibility corre-
sponds in our recordings to the rapid loss of the
Kir3.1* activation during the post-ligand washing
as shown in Fig.4A (right recordings). In order
to confirm the apparition of reversibility with LT-
tag insertion, we applied non LT-tagged and LT-
tagged chemokines sequentially in different orders
as shown in Fig. 5B and compare it with the
wt CXCL12 (without tags). The wt chemokine
displays an absence of reversibility in Fig. 5A
even at low concentration (30 nM) and this phe-
notype is conserved for the His- and Strep-tagged
chemokine (Fig. 5A). Insertion of the LT-tag
induces reversibility of the chemokine-evoked ac-
tivation even at the saturating concentration of
1 μM (Fig. 5B). When the CXCL12-LT-His is
applied first, the reversibility allows the subse-
quent, clear and not reversible activation induced
by CXCL12-His, while the reciprocal application
sequence shows a weak and irreversible CXCL12-
LT-His induced-activation due to the long last-
ing activation of the first-applied CXCL12-His.
Thus, application of non LT-tagged and LT-tagged
chemokines on the same oocyte during the same
recordings demonstrates the specific effect of the
LT tag on CXCL12-reversibility.
Similar electrophysiological characterizations
were performed on CCL5-tagged chemokines, and
Fig. 6A reveals that this chemokine applied on
CCR5 has an equivalent behavior than CXCL12-
effects on CXCR4. Thus, non-tagged CCL5 (wt
CCL5) induces a reversible activation of CCR5,
like the Strep-tagged version of this chemokine.
Surprisingly, insertion of the LT-tag abolished this
reversibility and decreased drastically (~2-fold of
the CCL5-evoked activation) the efficacy of the
chemokine (Fig. 6B). The only observed simili-
tude between tagged CCL5 and CXCL12 are the
increased efficacy of the Strep-tagged chemokines
in an about 2-fold amplitude compare to their wt
version.
Conclusion
CXCL12 and CCL5 chemokines are precious not
only for their physiological role in lymphocytes B
Figure 5: Lanthanid-binding tag affects the long-lasting activation in TEVC recordings.
A. Representative TEVC recordings showing the non-or weakly-reversible activation of indicated
chemokines. The non-tagged CXCL12 chemokine is in red. B. Sequential application of CXCL12-
His +/- LT tag during the same recording on the same oocyte but in different order show the rapid
“reversibility” of the activation induced by the LT-tagged CXCL12 chemokine.
Figure 6: Functional characterization of the tagged-CCL5 chemokines.
A. Representative TEVC recordings performed on Xenopus oocytes co-expressing CCR5 and Kir3.1*
and subjected to the indicated CCL5 chemokine applications at 1μM. B. Average current (+/- s.e.m.)
normalized in reference to the basal current (=1) for each indicated chemokines at 1μM. In red is the
non-tagged CCL5 chemokine.
chemotaxis, but also for the molecular characteri-
zation and biochemical studies of their related re-
ceptors which are notably involved in the HIV en-
try process. The pecuniary value of the commer-
cially available chemokines makes their affordable
quantity too low for long-standing and structural
studies of chemokine receptors. Home-made ex-
pression and purification of those chemokines ap-
pears as a prerequisite for the studies of chemokine
receptors at the molecular level. To simplify this
step and allow the possibility to undergo var-
ious experiments including fluorescent labelling,
the set up of a chemokine affinity chromatogra-
phy, functionalisation of SPR surfaces, several tags
have been added (His tag, Strep Tag, lanthanide-
binding tag). We demonstrated in this study that
the nature of the tag insertion clearly affected the
properties of the chemokines.
First of all, we observed that the addition of
single tags or of a combination of tags can have
unexpected effects on the biochemical properties
of the chemokine: insertion of the LT tag dramat-
ically enhanced protein expression and solubility,
addition of a Strep tag greatly disfavoured pro-
tein refolding. The important modifications linked
to addition of LT tag could be attributed to the
high negative charges of this sequence, that greatly
modify the isoelectric points of those highly basic
chemokines and could therefore influence their bio-
chemical behaviour.
It has been reported that modifications of the
CXCL12 and CCL5 sequences can highly alter
the chemokine functionality and receptor binding
properties Simmons et al. (1997); Mosier et al.
(1999); Pastore et al. (2003). This has been par-
ticularly observed when the N-terminus is affected,
which is absolutely coherent with the crucial role
played by this region for chemokine/receptor inter-
actions Crump et al. (1997); Kofuku et al. (2009).
Therefore the set up of a method to ensure that the
sequence engineering performed on the chemokines
did not modify the chemokine capacity to signal
Chemokine Tag(s) Recertor
activation*
Long-lasting
activation
Affinity Efficacy
CXCL12 Without (wt) ? + EC50=1.2 1
His + + = =
Strep ++ + = ++
LT-His + - = =
LT-Strep ++ - < =
CCL5 Without (wt) + - EC50=3.2 2
Strep ++ - =
LT-Strep < + =
Table 1: Summary of the tag effect on CXCL12 and CCL5 determine by TEVC.
* - Receptor activation through G proteins; 1 - data from Zhan et al. (2007); 2 - data from Blanpain
et al. (2003)
through its receptor was required. However the hy-
drophobic nature of those ligands render difficult
some straightforward ligand binding experiments
such as filter binding assays. To access the conse-
quences of chemokine sequence modifications both
on receptor binding capacity and signal transduc-
tion, we used here a simple system based on co-
expression of chemokine receptors and G protein-
activated channels in Xenopus oocytes and Two-
Electrode Voltage-Clamp recordings. This method
allowed us to record in real-time the receptor ac-
tivation and dose-response curves are easily exe-
cuted by sequential applications of increased lig-
and concentration in constant flow. We could de-
termine the effect of the tag insertion on the appar-
ent affinity, on the efficacy and the “reversibility”.
While the effects on the activity of chemokine
N-terminus modifications are clearly documented
to have rather dramatic effects on their receptor
binding activity and signal transduction capacity,
the experiments that we carried out indicate that
C terminus modifications do not abrogate those
functions but rather have a subtle tuning effect.
Although the C-terminus of CXCL12 and CCL5
has not been reported to be involved in recep-
tor binding mechanism, modifications of this re-
gion could affect the chemokine oligomerisation
and therefore its functionality. We first observed
that insertion of one tag (Strep or His) did not
alter the ability of CXCL12 or CCL5 to activate
Gi/o proteins via their respective receptors, how-
ever it appears that the Strep-tag increased the
efficacy of both chemokines. The consistency of
the responses got more confused with the addi-
tion of a second tag. This is clearly illustrated by
the various and somehow erratic effects attributed
to the LT-Tag insertion that can alternatively, de-
crease the apparent affinity (Strep-tagged CCL12),
increase the efficacy (His-tagged CCL12), induce
reversibility (Strep and His-tagged CCL12) or even
have the opposite consequences, including suppres-
sion of reversibility and diminution of efficacy on
CCL5 constructs.
We listed here those properties that could be
used for new applications (Table 1).
The major strength of the technique is that
without having to struggle with membrane pro-
tein expression, it gives an easy access to many
types of experiments that could be delicate with
other approaches such as the determination of an
EC50 by dose response tests or competition assays.
Besides it seems that internalisation processes are
rather limited in Xenopus oocytes, which clearly
ease the ligand binding assays as it enable the pos-
sibility of consecutive perfusions Cox & Crowder
(2004).
Besides, one other advantage of this approach
that has not been exploited in this study could
be to easily undertake structure/function studies
from the receptor side. The effects of modifications
on the GPCR sequences could be easily addressed
by this system both in term of ligand binding or
signaling. The interest of such changes has been
clearly illustrated by the strategy used to crys-
tallize and solve the high-resolution structure of
several GPCR Katritch et al. (2012). Indeed, the
modifications that have been required to obtain
crystallizable forms of the proteins could be easily
transferred to the mRNA injected in the Xeno-
pus oocytes. Comparative ligand binding assays
with the wild type and the modified GPCR could
thus be informative on the impact of such modifi-
cations.
This article describes the production of a
large range of functional chemokines modified at
their C terminus with different tags that could
open a broad way to undertake “in solution”
chemokine/chemokine receptor complex studies
including the possibility to perform pull down ex-
periments and the set up of affinity chromatogra-
phy column, the functionalisation of Biacore chips
(Strep and His tags) or even to track chemokines
or receptor/chemokine complex via the fluorescent
properties offered by the LT. We also report the
convenient use of an electrophysiology test to as-
sess receptor binding and signal transduction of
the tagged chemokines, which is a mandatory pre-
requisite before their utilization. Data obtained
by this technique validated that the C-terminus of
chemokines could be used to functionalised them
without interfering with their major functions.
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10. Receptor production
10.1. Molecular biology
CCR5 and CXCR4 clonings have been performed before my arrival. To circumvent the limitation
due to rare codons the nucleotide sequences of both receptors were optimized for the expression
in E. coli. Synthetic cDNA were produced in which the codons frequently used by E. coli were
selected. Receptors were cloned using a fusion strategy developed by Jean-Louis Banères and
Bernard Mouillac, targeting the GPCR expression towards E. coli inclusion bodies (IB) [104].
This is an alternative approach based on novel original fusion partners, which enable to produce
full-length receptors in high amounts, and is already applicable to a dozen of GPCRs. The
strategy is based on accumulation of the fusion-GPCR complexes in E. coli inclusion bodies
followed by a subsequent in vitro refolding. To target recombinant proteins to E. coli inclusion
bodies the combination of charged and β-turn forming residues are critical and have to correspond
to a high fraction of the selected protein sequence. Comparing these physicochemical parameters,
as a fusion partner, a fragment of the extracellular β-propeller domain of the human α5 integrin
(α5I) was chosen [104].
CCR5 had a N-terminal fusion with an α5 Integrin (α5I) fragment (residues from 231 to 514)
and a C-terminal His tag. The thrombin cleavage site was added to cleave the α5 Integrin part
from the His tagged GPCR. CCR5 construct was cloned into pET-21a(+) expression vector and
referred to as α5I-CCR5-His.
For CXCR4 receptor expression one fusion protein was not enough to enable an efficient ex-
pression in E. coli inclusion bodies, therefore an additional fusion protein was incorporated. A
fragment of the hormone arginine-vasopressin V2 receptor (V2) was added to the N-terminal side
of CXCR4 resulting in the α5I-V2-CXCR4, which was then cloned into pET-21a(+) expression
vector.
10.2. Expression and purification of α5I-CCR5-His
Cultures of Rosetta2 (DE3) competent bacteria were transformed with α5I-CCR5-His and grown
at 37°C in LB media to an OD600 nm of 1. Bacterial cultures where induced with 1 mM IPTG
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and glucose was added. Bacteria were grown for another 4 hours until cultures were harvested
by centrifugation.
Bacterial pellet containing expressed α5I-CCR5-His was resuspended in lysis buffer and cells
where lysed using a microfluidizer. The pellet containing inclusion bodies was extensively washed
first with lysis buffer containing 1 M Urea and then twice with lysis buffer containing 2 M Urea.
The inclusion body solubilization step was performed overnight using 6 M Urea to completely
solubilize the protein of interest. The presence of the His-tag at the C-terminus of the receptor
allowed protein purification over a Ni-NTA resin under denaturing conditions (Figure 10.1).
Figure 10.1.: SDS-polyacrylamide gel representing α5I-CCR5-His purification over a Ni-NTA
resin.
M - marker, IN - input to the Ni-NTA resin, FT - flow-through, W - wash, 1-11 - elution
fractions containing almost pure α5I-CCR5-His.
The protein was recovered by elution with 500 mM Imidazole containing buffer. The elution
fractions were pooled and dialyzed against thrombin digestion buffer to eliminate Urea.
Thrombin digestion kinetic was observed by collecting aliquots after 1 and 4 hour digestion
(Figure 10.2).
Figure 10.2.: SDS-polyacrylamide gel representing α5I-CCR5-His thrombin digestion.
M - marker, 1 - sample of non-digested α5I-CCR5-His, 2 - sample after 1 hour of thrombin
digestion, 3 - sample after 4 hours of thrombin digestion.
138
10.3. EXPRESSION AND PURIFICATION OF Α5I-V2-CXCR4-HIS
After 4 hour incubation the digestion was almost complete. The reaction was stopped by the
addition of 6 M Urea and 0.4 % SDS. The cleaved α5I fragment was separated from the CCR5-His
by a second Ni-NTA purification (Figure 10.3).
Figure 10.3.: SDS-polyacrylamide gel showing CCR5-His purification on Ni-NTA resin.
M - marker, IN - input sample to the Ni-NTA resin, FT - flow-through, E1-4 - elution fractions.
The flow through (FT) and wash (W) fractions contained the α5I protein fragment. The elution
fractions containing the CCR5-His were pooled and dialyzed against 0.8% SDS buffer until Urea
traces were removed.
Figure 10.4.: SDS-polyacrylamide gel of purified CCR5-His.
We obtained 0.46 mg of CCR5-His from one liter of bacterial culture (Figure 10.4).
10.3. Expression and purification of α5I-V2-CXCR4-His
Cultures of Rosetta2 (DE3) competent bacteria were transformed with α5I-V2-CXCR4 and grown
at 37°C in LB media to an OD600 nm of 1. Bacterial cultures where induced with 0.1 mM IPTG
and glucose was added. Bacteria were grown for another 4 hours until cultures were harvested
by centrifugation.
Bacterial pellet was resuspended in lysis buffer and cells where lysed using a microfluidizer. The
pellet containing inclusion bodies was extensively washed first with lysis buffer containing 1 M
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Urea and then twice with lysis buffer containing 2 M Urea. The inclusion body solubilization
step was performed overnight using 6 M Urea to completely solubilize the protein of interest.
The presence of the His-tag at the C-terminus of the receptor allowed protein purification over
a Ni-NTA resin under denaturing conditions (Figure 10.5).
Figure 10.5.: SDS-polyacrylamide gel representing α5I-V2-CXCR4 first step of purification.
M - marker, 1 -13 - elution fractions from Ni-NTA resin. The arrow marks the bands of
CXCR4 fusion which runs as expected around 110 kDa.
The protein was recovered by elution with a buffer containing 500 mM Imidazole. The elution
fractions were pooled and dialyzed against thrombin digestion buffer to eliminate urea.
Thrombin digestion kinetic was observed by collecting aliquots after 1, 3 hour and overnight di-
gestion at 20°C and at 37°C; 20 μl and 200 μl of each sample was loaded into a SDS-polyacrylamide
gel (Figure 10.6).
(a) Thrombin digestion at 20°C (b) Thrombin digestion at 37°C
Figure 10.6.: SDS-polyacrylamide gel representing α5I-V2-CXCR4 thrombin digestion.
(a) α5I-V2-CXCR4 digestion with thrombin at 20°C. (b) α5I-V2-CXCR4 digestion with
thrombin at 37°C. M - marker, 20 and 200 indicated the amount (μl) of loaded sample, ND -
non-digested sample, 1 hour - sample after 1 hour of digestion, 3 hours - sample after 3 hours of
digestion, O/N - sample after overnight digestion with thrombin. The arrow marks the bands
of CXCR4 fusion proteins.
As observed on the SDS-polyacrylamide gel, thrombin digestion did not work even after extensive
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dialysis against digestion buffer to remove traces of urea and SDS. To improve the thrombin
digestion a different buffer was used (20 mM Tris HCl pH 8.0, 150 mM NaCl, 1 mM DTT, 5 mM
CaCl2) but unfortunately no improvement was observed. Also thrombin was tested at different
concentrations, but even an increase up to 13 units of thrombin per milligram of fusion protein
did not allow the cleavage. The difficulties of thrombin digestion of CXCR4 fusion protein led
us to concentrate our efforts on CCR5 production.
10.4. CCR5 folding - previous works
The first assays of CCR5 folding was assessed before my arrival in a collaboration with J.-L.
Banères (Montpellier).
A first set of receptor folding conditions was tested where the denaturing agent (SDS) was
replaced by a detergent/lipids mixture that stabilized the native structure of the receptor. To
find the best conditions, various detergents were tested, while keeping constant the concentration
and nature of the lipids. Only the buffer containing 0.1mg/ml asolectin, 0.02% cholesteryl
hemisuccinate and n-Dodecyl-β-D-maltoside (DDM) (1/3 w/w) led to the re-solubilization of a
significant amount of receptor.
The ability of the receptor to bind its ligand was evaluated using fluorescence polarization with
an agonist, MIP-1β, which was labeled with a fluorophore (Texas-Red).
Figure 10.7.: Folded receptor interaction with MIP1β.
Fluorescence polarization measurements were performed with 50 nM MIP1β marked with
Texas-Red and folded CCR5 (white circles). The black circles represent polarization
measurements with recombinant BLT1 receptor and MIP1β (negative control experiment).
As shown in Figure 10.7, a specific interaction is clearly observed between the receptor and its
agonist and is not observed with an irrelevant receptor (leukotriene B4 receptor, BLT1) , taken
as a negative control.
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The specificity of this interaction is clearly demonstrated by the complete competition assay
between a fluorescent ligand and an excess of unlabeled agonist. Displacement is not observed in
the presence of SDF1α (ligand of CCR4) demonstrating the specificity of the interaction (Figure
10.8).
Figure 10.8.: Histograms representing fluorescence polarization signal between MIP1β-Texas Red
and the CCR5 receptor.
Interaction between MIP1β-Texas Red and the CCR5 receptor folded in detergents is indicated.
Back column - in the absence of competitor, red - in the presence of an excess of SDFα, blue -
in the excess of a unlabeled MIP1β.
Polarization tests have been performed at a ligand concentration well above the KD value of
CCR5 interaction with MIP1β (KD in the range of 0.2-0.5 nM estimated from cellular systems),
the amount of functional receptor can be estimated from the titration curve in Figure 10.7 as
corresponding to about 4% of the amount of soluble receptor obtained after CCR5 folding.
Several preliminary tests with the receptor in the presence of pMal-B100 a commercial amphipol
were performed. This time the receptor refolding yield was significantly higher than obtained
in the presence of detergents, about 50% of the protein was recovered in a soluble form in
the presence of pMal-B100. The amount of functional receptor was estimated by fluorescence
measurements and indicated that 20 to 30% of the total amount of soluble receptor was functional.
Those preliminary experiments suggested better refolding yield in amphipols that detergents.
Therefore we orientated our refolding towards Amphipol assisted methods.
10.5. Amphipol-assisted CCR5 folding
Optimal refolding of the receptor was obtained when the receptor was used at concentrations
ranging from 0.3 to 0.5 mg/ml.
For a CCR5 folding in A8-35 a protein:amphipol mass ratio of 1:5 was used. Receptor folding
was initiated by precipitating dodecyl sulphate as its potassium salt (KDS) by the addition
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of KCl followed by extensive dialysis to remove any SDS traces [327]. No significant protein
loss through precipitation occurred during amphipol mediated folding. The amount of protein
remaining soluble in the buffer was determined by calculating the soluble protein concentration
and monitored on SDS-polyacrylamide gel (Figure 10.10).
Figure 10.9.: SDS-polyacrylamide gel representing CCR5-His folding in A8-35.
M - marker; 1 - sample of CCR5 alone, no detergent or surfactants were added; 2 - CCR5
refolded with A8-35 at protein/amphipol weight ratio 1:5; 3 - CCR5 refolded in the presence of
A8-35 and asolectin at 1:5:1 protein:amphipol:lipid weight ratio.
The effect of lipid addition on the folding process was tested. In the presence of A8-35 with 1:5
protein:A8-35 ratio over 45% of CCR5 remained soluble. Addition of lipids at a 1:5:1 protein:A8-
35:lipid weight ratio allowed around 61 % of CCR5 to remain soluble (Figure 10.10).
Figure 10.10.: Histograms representing CCR5 folding in different conditions.
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Therefore, the amphipol lipid combination slightly improved the amount of receptor maintained
soluble after folding showing the positive impact of lipid on the receptor folding procedure.
Folding with non-ionic amphipols NAPols was then tested (Figure 10.10). Higher concentration
of amphipols were used for folding in NAPol. Two conditions were tested 1:10 protein:NAPol
weight ratio and 1:10:1 protein:NAPol:Lipid weight ratio. In both conditions over 60% of CCR5
remained soluble after folding. However, in the presence of lipids less aggregation was observed.
Folding of CCR5 in three different amphipols, A8-35, NAPol and BAPol was tested in the
presence of lipids (Figure 10.10).
The best conditions of folding have been obtained in the presence of NAPol in a 1:10:1 pro-
tein:NAPol:lipid weight ratio which maintain over 86% of the sample soluble.
The CCR5 folded in NAPols can be stored for months at room temperature (Figure 10.11).
Figure 10.11.: Time-dependent CCR5/NAPol solubility.
Folded CCR5 functionality was assessed by ligand binding assay using Surface Plasmon Reso-
nance (SPR) experiments.
10.6. Improvements
CCR5 over-expression greatly differs from one culture to another. The overall purification scheme
being quite tedious, we wanted to be able to assess the initial level of over-expression before un-
dertaking the inclusion body solubilization. The C-terminal His tag initially seemed appropriate.
Therefore, before purification the samples were taken from expression cultures and analyzed on
a SDS-polyacrylamide gel and Western Blot using an anti-His antibody.
144
10.7. EXPRESSION AND PURIFICATION OF Α5I-CCR5-HIS-C9
However, for unexplained reasons, anti-His identification of the expressed CCR5 was very weak
in the best cases and often undetectable. Even the purified protein could not be visualized in
most of the anti-His Western blot. This type of problem has been reported for several other
GPCR detection [personal communications]. Therefore, it was impossible to perform a rapid
and early screen of the expression prior starting the purification process.
A second construct was thus created for CCR5. A C9 tag, a highly antigenic nine-amino acid
sequence of the rhodopsin carboxyl tail (TETSQVAPA), which allows the detection by the anti-
rhodopsin 1D4 monoclonal antibody was added on the carboxyl terminus of α5I-CCR5-His re-
sulting in α5I-CCR5-His-C9 construct. The additional C9 tag drastically improved the GPCR
detection using 1D4 antibody in Western blots.
10.7. Expression and purification of α5I-CCR5-His-C9
The expression and purification of α5I-CCR5-His-C9 were carried out as described for α5I-CCR5-
His.
Bacterial pellet was resuspended in lysis buffer and cells where lysed using a microfluidizer. The
inclusion body were solubilized in 6 M Urea and fusion protein was purified using a Ni-NTA
resin under denaturing conditions (Figure 10.12).
Figure 10.12.: SDS-polyacrylamide gel representing α5I-CCR5-His-C9 purification over a Ni-NTA
resin.
M - marker; 0 - sample before induction, I - sample after induction, FT - flow through from the
Ni-NTA resin. The arrow indicates α5I-CCR5-His-C9.
A conclusive double Western blot carried out on the same samples identified via an anti-His
and a 1D4 antibody can be observed in Figure 10.13. The tremendous improvement of the C9
insertion is obvious.
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(a) anti-His antibody (b) 1D4 antibody
Figure 10.13.: Western blotting representing α5I-CCR5-His-C9 purification over a Ni-NTA resin.
Western blotting of α5I-CCR5-His-C9 purification using Ni-NTA resin using (a) anti His
antibody, (b) 1D4 antibody. M - marker, 0 - sample before induction, I - sample after
induction, FT - flow through from the Ni-NTA resin.
The elution from the Ni-NTA column were pooled and dialyzed against thrombin digestion buffer
to eliminate Urea. Thrombin digestion kinetics was observed by collecting aliquots after 1, 2 and
3 hours of digestion (10.14).
Figure 10.14.: SDS-polyacrylamide gel representing α5I-CCR5-His-C9 digestion with thrombin.
M - marker; 1 - non digested sample; 2 - sample after 1 hour of digestion; 3 - sample after 2
hours of digestion; 4 - sample after 3 hours of digestion.
After one hour the digestion was completed. The reaction was stopped by the addition of 6
M Urea and 0.4 % SDS. The cleaved α5I fragment was separated from the CCR5-His-C9 by a
second Ni-NTA purification (Figure 10.15).
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Figure 10.15.: SDS-polyacrylamide gel representing CCR5-His-C9 purification on Ni-NTA resin.
M - marker; 1 - input, sample after thrombin digestion; 2-3 - flow-through; 4-5 - wash fractions;
6-9 - elution fractions.
The flow through (FT) and wash (W) fractions contained the α5I protein. The elution fractions
containing the CCR5-His-C9 were pooled and dialyzed against 0.8% SDS buffer until Urea traces
were removed.
Arround 2.2 mg of CCR5-His-C9 were obtained from one liter of bacterial culture.
CCR5-His-C9 folding was performed in the presence of NAPol and lipids in a 1:1:10 pro-
tein:lipid:NAPol weight ratio as previously described and analyzed on a SDS-polyacrylamide
gel. As before the amount of protein maintained soluble was determined (82%).
Figure 10.16.: SDS-polyacrylamide gel representing the sulubilized CCR5-His-C9 in NAPol.
M - marker, 1 - CCR5-His-C9 before the SDS precipitation, 2 - CCR5-His-C9 after folding in a
1:1:10 protein:lipid:NAPol weight ratio.
Solubilized CCR5-His-C9 was extensively dialyzed against 30 mM Potassium phosphate pH 8.0,
150 mM KCl buffer. Over 1 mg of folded CCR5-His-C9 was obtained form one liter of bacterial
culture. This sample was later used for SPR analysis.
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11. Analysis of CCR5 - RANTES interaction
using SPR
11.1. Introduction on Surface Plasmon Resonance
In 1990, Pharmacia AB, Uppsala, Sweden introduced the Biacore technology, which uses the
Surface Plasmon Resonance (SPR) phenomenon that occurs in thin conducting films at an inter-
face between media of different refractive index. In Biacore, the media are the glass of the sensor
chip and the sample solution, and the conducting film is the gold layer on the sensor chip surface.
The gold layer present on the sensor chip creates the physical conditions required for SPR. The
SPR biosensor technology allows the real-time detection and monitoring of biomolecular binding
events. This technology is widely used today, due to its high sensitivity and speed of analysis.
Figure 11.1.: Ligand, analyte and capturing molecule in relation to the sensor surface.
Figure from biacore.com.
Biacore monitors the interaction between two molecules, one is the ligand attached to the sensor
surface (the sensor chip), the other molecule is free in solution (analyte) delivered to the surface
in a continuous flow (Figure 11.1). Ligand attachment to the surface may be covalent or through
high affinity binding to another molecule, the capturing molecule, which is covalently attached
to the surface.
The changes of refractive index are related to the mass concentration changes at the sensor chip
surface (Figure 11.2).
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Figure 11.2.: Overview of Biacore SPR technology.
Ligand is represented as red Y-shapes and analyte is seen as yellow spheres. SPR measures
changes in the resonance angle in real time. Angle I = no analyte binding. Angle II = analyte
binds. Figure from biacore.com.
SPR measures changes in the resonance angle (which are directly related to refractive index and
thus to the mass concentration of dissolved material close to the chip surface) in real time. The
change in the SPR is directly related to the amount of analytes/biomolecules/molecules bound
near the surface of the chip.
SPR follows the binding of analyte to the immobilized ligand and that leads to the detection of
mass concentrations at the sensor surface. When analyte binds to a ligand the mass concentration
increases, when they dissociate the mass decreases. This simple principle forms the basis of the
sensorgram, the data output of the technology is the sensorgram, which is a plot of response
units against time, a continuous, real-time monitoring of the association and dissociation of the
interacting molecules (Figure 11.3).
Figure 11.3.: Schematic illustration of a sensorgram.
The bars below the sensorgram curve indicate the solutions that pass over the sensor surface.
Figure from biacore.com.
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The sensorgram provides both qualitative and quantitative information in real-time on specificity
of binding, concentration of active molecules in a sample, kinetics and affinity.
The SPR response is measured in Response (or Resonance) Units (RU) and is proportional to
the molecular mass on the surface (Figure 11.4). Rmax describes the maximum binding capacity
of the surface. This means that for a molecule of a given mass the response is proportional to the
number of molecules at the surface for sensor chip CM5. 1000 RU typically corresponds to 1 ng
of protein bound per 1 mm2, however the exact conversion from RU to protein amount depends
on the sensor surface and the analyte molecule.
Rmax =
MWA
MWL
× RL × n
Figure 11.4.: Equation to calculate maximal binding capacity.
MWA - molecular weight of analyte, MWL - molecular weight of ligand, RL- the amount of
immobilized ligand in RU, n - stoichiometric coefficient.
SPR technology is used to characterize molecular interactions involving small molecules, proteins,
polysaccharides, lipids and nucleic acids. Experiments are performed either with purified analytes
or with analytes present in crude media such as cell or bacterial lysates, tissue extracts and
biological fluids.
11.1.1. Sensor surface properties
The sensor chip is a glass slide coated with a thin layer of gold, which is commonly functionalized
with carboxymethylated dextran matrix (Figure 11.5). Ligands to the dextran matrix can be
attached using a variety of methods.
Figure 11.5.: Schematic illustration of the structure of the sensor chip surface.
Figure from biacore.com.
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The gold layer and dextran matrix on the sensor surface are stable under a wide range of condi-
tions, including extreme pH (from pH 1.5 to pH 8.5), moderate concentrations of many organic
solvents (up to 30% DMSO, 40 % glycerol, 40 % ethylene glycol) or high salt concentrations
(up to 2M MgCl2). Once the ligand has been immobilized, the stability of the sensor surface is
determined by the stability of the attached ligand.
11.1.2. Ligand immobilization methods
Different strategies exist for the ligand immobilization onto the sensor surface. A range of
various sensor chips are available for use in Biacore systems. The discussion below is focused
on immobilization strategies based on biomolecule capture by His-tag and biotin-tag as well as
covalent immobilization by amine-coupling chemistry which are the techniques used in this thesis
(Table 11.1).
Sensor Chip Surface type Applications
CM4 Sensor Chip CM-dextran with lower
carboxymethylation
level than CM5
For low immobilization
levels and reduced
non-specific binding
SA Sensor Chip CM-dextran with
immobilized
streptavidin
For capture of
biotinylated ligands
NTA Sensor Chip CM-dextran with
immobilized NTA
For capture of
poly-histidine tagged
ligands
Table 11.1.: Biacore sensor chips used in this study.
11.1.3. Covalent immobilization methods
Molecules can be attached to the chip surface by covalent immobilization. There are wide range
of well-defined chemistries but the simplest and the most commonly used is amine coupling.
11.1.3.1. Amine coupling
Amine coupling is the most widely applied approach for covalent immobilization of the biomolecules
to the sensor surface. The matrix on CM-series of sensor chips is composed of a linear car-
boxymethylated dextran, which is covalently attached to a gold surface presents itself as a hy-
drogel under aqueous conditions. The matrix provides a hydrophilic 3-dimensional environment
to biomolecules, the carboxyl groups of the matrix serve for covalent immobilization of ligands
by amine coupling chemistry (Figure 11.6).
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Figure 11.6.: Schematic view of amine coupling of ligands to the sensor surface.
An overview of amine-coupling using N-hydroxysuccinimide (NHS) and
N’-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC). Figure from biacore.com.
The dextran matrix on the sensor chip surface is first activated with a mixture of EDC (1-
ethyl-3-(3-dimethylaminopropyl)- carbodiimide) and NHS (N-hydroxysuccinimide) to give reac-
tive succinimide esters. Ligand is then passed over the surface and the esters react spontaneously
with uncharged amino groups and other nucleophilic groups to link the ligand covalently to the
dextran.
Unreacted esters are subsequently blocked with 1 M ethanolamine, which also releases loosely-
bound ligand from the surface.
The ligand to be coupled must be as pure as possible and storage buffer free from primary amines
such as Tris, glycine or stabilizing proteins. As the carboxymethylated matrix is negatively
charged in the running buffer (pH 7.4), the ligand must have a positive charge so that it is not
electrostatically repelled from the surface during the coupling reaction. By using coupling buffers
with a pH below the isoelectric point of the ligand, the positive net charge of the ligand can be
achieved.
In some cases, amine coupling may involve amine groups at or near the active site of the ligand
and attachment would lead to the loss of activity. However, it is common that proteins contain
several amine groups so that efficient immobilization can be achieved without seriously affecting
the biological activity of the ligand.
11.1.3.2. Conditions for ligand immobilization
For an efficient amine coupling method the ligand immobilization conditions should be deter-
mined.
This can be investigated quickly and easily using an intact CM surface and injecting ligand
diluted in buffers of different pH, a process called pH-scouting or pre-concentration.
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Before covalent bonds are formed between ligand and matrix, the ligand molecules are directed
to the surface due to electrostatic attraction. The magnitude of this attraction depends on the
net charge of the ligand, which in turn depends on pH of the buffer. The stronger the attraction,
the more of the ligand will be immobilized. Therefore it is useful to determine the optimal pH
of the buffer.
The carboxymethylated surface of the sensor chip carries a net negative charge at pH values
above about 3.5, so to achieve efficient pre-concentration the pH of the buffer should be higher
than 3.5 and lower than the isoelectric point of the ligand. In some cases the optimal pH is
a compromise between efficient pre-concentration and the stability of the ligand. Therefore, a
choice of pH can be a critical parameter in determining the success of immobilization (Figure
11.7). The experimental procedure for finding the appropriate immobilization pH consists of
several injections of the ligand diluted in buffers of different pH.
Figure 11.7.: Electrostatic attraction of the ligand to the CM-dextran.
Ligand is concentrated on the surface through electrostatic attraction when the pH lies between
the pK a of the surface and the isoelectric point of the ligand. If the pH is too high or too low,
ligand will not be attracted to the surface. Figure from biacore.com.
An additional requirement for efficient pre-concentration is a low ionic strength in the immo-
bilization buffer. In general, a maximum of 10-15 mM monovalent ions is recommended. It
is required to use high concentration of the ligand due to the phenomenon of the electrostatic
attraction. For most proteins, concentrations of 5–50 μg/ml are sufficient.
Once pre-concentration conditions have been established the surface should be washed with
ethanolamine to remove all loosely bound ligand molecules and immobilization can be performed.
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11.1.3.3. Results of immobilization
The result of immobilization is the amount of ligand remaining on the surface at the end of
the immobilization procedure, measured as the response relative to the baseline after surface
activation (Figure 11.8).
Figure 11.8.: Sensorgram from a typical amine coupling.
The distinction between the amount of ligand bound and the amount immobilized is
illustrated. Figure from biacore.com.
11.1.4. Capturing techniques
Several capturing approaches can be considered, they are based on biospecific interaction between
ligand and capturing molecule. The capturing molecule is normally covalently immobilized on
the surface. The advantage of using capturing techniques is that the ligand orientation is known.
The disadvantage is that the ligand surface might be unstable - ligand dissociates from the
surface and has to be re-injected. Also, it could be difficult to find regeneration conditions, as in
most cases the regeneration of the surface involves ligand removal from the capturing molecule
together with bound analyte.
11.1.4.1. Streptavidin-biotin capture
On the surface of SA Sensor Chip streptavidin is covalently attached to a dextran matrix. It is
designed to capture biotinylated ligands (Figure 11.9).
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Figure 11.9.: Schematic view of biotinylated ligand capture by high affinity binding to strepta-
vidin on Sensor Chip SA.
Figure from biacore.com.
Biotin may be introduced to a variety of biomolecules including proteins, carbohydrates, lipids
and, as in this work, amphipols. The affinity of streptavidin for biotin is very high (KD ≈ 10−15
M), the biotinylated ligand cannot be removed from the streptavidin surface, so the ligand is
permanently attached to the surface. Therefore, streptavidin-biotin capture is more similar to
covalent attachment than to other capturing approaches.
11.1.4.2. Antibody-based capture
Due to their high specificity and affinity monoclonal antibodies can be used as capturing molecules
in Biacore. They can be immobilized on the sensor surface using amine-coupling method (Figure
11.10).
Figure 11.10.: Schematic view of antibody-based capture.
Antibody-based capture relies on the specific binding between an immobilized antibody and
the antigenic epitope on the ligand. Figure from biacore.com.
Antibodies designed against chosen epitopes on the ligands enables ligands to be captured in
controlled orientations.
156
11.1. INTRODUCTION ON SURFACE PLASMON RESONANCE
11.1.4.3. Capture of histidine-tagged molecules
It is common to include a poly-histidine tag to recombinant proteins for affinity purification
purposes and the same principle can be applied to capture recombinant proteins on the sensor
surface in Biacore. A commonly used poly-histidine tag can chelate Ni2+ ions in complex with
nitrilotriacetic acid (NTA), and therefore can be used for capturing his-tagged constructs on NTA
Sensor Chip (Figure 11.11). By using NTA Sensor Chip the orientation of the histidine-tagged
ligands can be controlled.
Figure 11.11.: Schematic view of the chip surface of NTA Sensor Chip.
Figure from biacore.com.
The captured His-tagged proteins can be removed from the surface by injecting EDTA, which
removes the metal ions and releases the his-tagged ligand. This allows to use the sensor chip for
multiple experiments.
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11.2. Results
To test CCR5 functionality SPR experiments were performed. CCR5 samples folded in the
presence of lipids (L) and amphipols: A8-35 (CCR5/A8-35/L), NAPol (CCR5/NAPol/L) and
BAPol (CCR5/BAPol/L) were tested. Two different versions of CCR5, CCR5-His and CCR5-
His-C9, were used. Three functionalization approaches were considered. The presence of these
two tags allowed non-covalent capture on Ni2+-NTA and on a 1D4 antibody functionalized sensor
chip, respectively. On the other hand the use of the biotinylated amphipol (BAPol), provided
the possibility of a strong non-covalent capture on SA sensor chip.
11.2.1. CCR5 capture on NTA sensor chip
Figure 11.12.: Schematic representation of CCR5/NAPol immobilization on NTA sensor chip.
11.2.1.1. Development of the SPR assay to study CCR5 - chemokine interaction
While working with NTA sensor chip the first step is to load Ni2+ on the chosen active flow cell
surface. In our case flow cell 2 (Fc2) was chosen for receptor immobilization, therefore it was
loaded with Ni2+, while leaving Fc1 intact. The 4 min injection of CCR5-His/NAPol/L (at a
60 μg/ml receptor concentration) gave a final binding response of 643 RU on Fc2 while nothing
bound to Fc1.
Binding assays were then performed using an irrelevant ligand SDF1α-Strep (specific for CXCR4)
and then a CCR5 specific ligand, RANTES-Strep. SDF1α-Strep (at 500 nM) was injected first
over the CCR5-His/NAPol/L surface followed by a RANTES-Strep (at 500 nM) injection (Figure
11.13).
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(a)
(b)
Figure 11.13.: Normalized sensorgrams representing NTA chip functionalization and chemokine
binding test.
(a) The CCR5-His/NAPol/L was injected over the reference surface Fc1 (red) and Ni2+
activated surface Fc2 (blue). Subsequently SDF1α-Strep (500 nM) and RANTES-Strep (500
nM) were injected over both reference and receptor functionalized surfaces. (b) Reference
surface corrected sensorgrams representing the same injections as panel (a). Reference surface
corrected sensorgram refers to a differential sensorgram, where a control surface response is
subtracted from the raw active surface sensorgram.
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Analysis of the subtracted curve (Figure 11.13b) allows us to eliminate the bulk effects observed
in the Figure 11.13a. The absence of SDF1α-Strep binding shows the specificity of the interaction
with the receptor. The fact that RANTES-Strep bound to CCR5 captured surface indicates that
CCR5/NAPol/L is active and specific. Unfortunately, the baseline was not stable and one hour
after CCR5/NAPol/L injection only 368 RU of receptor remained on the surface.
(a)
(b) (c)
Figure 11.14.: Normalized sensorgrams showing RANTES-Strep interaction with CCR5-
His/NAPol/L surface.
(a) Sensorgrams representing absolute response on reference surface Fc1 (red) and Ni2+
activated surface Fc2 (blue) during the following injections: 1, 2 - CCR5-His/NAPol/L, 3 - 8
RANTES-Strep at 4 nM, 12 nM, 37 nM, 111 nM, 333 nM and 1000 nM, respectively. (b)
Reference surface corrected sensorgrams representing the same injections as panel (a). (c)
Reference surface corrected overlaid sensorgrams showing RANTES-Strep (4 nM - 333 nM)
interaction with CCR5-His/NAPol/L.
To evaluate the active receptor amount and to obtain the affinity value (KD), the titration
of RANTES-Strep was performed. Prior to that, the active surface (Fc2) was regenerated and
receptor was re-captured up to a final response of 660 RU via two successive injections to increase
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the immobilization level. Despite the unstable surface after receptor immobilization the titration
of chemokine was performed. The expected affinity of RANTES interaction with CCR5 is at low
nM range (0.2 - 6.2 nM) as described in the literature [372]. However, CCR5 being expressed
in E. coli, it missed post-translational modifications that may contribute to this high affinity.
Therefore, a range of 4 nM - 1000 nM concentrations of RANTES-Strep was chosen for the
analysis. The lowest concentration of RANTES-Strep (4 nM) was first injected (Figure 11.14).
It is obvious that there is no non-specific RANTES-Strep interaction with the reference surface
except for the last injection of 1000 nM (Figure 11.14a). RANTES-Strep binding responses
are concentration dependent, but the continuous decrease of the baseline due to the receptor
dissociation from the NTA surface complicates RANTES-Strep binding responses (Figure 11.14c).
Nevertheless, we plotted RANTES-Strep binding responses against the used concentrations to
see the binding pattern (Figure 11.15).
Figure 11.15.: Concentration dependency of RANTES-Strep binding responses.
Obviously the obtained binding curve significantly deviates from the standard Langmuir binding
isotherm. We can observe two phases of the curve, the first part being linear and a second part
with a tremendous slope increase. To elucidate the reason of this deviation we calculated the
theoretical binding capacity of the prepared surface and compared with the observed binding
responses.
660 RU of the complex were bound to the sensor chip, the MW of RANTES-Strep equal to
10 kDa, we estimate that we have ~100 kDa of NAPol bound per receptor (43 kDa) monomer
[337, 336], then calculated theoretical Rmaxis 46 RU (Figure 11.16).
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Rmax =
MWRANTES−Strep
MWCCR5/NAPol/L
× RCCR5/NAPol/L × n
Rmax =
10 kDa
143 kDa× 660RU ×n = 46RU ×n
Figure 11.16.: Calculation of CCR5/NAPol/L maximal binding capacity.
n - stoichiometry index. If the chemokine interacts with the receptor as 1:1, then the
stoichiometry index would be equal to 1. If the chemokine interacts with the receptor as 1:2,
then the stoichiometry index would be equal to 0.5.
Surprisingly when RANTES-Strep concentration is higher than 37 nM the amount of bound
RANTES-Strep significantly exits the expected theoretical Rmaxvalue. For example, 1000 nM
RANTES-Strep injection gives 1500 RU binding response, which is approximately 30 times higher
than the expected value. This theoretical Rmaxwas calculated excluding the lipids that could
be present in the receptor complex, if we included the lipids in the calculation, the theoretical
Rmaxvalue would be even lower. These high RANTES-Strep binding responses could be explained
by concentration dependent increase of the chemokine MW, i.e. oligomerization. Indeed, it is
well known that RANTES oligomerize at high concentrations (1 μM) [277].
Although the interaction data were complicated (due to the unstable baseline) we have tried to
extract the rough kinetic parameters for the interaction. The fitting has been performed on two
of the conditions tested that fulfilled the following criteria: RANTES-Strep should not be in an
oligomeric form (lower than 1000 nM concentration), it should be from a part of the experiment
with a reduced surface leaking. For this reason two sensorgrams representing 111 nM and 333
nM RANTES-Strep binding to CCR5/NAPol/L surface were chosen to perform separate fitting
of Langmuirian dissociation and association differential rate equations to the last 50 s interval
of the dissociation phases and to the early portions of 150 s intervals of the association phases,
respectively to calculate the interaction parameters. The determined rate constants and the KD
are listed in Table 11.2.
Ligand Conc. ka, × 104M−1s−1 kd, × 10−3s−1 KD, nM
RANTES-Strep
111 nM 7.61 4.03 53
333 nM 2.05 1.3 63.4
Table 11.2.: Apparent RANTES-Strep - CCR5 interaction parameters.
The obtained KDvalues are at low nM range which are not far from to the published ones [372]
considering the absence of post-translational modifications on E. coli expressed CCR5.
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11.2.1.2. Chemokine tag influence for the interaction with the receptor
The surface of the NTA sensor chip was prepared as described above. Because of the surface
leaking and to start the experiment with the high receptor level on the surface CCR5/NAPol/L
was coupled by three successive injections and the final binding response was approximately 500
RU (before injection of RANTES-Strep) (Figure 11.17).
Figure 11.17.: Normalized reference surface corrected sensorgram showing a comparison of dif-
ferent chemokine interaction with the CCR5/NAPol/L surface.
Injections: blue - three successive injections of CCR5/NAPol/L (60μg/ml), red - SDF1α-Strep
(500 nM), green - RANTES-Strep (500 nM), cyan - RANTES-LT-Strep (500 nM).
A big difference in binding responses was observed when comparing the responses of RANTES-
Strep and RANTES-LT-Strep injections. The calculated theoretical Rmaxvalue is roughly 35 RU
while RANTES-Strep binding clearly exceeds this value by more than 10 times. This might
be caused by oligomerization of this chemokine. On the other hand RANTES-LT-Strep binding
response is 50 RU, which is in the range of expected binding capacity of the prepared surface. We
can conclude that RANTES-LT-Strep is binding as a monomer to CCR5 while RANTES-Strep
is clearly oligomeric (500 nM) at concentration lower than what has been published to trigger
oligomerization (1μM).
Receptor capturing on the NTA sensor chip was not stable and the surface capacity was decreasing
significantly, which does not allow to set up a proper interaction test. Hence, we decided to
consider different immobilization approaches to improve the surface stability.
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11.2.2. CCR5 immobilization on CM4 sensor chip
From the Ni-NTA sensor chip data to fit kinetic binding data with simple interaction models was
a hard task. Therefore the experimental design was improved by means of employing a relatively
low-capacity surface (CM4) and orienting the immobilization of the ligand to the flow-cell surface.
Usually the proteins are immobilized covalently on the sensor chips of CM series by amine
coupling chemistry, which in most cases results in stable ligand surfaces. In order to keep the
receptor oriented the we did not perform the amine coupling directly with the receptor. For this
reason the C9 tag was introduces on the C-terminus of the CCR5 (Figure 11.18).
Figure 11.18.: Schematic representation of 1D4 capture on CM4 sensor chip and CCR5/NAPol
binding.
A linear C9 peptide tag (TETSQVAPA), located at the C-terminus of the receptor and recognized
by the 1D4 monoclonal antibody [373], gives the opportunity of a non-covalent capture of the
receptor via the C9 interaction with the latter antibody. Hence, the 1D4 can be covalently
immobilized by amine coupling and the prepared surface can be used for biospecific capture of
the receptor as it was previously published [372].
11.2.2.1. Optimization of the antibody immobilization conditions
CM4 sensor chip was chosen for SPR measurements because it has a lower carboxylation level of
the dextran matrix than CM5 sensor chip, i.e. lower amount of negative charges, which reduces
the possibility of non-specific electrostatic interactions.
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Amine coupling requires the protein to be prepared in acidic pH so that the molecules would
have a positive net charge, which allows electrostatic attraction to negatively charged matrix
surface. The optimal buffer pH, which would allow the highest yield of protein immobilization,
can be determined by performing pre-concentration tests. For this reason the protein has to be
diluted in buffers of different pH and injected on the intact sensor chip surface.
It is necessary to have a sufficient amount of the 1D4 antibody immobilized so that efficient
receptor capture can be achieved. We tested 1D4 pre-concentration in four different pH buffers:
4.0, 4.5, 5.0 and 5.5 (Figure 11.19a).
(a) (b)
Figure 11.19.: Test of 1D4 antibody pre-concentration on CM4 sensor chip.
(a) Sensorgram showing injections of 1D4 antibody (5 μg/ml) in 10 mM sodium acetate buffers
at different pH: orange - pH 4.0, green - pH 4.5, cyan - pH 5.0, black - pH 5.5. (b) Histogram
representation of the slope values of each injection corresponding to different pH.
The pre-concentration efficiency can be evaluated by the slope value of the response during the
injection. As can be seen from the Figure 11.19b the highest slope value is achieved at pH 4.5.
Hence, this buffer was chosen for 1D4 immobilization.
11.2.2.2. 1D4 antibody immobilization by amine coupling
The monoclonal antibody 1D4 was immobilized on CM4 sensor chip using standard amine-
coupling chemistry on the Flow cell 2. The CM-dextran surface was activated by a 10-min
injection of EDC/NHS mixture. Then 1D4 antibody was injected to the surface with a 7-min
injection in 10 mM sodium acetate pH 4.5. Remaining activated carboxyl groups were blocked
by a 10-min injection of ethanolamine (Figure 11.20).
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Figure 11.20.: The sensorgram representing 1D4 immobilization by amine coupling.
Injections: blue - EDS/NHS, red - 1D4 (5 μg/ml), cyan - ethanolamine.
The final response of immobilized 1D4 antibody on Fc2 was 3400 RU. The reference surface (Fc1)
was activated by a 10-min injection of EDC/NHS mixture and blocked by a 10-min injection of
ethanolamine.
11.2.2.3. Receptor capture on 1D4 antibody surface
The prepared 1D4 antibody surface on the Fc2 was used to capture the receptor. The mixture
of CCR5/NAPol/L (60 μg/ml) was injected over the Fc2 surface (Figure 11.21).
Figure 11.21.: Normalized sensorgram showing CCR5/NAPol/L binding on 1D4 surface.
The final response of captured CCR5/NAPol/L was 700 RU.
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11.2.2.4. The CCR5 surface activity test
First we checked whether RANTES-Strep could non-specifically interact with 1D4 antibody
surface on Fc1 (Figure 11.22).
Figure 11.22.: Sensorgram representing RANTES-Strep injection over 1D4 surface.
There was no RANTES-Strep interaction with 1D4 surface observed. Then several injections
of chemokines RANTES-Strep and SDF1α-His were performed to test activity and specificity of
CCR5/NAPol/L surface (Figure 11.23).
Figure 11.23.: Reference surface corrected sensorgram showing injections of chemokines onto
CCR5/NAPol/L surface.
Different color boxes represents the different injections: red background – injection of 200 nM
RANTES-Strep, green background – injection of 200 nM SDF1α-His, blue background –
injection of buffer HBS-N.
The responses of RANTES-Strep and SDF1α-His were double referenced [374, 375, 376]. While
using low-capacity surfaces it intrinsically leads to lower signal-to-noise ratio. However, in SPR
analysis there are systematic artifacts arising from the sample application, which can be removed
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using a two-step data correction (or double referencing). First, data is subtracted from a reference
surface. The systematic artifacts (also called bulk effects) are essentially equal between the
reaction and reference flow cells, and can be removed by subtracting the reference surface data
(Fc1) from the reaction surface data (Fc2). The second referencing step is subtracting blank
injections. The increase of the signal response during the analyte injections could be also observed
when running buffer was injected over the ligand surface. Subtracting the running buffer data
from all binding responses collected under the same conditions can eliminate this drift and allow
us better analysis of chemokine interaction (Figure 11.24).
Figure 11.24.: Normalized and double referenced sensorgrams showing the specificity of CCR5
surface.
Injections of chemokines onto CCR5/NAPol/L surface: blue - 200 nM RANTES-Strep, red -
200 nM SDF1α-His.
Due to the double referencing the sensorgram of SDF1α-His becomes flat and we can better
evaluate RANTES-Strep specific interaction.
Rmax =
MWRANTES−Strep
MWCCR5/NAPol/L
× RCCR5/NAPol/L × n = 10 kDa143 kDa × 700RU ×n = 49RU ×n
Figure 11.25.: Calculation of CCR5/NAPol/L maximal binding capacity.
n - stoichiometry index. If the chemokine interacts with the receptor as 1:1, then the
stoichiometry index would be equal to 1. If the chemokine interacts with the receptor as 1:2,
then the stoichiometry index would be equal to 0.5.
Once again, the calculated theoretical Rmax is 49 RU (Figure 11.25) while we observe a RANTES-
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Strep binding of 52 RU (Figure 11.24). From this results it is possible to conclude that at 200
nM concentration RANTES-Strep is monomeric and is interacting with the receptor at 1:1 ratio.
11.2.3. Chemokine interaction with amphipols
To be absolutely sure that the observed binding of RANTES result from a specific interaction
with the CCR5 and not from non-specific binding to the amphipols some control experiments
were needed. There are two possibilities monitor the RANTES specific binding. The first and
best option would be to prepare the control surface with another GPCR, that do not bind
RANTES, folded in amphipols. The second option is to prepare a RANTES surface and inject
amphipols. This control was prepared. As RANTES supports well acidic pH buffers there was
no problem for its covalent immobilization on the CM4 sensor chip by amine coupling chemistry.
For better RANTES-Strep immobilization pre-concentration experiments were performed. RANTES-
Strep was prepared in 10 mM NaAcetate buffers at pH 4.0; 4.5; 5.0; 5.5; 6.0. The pre-
concentration efficiency can be evaluated by the slope value of the response during injection.
As can be seen from the Figure 11.26 the highest slope value is achieved at pH 5. Hence, this
buffer was chosen for RANTES-strep immobilization.
Figure 11.26.: Histograms representing RANTES-Strep pre-concentration.
RANTES-Strep was immobilized on CM4 sensor chip using standard amine-coupling chemistry
on the Flow cell 2. The CM-dextran surface was activated by a 10-min injection of EDC/NHS
mixture. Then the RANTES-Strep was injected to the surface with a 7-min injection in 10 mM
NaAcetate pH 5. Remaining activated carboxyl groups were blocked by a 10-min injection of
ethanolamine. The final response of immobilized RANTES-Strep on Fc2 was 437.5 RU. Flow
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cell 1, the reference surface, was activated by a 10-min injection of EDC/NHS mixture and
blocked by a 10-min injection of ethanolamine. Both amphipols NAPol and A8-35 were tested
for nonspecific interaction with RANTES-Strep (Figure 11.27).
The final NAPol concentration in the receptor solution used for the SPR experiments described
before, was 1.17 mg/ml. The same concentration and five times less (0.234 mg/ml) of both
amphipols were used to test the interaction with RANTES-Strep. Amphipols were injected at
two flow rates: 100 μl/min and 20 μl/min.
(a) NAPol
(b) A8-35
Figure 11.27.: Reference surface corrected sensorgrams showing injections of NAPol and A8-35
onto RANTES-Strep surface.
Injections: (a) NAPols, (b) A8-35 over RANTES-Strep surface.
For better evaluation of amphipols interaction with RANTES-Strep the final responses were
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plotted in a histogram representation (Figure 11.28).
Figure 11.28.: Histograms representing NAPol and A8-35 interaction with RANTES-Strep sur-
face.
Non-specific NAPol interaction with RANTES-Strep is lower when the flow rate is 20 μl/min
and that was the flow rate used for CCR5 interaction test. There was no significant difference of
concentration of NAPol used at the flow rate 20 μl/min. At high flow rate (100 μl/min) the lower
non-specific interaction was observed when the NAPol was injected at smaller concentration
(0.234 mg/ml). Using high NAPol concentration at the high flow rate increased non-specific
interaction with RANTES-Strep. Therefore, NAPol non-specific interaction to RANTES-Strep
is sensitive to the flow rate; at the low flow rate non-specific interaction was reduced. A8-35
non-specific interaction with RANTES-Strep was similar at lower concentrations independent to
the flow rate. Whereas using high concentration of A8-35 a higher flow rate (100 μl/min) led to
slightly lower non-specific interaction comparing to low flow rate (20 μl/min).
Globally, the amphipol interaction with RANTES-Strep is rather low and non-specific NAPol
interaction to RANTES-Strep is lower than with A8-35.
11.2.4. CCR5 immobilization on a SA sensor chip
We also tested the functionalization of a surface via the biotin moiety of CCR5 refolded in BAPol
on a SA sensor chip (Figure 11.29).
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Figure 11.29.: Schematic representation of CCR5/BAPol immobilization on SA sensor chip.
When this experiment was performed we only had access to the Strep tagged version of RANTES
and could not investigate ligand binding to the receptor surface.
SA sensor chip with pre-immobilized Streptavidin was used for the capture of CCR5 folded in
BAPols. The Fc2 of the SA sensor chip was functionalized with CCR5/BAPol/L mixture at 60
μg/ml concentration up to 818 RU (Figure 11.30).
Figure 11.30.: Normalized sensorgram showing CCR5/BAPol/L functionalization on SA sensor
chip.
It was observed that this CCR5/BAPol/L prepared surface was stabilizing quite fast and did not
display any leaking. At this time, we decided to prepare RANTES without any tag to be able
to test its binding to this surface.
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11.2.5. CCR5 surface stability
With all available tools the surface stability during SPR experiments was evaluated.
Three different surfaces were prepared and their schematic representation is shown in Figure
11.31.
(a) NTA Sensor Chip (b) SA Sensor Chip (c) CM4 Sensor Chip
Figure 11.31.: Schematic representation of the different surfaces prepared for SPR experiments.
The stability of three different surfaces was evaluated by measuring: the amount (in RU) of
captured receptor, the slope over the 100 seconds and after 900 seconds from the receptor injection
and by calculating the percentage of captured receptor dissociation per second (Table 11.3).
Immobilization Amphipols slope Bound
receptor
RU
% of captured
ligand
dissociation
per second
His tag CCR5/NAPol -0,793 897 -0,08
Biotin moiety of BAPol CCR5/BAPol -0,161 858 -0,02
via C9 tag CCR5/NAPol -0,303 900 -0,03
Table 11.3.: Three different surface stability comparison.
From the calculated values it appeared that a maximal stability was achieved with a CCR5/BAPol
surface on the SA sensor chip and was very close to the values observed with functionalization
of CCR5/NAPol on the CM4 sensor chip. As observed earlier CCR5/NAPol on the NTA sensor
chip was the least stable. Nevertheless we were able to capture similar amount of the receptor
onto all surfaces.
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12. Résumé des résultats en français
12.1. Production de chimiokines
La première partie des résultats décrira l’ingénierie des différentes versions de deux ligands des
co-récepteurs du VIH, RANTES (pour CCR5) et SDF1α (pour CXCR4). Ces chimiokines re-
combinantes constituent des outils essentiels afin d’évaluer la fonctionnalité du récepteur repliée
et par la suite seront utilisées pour étudier les complexes récepteur/ligand. Les chimiokines
disponibles dans le commerce sont très chères, la production recombinante a été réalisée dans E.
coli. Nous avons profité d’une approche d’expression recombinant pour introduire des étiquettes
différentes avec des objectifs divers. Plusieurs modifications ont été introduites à l’extrémité
C-terminal telles que des étiquettes Strep, His et un site de liaison des Lanthanides. L’étiquette
Strep a été introduite afin de à constituer une chromatographie d’affinité. L’étiquette « Lan-
thanide » a été introduite pour des expériences de luminescence. Afin de mettre en place des
protocoles de production de chimiokines les stratégies déjà publiées dans la littérature ont été
examinées. Deux approches différentes ont été envisagées.
La première méthode consistait à fusionner la protéine liant le maltose (MBP) à la partie N-
terminale des chimiokines [361]. Il a été démontré que la fusion MBP améliore la solubilité des
protéines, un repliement approprié, une purification globale via une chromatographie d’affinité
et qu’elle protège de la protéolyse [363, 362, 361]. Selon les auteurs cette stratégie de fusion a
entraîné de haut rendement d’expression des chimiokines fonctionnelles. Il a été indiqué que l’aide
d’un système de double fusion comprenant une étiquette et une fusion avec la MBP augmentait la
pureté des chimiokines. Les activités de liaison des chimiokines recombinantes, MBP-RANTES
et MBP-SDF1α, à leur récepteur a été confirmée par cytométrie en flux en utilisant des cellules
exprimant des récepteurs CCR5 et CXCR4 sur leur surface [361].
La deuxième approche a consisté en la production de chimiokines dans les corps d’inclusion chez
E. coli [364]. Cette méthode exige la lyse des cellules et l’isolement des corps d’inclusion suivie
de la solubilisation des protéines et de leur renaturation.
Au début de ma thèse la première approche semblait plus prometteuse puisque des chimiokines
fonctionnelles étaient directement produites, en évitant l’étape délicate de repliement. Par con-
séquent, les chimiokines ont d’abord été produites en utilisant cette stratégie.
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Les chimiokines RANTES et SDF1α ont été commandées sous forme de gènes synthétiques,
où tous les nucléotides ont été optimisés pour l’expression dans E. coli. La construction de
la chimiokine contenait plusieurs éléments. Un site de clivage par le facteur Xa (Xa) permet
le clivage de la MBP de la chimiokine. Les chimiokines ont également une étiquette Strep à
leur extrémité C-terminale (Strep), ceci facilite l’étape de purification et permettra la création
ultérieure d’une colonne d’affinité. Nous avons ajouté l’étiquette de fixation des Lanthanides
(LT) à l’une des constructions. Cette étiquette spécifique lie le terbium (Tb). Le but de cette
étiquette était de faciliter le suivi de la chimiokine par fluorescence et aussi de résoudre une
future structure du complexe entre la chimiokine et le récepteur.
Nous avons cloné les chimiokines SDF1α et SDF1α-LT afin d’étudier l’interaction avec le récepteur
CXCR4 et les chimiokines RANTES et RANTES-LT pour l’interaction avec le récepteur CCR5.
Toutes les constructions ont été vérifiées par séquençage.
Plusieurs purifications des chimiokines ont été réalisées et il a été conclu que des optimisations
étaient nécessaires pour améliorer la purification. Tout d’abord le facteur Xa clivait de manière
non spécifique et imprévisible la protéine donc nous avons dû changer le site de clivage par celui
de la protéase PreScission.
Finalement nous avons été confrontés à de nombreux problèmes avec fusion à la MBP. Après
clivage de la MBP des étapes de purification supplémentaires ont été nécessaires afin d’éliminer
la protéine de fusion. Le clivage était incomplet, les contaminations de l’échantillon par MBP
étaient toujours présentes et les protéines agrégeaient.
La production de chimiokines avec la fusion MBP a été remplacée par une expression dans
les corps d’inclusion d’ E. coli [364]. Les premières constructions essayées ont été SDF1α-His
et SDF1α-LT-His. Après optimisation des protocoles d’expression, la purification de 3 mg de
SDF1α-LT-His a été obtenue à partir de un litre de culture bactérienne. La production de
SDF1α-His a était plus efficace et environ 7.8 mg de SDF1α-His ont été obtenus par litre de
culture bactérienne.
Des constructions similaires ont été produites avec une étiquette Strep C-terminale pour la
production ultérieur d’une colonne d’affinité pour les récepteurs de chimiokines. Étonnamment
ce changement d’étiquette d’affinité a considérablement réduit le rendement de la production de
chimiokines, en particulier pour les constructions sans étiquette LT que pour RANTES-Strep et
SDF1α-Strep, 0.2 mg ont été obtenus par litre de culture bactérienne pour deux chimiokines.
Pour évaluer la fonctionnalité de ces chimiokines, des expériences de contrôle ont été effec-
tuées. Pour la caractérisation structurale (uniquement la formation de ponts disulfures a été
évaluée) une analyse par spectrométrie de masse a été réalisée utilisés. Pour chacune des con-
structions, deux conditions ont été testées, l’une sans DTT (agent réducteur) et une avec DTT.
L’augmentation de la masse de 4 Dalton dans l’échantillon avec DTT a confirmé la formation de
deux ponts disulfure caractéristiques de cette famille de chimiokines.
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Il est connu que les modifications sur la partie N-terminale des chimiokines affectent considérable-
ment l’interaction avec leur récepteur. Rien n’a été jusqu’ici signalé pour des modifications en
C-terminales. Afin de caractériser la liaison au récepteur et la transduction du signal déclenché
par les chimiokines recombinantes une méthode originale de double électrode (Two-Electrode
Voltage Clamp (TEVC)) a été utilisée. Les récepteurs de chimiokines et des canaux potassiques
activés par les protéines G ont été co-exprimés dans des ovocytes de Xenope. La liaison du ligand
au récepteur de chimiokine provoque l’activation des protéines G qui aurait une incidence sur
l’ouverture du canal ionique. Des mesure en temps réel de l’activation des canaux ioniques permet
l’évaluation de l’activité biologique des chimiokines à la fois quantitativement et qualitativement.
Pour cette expérience des ovocytes de Xenope ont été transfectés avec deux ARNs: le GPCR
(CXCR4) et Kir3.1* un canal potassique activé par les protéines G. Les chimiokines SDF1α-His
et SDF1α-LT-His ont été testées. Lors de la liaison des chimiokines à CXCR4 les protéines G
ont été activées qui ont agi sur les canaux Kir3.1*. Avec cette expérience, nous démontrons la
capacité de notre chimiokines modifiées en C-terminale à lier leurs récepteurs et à déclencher la
signalisation via les protéines G.
Il a été observé que la présence de l’étiquette LT augmente la dissociation de SDF1α-LT-His (ac-
tivation est réversible) de son récepteur, tandis que la présence de l’étiquette LT pour RANTES-
Strep aboli la réversibilité et considérablement diminue l’efficacité de la chimiokine. À cette
étape, nous pouvons conclure que la partie C-terminale de la chimiokine peut accueillir des mod-
ifications sans abroger la liaison au récepteur. Cependant, la combinaison des étiquettes, His ou
Strep avec le LT, a un effet de « réglage » subtil sur l’affinité, l’efficacité, et la réversibilité de
liaison au récepteur.
Le troisième contrôle de la fonctionnalité chimiokine était un essai de chimiotactisme. Le chimio-
tactisme est le mouvement caractéristique des cellules le long d’un gradient de concentration
chimique soit en direction soit loin du stimulus chimique. Ce mécanisme permet aux lymphocytes
de se mouvoir selon un gradient de chimiokines. Pour cette expérience des cellules exprimant
CXCR4 et CCR5 à leur membrane ont été utilisés. Des expériences ont été effectuées en utilisant
la stratégie de la chambre de Boyden. Celle ci présente deux compartiments: le compartiment in-
férieur contient les chimiokines et le compartiment supérieur les cellules. La membrane filtrante
sépare les deux compartiments, les cellules peuvent passer au travers. Dans le compartiment
inférieur différentes concentrations de la chimiokine ont été ajoutés, tandis que dans le comparti-
ment supérieur du même concentration de cellules a été maintenue. Après incubation, la quantité
de cellules dans le compartiment inférieur a été déterminée. Les résultats ont montré que les
chimiokines SDF1α-His, SDF1α-Strep, RANTES-Strep induisent un chimiotactisme. Pour les
chimiokines portant l’étiquette LT les résultats étaient différents, SDF1α-LT-His a montré une
baisse d’activité par rapport aux autres chimiokines, le chimiotactisme était douteux dans le cas
de SDF1α-LT-Strep et il était assez clair que RANTES-LT-Strep n’est pas actif.
Les chimiokines repliées étaient fonctionnelless et adaptées pour les essais de liaison aux récep-
teurs. L’étiquette lanthanide supplémentaire permet d’améliorer les niveaux d’expression des
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chimiokines et de la solubilité des protéines. Toutefois, la présence de l’étiquette LT perturbe
le chimiotactisme: certaines chimiokines portant une étiquette LT étaient moins efficaces et cer-
taines n’ont pas induit du tout la migration des cellules. Néanmoins, les chimiokines portant
l’étiquette LT étaient capables de se lier à leur récepteur et de transduire un signal comme il a
été indiqué par la méthode TEVC.
12.2. La production des récepteurs
Nous avons exprimé le récepteur CCR5 fusionné au domaine extracellulaire d’une sous-unité
de l’integine α5β1 dans les corps d’inclusion de E. coli, comme décrit précédemment [104]. La
stratégie est basée sur l’accumulation des complexes protéine fusion/RCPG dans les corps in-
clusion, leur purification suivi d’un repliement in vitro. Pour cibler les protéines recombinantes
vers les corps d’inclusion de E. coli la combinaison de charge et de résidus formant des β-tour
sont critiques et doivent correspondre à une fraction élevée de la séquence protéique. C’est
sur ces paramètres physico-chimiques qu’un fragment du domaine extracellulaire de β-hélice de
l’intégrine humaine α5 (α5I) a été choisi [104].
Les corps d’inclusion ont été recueillis après lyse des cellules en utilisant un microfluidiseur. Après
de longs lavages les culots ont été solubilisés dans un tampon contenant de l’urée. L’étiquette His
à l’extrémité C-terminale des co-récepteurs a permis la purification des protéines sur une résine
Ni-NTA en conditions dénaturantes. Nous avons obtenu plusieurs mg de protéine de fusion à
partir d’un litre de culture bactérienne. La dialyse et digestion par la thrombine ont été réalisées
pour éliminer la protéine de fusion. Le co-récepteur a ensuite été sélectivement purifié sur résine
Ni-NTA.
L’expression de récepteur CXCR4 a été plus compliquée que CCR5. Même la fusion avec le
domaine extracellulaire d’une sous-unité de l’integine α5β1 n’était pas suffisante pour perme-
ttre l’expression. Nos collaborateurs J.-L. Banères et B. Mouillac (Montpellier) ont observé
l’expression de CXCR4 pour une triple fusion formée du domaine extracellulaire de l’ integine et
d’un fragment du récepteur V2 de la vasopressine. Nous essayons actuellement de déterminer les
meilleures conditions de culture en changeant les paramètres classiques tels que la température
d’expression, ou les milieux.
La production du récepteur est la partie la plus difficile du projet. De nombreux problèmes
ont été rencontrés lors des différentes étapes de l’expression et la purification. Résoudre ces
problèmes a nécessité beaucoup de temps. Une fois que le récepteur a été exprimé et purifié le
repliement a été réalisé. Cette étape est très délicate. De nombreux laboratoires rencontrent
des problèmes pour obtenir des récepteurs repliés et fonctionnels. Une approche alternative au
repliement en détergent a été entreprise grâce à notre collaborateur Jean-Luc Popot (IBPC,
Paris) qui nous a fourni différents types d‘amphipoles. Les amphipoles (APols) sont de courts
polymères amphipatiques qui peuvent maintenir les protéines membranaires intégrales solubles
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dans l’eau. Plusieurs types de d’APols ont été conçus, synthétisés et testés. Pour cette étude
l’A8-35 a été utilisé, il s’agit du premier amphipole a avoir été validé, sa solubilité est due à
la présence d’hydrates de carbone. Le second APol utilisé est à base de glucose, il s’agit d’un
amphipole non ionique (NAPol). Une version biotinylé de l’A8-35, le BAPol a également été
considéré.
Différentes conditions ont été testées pour le repliement. Pour évaluer ces conditions, le pour-
centage de récepteurs solubles restant après la procédure de repliement a été estimé. Depuis
les premiers essais il a été observé qu’une combinaison d’A8-35 et de lipides a permis à environ
61% de CCR5 de rester soluble (Figure 10.10). Les meilleures conditions de repliement ont été
obtenues en présence d’une protéine dans ratio de poids de 1:10:1 protéines:NAPol:lipide, ces
conditions maintiennent plus de 86% de l’échantillon soluble.
Une deuxième construction de CCR5 a été créé, un nouvelle épitope, l’étiquette C9, a été ajouté à
l’extrémité C-terminale de la construction CCR5-His. L’étiquette C9 est une séquence hautement
antigénique de neuf d’acides aminés de la rhodopsine bovine (TETSQVAPA), elle permet une
détection par l’anticorps monoclonal anti-rhodopsine 1D4. Cette séquence a été ajoutée à la
terminaison C-terminale de α5I-CCR5-His résultant en α5I-CCR5-His-C9.
L’étiquette supplémentaire C9 a considérablement amélioré la détection en Western blot en
utilisant l’anticorps 1D4. Les rendements de production sont les suivants: 0.5 mg de CCR5-
His et 2.2 mg de CCR5-His-C9 ont été obtenus à partir d’un litre de culture bactérienne. Le
repliement de CCR5 en présence de trois amphipoles différentes, l’A8-35, l’ amphipole non-
ionique (NAPol) et la version de biotinylé de l’A8-35 (BAPol) ont été testés en présence ou non
de lipides (Fig. 10.10). Les meilleures conditions de repliement ont été obtenus en présence
d’NAPol dans un rapport massique 1:10:1 protéines: NAPol: lipide Cette condition maintient
plus de 80% de CCR5 soluble.
12.3. Analyse de l’interaction CCR5 – RANTES par SPR
Pour tester la fonctionnalité de CCR5 des expériences de SPR ont été réalisées. Les échantil-
lons de CCR5 replié en présence de lipides (L) et amphipoles: A8-35 (CCR5/A8-35/L), NAPol
(CCR5/NAPol/L) et BAPol (CCR5/BAPol/L) ont été testés. Deux versions différentes de
CCR5, CCR5-His et CCR5-His-C9, ont été utilisées. Trois approches de fonctionnalisation ont
été considérées (Fig. 11.31). La présence de deux étiquettes C-terminales différentes sur CCR5 a
permis soit une capture non covalente sur le biocapteur NTA via l’étiquette His soit une liaison
sur la pice CM4 fonctionalisée avec l’anticorps 1D4 via l’étiquette C9. L’utilisation de l’amphipol
biotinylé (BAPol) a également permis une autre méthode de capture non-covalente de capture
sur un biocapteur SA. Avec tous ces outils, trois différentes surfaces de CCR5 ont été préparées
pour des expériences de liaison de ligand en utilisant l’analyse SPR. Il a été montré que notre
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récepteur produit est fonctionnel et peut lier spécifiquement son ligand - RANTES et n’interagit
pas avec SDF1α (un ligand non spécifique) (Fig 11.24).
Pour évaluer la quantité de récepteur fonctionnel et d’obtenir le KD , le titrage de RANTES-
Strep a été effectué. L’affinité attendue pour l’interaction de RANTES avec CCR5 est de l’ordre
de quelques nanomomolaire (0.2 à 6.2 nM) telle qu’énoncée dans la littérature [372]. Toutefois,
CCR5 étant exprimé dans E. coli, les modifications post-traductionnelles qui peuvent contribuer
à cette grande affinité ne sont pas présente. Par conséquent, une gamme de concentration de
RANTES-Strep allant de 4 nM à 1000 nM a été choisie pour l’analyse. Bien que les données
d’interaction aient été difficiles à analyser (en raison de la ligne de base instable), nous avons
essayé d’extraire les paramètres cinétiques bruts pour l’interaction. Malgré la baisse de ligne de
base, deux lots de données avec différentes concentrations de RANTES (111 nM et 333 nM) nous
ont permis de calculer des paramètres cinétiques bruts pour l’interaction. Les KD calculés, 53
nM et 63 nM, présentent 1 à 2 log de différence avec les valeurs publiées dans la littérature (0.2
à 6.2 nM) [372].
Le récepteur CCR5 a été produit et purifié dans les corps d’inclusion chez E. coli, son repliement
a été évaluée en utilisant trois différents amphipoles: l’A8-35, le NAPol et le BAPol. La stabilité
des trois différentes surfaces pour les mesures de SPR a été évaluée. A partir des valeurs calculées
il est apparu qu’une stabilité maximale était obtenue avec une surface CCR5/BAPol sur la puce
SA et était très proche des valeurs observées avec fonctionnalisation de CCR5/NAPol sur la puce
CM4. Comme indiqué précédemment, la surface NTA fonctionnalisé avec CCR5 en NAPol était
la moins stable. Néanmoins nous avons pu fixer les quantités similaires de récepteur sur toutes
les surfaces.
180
Part IV.
Discussions, conclusions and future
perspectives
181

13. Discussions, conclusions and future
perspectives
13.1. State of the art at the beginning of my Ph.D.
Every single step while working with GPCRs is delicate. Indeed, their over-expression, purifi-
cation, stabilization and crystallization are always difficult. Different expression systems have
been tested for GPCR production such as Escherichia coli (E. coli) [117], Saccharomyces cere-
visiae (S. cerevisiae), Pichia pastoris (P. pastoris) [115, 377], insect cells [378], mammalian cell
lines [379], as well as expression in photoreceptor cells of Drosophila [380], Xenopus [381], mouse
[382] and cell free synthesis [383]. Most of the GPCRs for which structure has been solved were
produced in insect cells expression system. In every case, variety of different protein modifica-
tions were required, their sequences were often heavily engineered and most of them contained
a T4L fusion. Besides insect cell expression is an expensive system and is not affordable for
many laboratories. Moreover, the quantities of produced receptors are limited. Therefore, the
development of alternative strategies for functional GPCR production in large amounts is still
of great interest.
Our team has been part of a network funded by the ANRS that undertook the survey of a large
panel of recombinant over-expression systems (E. coli, H. polymorpha, insect cells, mammalian
cells). However, after three years of investigations all the approaches were abandoned except for
the E. coli expression system. In contrary to the expensive eukaryotic expression system, E. coli
can be an interesting alternative for GPCR expression. This system is inexpensive and affordable
for many laboratories. Attempts to express GPCR in E. coli inner membrane generally led to
high toxicity and limited expression. An alternative approach consists in GPCR expression as
insoluble inclusion bodies (IBs) that accumulates in the E. coli cytoplasm. This strategy presents
several advantages: IB expression is not toxic; it allows high expression levels and enable a first
step of purification. Therefore, targeting GPCRs to IBs via a protein fusion strategy has been
considered.
In the laboratory different N-terminal fusions have been tested, such as GST, the carbohydrate-
binding domain of a Lectin (DC-SIGN), which was highly expressed in E. coli inclusion bod-
ies. These strategies did not trigger a huge GPCR expression improvement (only a slight en-
hancement was observed with the Lectin fusion). Collaboration with Jean-Louis Banères (In-
stitut des Biomolécules Max Mousseron (IBMM), Montpellier) and Bernard Mouillac (Institut
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de Génomique Fonctionnelle, Montpellier) was established and they have developed a rather
generic fusion strategy with an α5 Integrin fragment to target GPCR expression towards IBs.
This approach initially developed with BLT1 receptor was further applied to serotonin receptor
[384, 104, 385, 342, 386]. More recently this strategy was extended to several other GPCRs
including: the catecholamine β3AR, the hormone arginine-vasopressin V2 receptor, oxytocin
(OT) receptor (OTR), the chemokine-like ChemR23 receptor, the cannabinoid CB1 receptor,
the bioactive lipid leukotriene BLT2, CysLT1 and CysLT2 receptors [104]. They have attempted
the α5I fusion to CCR5 and CXCR4 but although the former was efficiently expressed, a double
fusion with α5I and a fragment of vasopressin receptor for CXCR4 receptor was necessary to
enable CXCR4 expression. The GPCR genes were optimized for E. coli expression system to cir-
cumvent the limitation due to rare codons. The fusion protein was recovered from the inclusion
bodies under denaturing conditions, i.e. in the presence of Urea, and purified by immobilized
metal affinity chromatography on a Ni2+ -NTA column. The fusion constructs contained a C-
terminal His tag, which facilitates purification in denaturing conditions. Once the fusion partner
was cleaved off, the GPCR was re-purified. Then the GPCR was available for further folding
approaches.
Preliminary tests were performed by Jean-Louis Banères and clearly indicated a folding far more
efficient in amphipols than in detergents. Therefore amphipol assisted folding was considered.
Development along these methods have been started in the group in the context of an ANR
contract (coordinated by J.-L. Popot) and of FP7, Marie Curie, Initial Training Network, SBMP,
supporting me for my Ph.D. studies.
The use of amphipols presents many potential advantages. Amphipols do not compete with
protein-protein interaction, they do not disrupt protein complexes allowing them to be in the
required stoichiometry [328, 313]. The protein/amphipol complex could easily accommodate
lipids, and co-factors, which could be necessary for protein stabilization and/or activation. To
validate the receptor folding strategy in amphipols we need to set up a molecular interaction test
using both folded receptor and its ligand – chemokine.
In order to be able to access the functionality of the folded receptors, their ligands were required.
Therefore a “home made” chemokine production needed to be established. At this stage I joined
the project and I was in charge of a chemokine production strategy set up. This allowed us
to produce “functionalized” chemokines carrying different tags such as His tag, Strep tag or
Lanthanoid binding tag (LT), which could be used for different applications such as affinity
purification, anchorage on solid support or chemokine visualization.
184
13.2. CHEMOKINE PRODUCTION AND FUNCTIONAL VALIDATION
13.2. Chemokine production and functional validation
13.2.1. Achievements
In order to set up a chemokine production strategy, protocols already published in the literature
were examined. Two different approaches were considered. The first method was based on fusing
the Maltose Binding Protein (MBP) to the N-terminal part of chemokines [361]. The second
method consisted in chemokine production in E. coli inclusion bodies [364]. Having already to
produce the receptor in E. coli inclusion bodies we initially wanted to avoid the refolding step
for the chemokine production, therefore, the MBP fusion strategy was attempted first.
Unfortunately many problems were faced with the fused MBP constructs. First of all, the Factor
Xa protease was not specific. Additional search for other suitable proteases was performed. After
the MBP cleavage, extra purification steps were necessary to remove the cleaved fusion protein.
The MBP itself was highly contaminating following purifications and it was not always easy to
eliminate it. Nevertheless, after MBP cleavage chemokines precipitated and only the ones with
the LT remained soluble. The additional LT unpredictably improved chemokine expression and
solubility. That was probably due to its charges; chemokines are basic proteins (pI around 9)
and the additional LT shifted the pI below 7. Using the MBP fusion strategy we could obtain
very little amounts of proteins, though they were not able to induce chemotaxis. Consequently,
the chemokine production strategy was changed.
The second approach consisted in chemokine production in E. coli inclusion bodies [364]. First,
two SDF1α versions, SDF1α-His and SDF1α-LT-His, were produced. The correct folding was
confirmed by the presence of two disulfide bridges revealed by Mass Spectroscopy analysis. Func-
tional activity was confirmed by chemotaxis assay. Receptor binding and signaling was assessed
using an electrophysiology recording strategy. Using the Two-Electrode Voltage Clamp method,
ligand binding to the chemokine receptor was recorded in real-time by measuring ion channel
activation (Figure 13.1).
From that point, other chemokine constructs were designed. Considering the advantages in
the production steps of the additional Lanthanoid Binding Tag, all chemokine versions were
produced with and without the LT resulting in: SDF1α-Strep, SDF1α-LT-Strep, RANTES-Strep,
RANTES-LT-Strep. The additional LT drastically changed the chemokine properties. Their
pI, very basic (RANTES-Strep – 9.00; SDF1α-Strep – 9.7) was changed with the LT addition
(RANTES-LT-Strep – 4.81; SDF1α-LT-Strep – 5.89). As before, the LT tremendously increased
chemokine expression and solubility levels. Differences were observed in SDF1α production for the
various affinity tag addition: His tagged chemokines were produced with higher yield than Strep
tagged chemokine, that might be due to the tryptophan present in the Strep tag, as tryptophan,
due to its amphipathy, is more sensitive during the protein folding procedure. The functionality
of the new produced chemokines was equally assessed. Electrophysiology recording data enabled
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to follow receptor binding and signal transduction, demonstrated that the addition of His or
Strep tag on the C-terminus of chemokines did not alter their ability to activate Gi/o proteins
via their receptors. These observations validate our initial approach to functionalize chemokines
via their C-terminus. However, the combination of tags, His or Strep with the LT, had some
“tuning” effect on chemokine affinity to their receptor, efficiency, and binding reversibility.
Figure 13.1.: Schematic representation of channel gating through G proteins.
Upon binding of its ligand at an extracellular site, a transmembrane GPCR adopts a new
conformation that triggers gating changes of Kir 3.1* channel through intracellular G-protein
activation reporting GPCR ligand binding. Figure adapted from [387].
Overall, chemokine production from E. coli inclusion bodies was satisfactory. Refolded chemokines
were functional and suitable for the receptor binding assays. The additional LT improved
chemokine expression levels and protein solubility. However, the presence of LT disturbed the
chemotaxis assay: some chemokines bearing a LT were less efficient and some were not inducing
cell migration at all. Chemokines bearing LT were able to bind their receptor. Up to this stage,
all tests in electrophysiology were performed where LT was not loaded with terbium. Although,
the chemokine production was not the main goal of my thesis, one year and a half were necessary
to establish functional chemokine production strategy.
13.2.2. Perspectives
Chemokine production strategy being set up now, different chemokine mutants that are unable
to oligomerize or cannot interact with heparan sulfate could be produced and characterized using
the various tests that were set up or available in the institute: electrophysiology recordings and
chemotaxis assay.
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The introduced Lanthanoid Binding Tag could introduce some fluorescent properties usable for
the study of receptor-ligand interaction. Recently the use of lanthanoids was highlighted in
a study where the ligands of GPCRs were labeled with lanthanoids and were used to study
their receptor dimer/oligomeric nature in live cells using time-resolved FRET strategy [369]. In
addition, the production of functionalized chemokines would open the way to useful techniques
such as affinity chromatography, pull-down experiments or SPR measurements.
Finally, we have also developed a functional expression system, in collaboration with M. Vivaudou
group, that will enable us to perform structure/function studies [387]. This system is based on ion
channels heterologously expressed in Xenopus oocytes. The Kir6.2, inward rectifier potassium
channel is not regulated by G proteins, but has the particularity to be regulated by another
membrane protein SUR (Sulfonylurea receptor). Inspired by this rather unique design, our
collaborators C. Moreau and M. Vivaudou (Grenoble, IBS) postulated that, if SUR could be
replaced by another receptor such as a G-protein-coupled receptor (GPCR), an ion channel
sensitive to GPCR ligands could be created and utilized to convert chemical information into
a direct electrical signal (Figure 13.2) [387]. They created an Ion-Channel-Coupled Receptor
(ICCR) between a GPCR and Kir6.2 channel. Upon binding of its ligand at an extracellular
site, a transmembrane GPCR adopts a new conformation that triggers gating changes of the
fused Kir6.2 reporting GPCR ligand binding. The strategy was validated using muscarinic M2
receptor and later on applied to dopaminergic D2 receptors. To create functional ICCRs with
CXCR4 and CCR5 we are actually trying to determine the optimal linker sequence between
those two components since the communication between the GPCR and the ion channel has to
be optimal for each new construct.
Figure 13.2.: Schematic representation of ion-channel-coupled receptors (ICCR) principle.
In an ICCR, the GPCR is mechanically coupled to an ion channel. When the GPCR binds a
ligand and changes conformation, this change is directly transmitted to the channel and results
in a change in channel gating and in the ionic current of the channel. Figure adapted from [387].
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This strategy opens the ways to the study of structure/function relationship as the consequences
of sequence modification could be directly evaluated in term of signal transduction. This could
be of great interest to determine modified functional form favorable to crystallogenesis.
13.3. Receptor production
13.3.1. Achievements
Before my arrival, CCR5 production strategy had been developed and CCR5 folding had been
carried out in A8-35. The functionality of the amphipol folded receptor had to be assessed.
Gel Filtration experiments were set up on one hand, with CCR5 folded in A8-35 and on the
other, with CCR5 folded in A8-35 and in complex with some chemically produced fluorescently
labeled chemokines. Unfortunately, although a clear co-elution of the GPCR and the chemokine
was observed, the possibility of a non-specific interaction between the hydrophobic and cationic
chemokine and the charged A8-35 could not be ruled out, as it was also observed that the
fluorescently labeled chemokine was co-eluting with free amphipol. Therefore, the uncharged
NAPol appeared at this point as a promising alternative to carry out the receptor folding. At
this step I joined the group.
Handling membrane proteins is never an easy task. Even thought the expression strategy was
established earlier, it was not always working as expected. First of all, it was not always re-
producible. The level of expressed protein was varying from nothing to moderate levels. The
problems in Western Blots with anti-His antibody complicated the detection. At that time, a new
epitope, the C9 tag, was added to the C-terminus of the CCR5-His constructs. Fortunately, the
additional C9 tag improved the protein detection in Western Blotting using 1D4 antibody, which
was shown to be more specific and more reliable than the anti-His antibody. From this point
improvement of the receptor production has been possible, we have now access to a satisfactory
level of receptor produced in a reproducible way.
Once the receptor was produced and purified, its folding was tested. Receptor folding was
assessed using three different amphipols: A8-35, NAPol and BAPol. It was shown that the mix
of lipids and amphipols improved CCR5 solubility and stability.
In vitro synthesis of CCR5 and CXCR4 was also attempted. Not all prepared constructs were
equally expressed.
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13.3.2. Perspectives
The purification of the CXCR4 still needs to be optimized, the conditions of the thrombin cleavage
need to be determined and the receptor purification should be undertaken. Subsequently, CXCR4
folding strategies could be established with protocols similar to those applied to CCR5.
Now, that functional receptor and chemokine are available, their complex should be formed and
characterized by several techniques including BN-PAGE gels, MALS (Multi Angle Light Scatter-
ing), Gel Filtration methods, analytical ultracentrifugation in order to assess its homogeneity and
stoichiometry status. Having access to the purified GPCR would even allow the reconstitution
of complexes with CD4-gp120 or with G proteins for future characterization at the molecular
level.
The introduced Strep tag for the chemokine allows the subsequent creation of affinity column
(Figure 13.3), where the chemokine bound to the Strep-Trap column could be use to trap the
receptor correctly folded in amphipols.
Figure 13.3.: Schematic representation of chemokine affinity column.
This experiment would allow us to estimate the folding yield of the receptor by ligand binding
experiments. These tools will also be convenient and necessary to sort out correctly folded
receptor molecules from the mix of functional and non-functional receptors that will result from
the folding steps.
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13.4. Surface Plasmon Resonance
13.4.1. Achievements
To evaluate the functionality of the produced CCR5, SPR experiments were performed. The
advantage of using a receptor folded in amphipols for the SPR experiments is that there is no
need to add the amphipols to all used buffers.
The presence of two different C-terminal tags on the CCR5 allowed a non-covalent capture on
NTA sensor chip through the His tag and on 1D4 antibody functionalized CM4 sensor chip to
capture receptor through the C9 tag. The use of biotinylated amphipol BAPol provides the
means to use another strong non-covalent capture on SA sensor chip. With all these tools three
different CCR5 surfaces were prepared for ligand binding experiments using SPR analysis.
Our first choice was to functionalize the NTA sensor chip with the CCR5 folded in NAPols
through the C-terminal His tag. Using this approach, the receptor is orientated. However
the baseline was not stable, which complicated the ligand binding assays. This is a common
problem while working with His-tagged receptors on NTA sensor chips [376]. Nevertheless, it
was clear that our produced receptor is functional and could specifically bind its ligand - RANTES
and was not interacting with SDF1α (non specific ligand). Despite the dropping baseline, two
data sets with different RANTES concentrations (111 nM and 333 nM) allowed us to calculate
rough kinetic parameters for the interaction. Separate fitting of Langmuirian dissociation and
association differential rate equations were performed. The calculated KD values, 53 nM and 63
nM, were in 1 to 2 log difference comparing to what was published in the literature (0.2 - 6.2
nM) [372].
The N-terminus of CCR5, when produced in eucaryotic systems, undergoes post-translational
modifications. In particular, the addition of sulfate groups to tyrosine 3, 10, 14 and 15 is required
for high affinity interaction with its ligand [388]. Some studies have been shown, that lack of
sulfation lowers the affinity between the receptor and its ligand [389]. Indeed, the difference we
observe between our receptor and natural receptor (containing post-translational modifications)
could be explained by this fact and is understandable.
To improve the baseline stability we used the strategy described by Navratilova and co-workers
[372]. For this approach we used CM4 sensor chip where the 1D4-capturing antibody was immo-
bilized on the carboxydextran matrix that coats the CM4 sensor chip surface. CCR5 expressed
with a C-terminal C9 tag trapped in NAPol was captured. CCR5 specificity was confirmed
using SDF1α as a negative control, which does not bind the receptor and RANTES, the specific
ligand, interacting with the CCR5 surface. The calculated theoretical receptor maximal binding
capacity was 49 RU and the obtained RANTES binding value was 52 RU. These two values
are very close and it is possible to conclude that RANTES at used concentration (200 nM) is
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monomeric. It is possible to extrapolate that RANTES interacts with its receptor as a 1:1 re-
ceptor:chemokine ratio. At this step it is also possible to estimate that most of the captured
NAPOL folded receptor is functional.
The third CCR5 surface was prepared using SA sensor chips, where CCR5 folded in BAPols
was immobilized via its biotin moiety. At that time, only RANTES-Strep was available so we
could not perform ligand-binding assay. This experiment was only performed to test the surface
baseline stability. From our observations and calculations, CCR5/BAPol surface on SA sensor
chip was slightly more stable than the 1D4 functionalized CM4 surface.
Within the first SPR experiments, the difference between RANTES-Strep and RANTES-LT-
Strep was observed in terms of oligomerization. It was observed that RANTES-LT-Strep binding
response was close to the calculated possible maximal response for the prepared CCR5 surface,
while RANTES-Strep clearly exceeds this value by more than 10 times suggesting a possible
chemokine oligomerization. The impact of the C-terminal chemokine tag to the oligomerization
effect could be better evaluated. Now, having a stable CCR5 surface concentration titrations
could be performed and the affinity KD could be calculated for each chemokine construct.
At this stage, further optimization of SPR surface, were required to better characterize the
interactions. Unfortunately, at the end of my Ph.D. the access to NAPol (through J.-L. Popot
lab) was limited by the difficulty of its chemical synthesis. Further development will have to wait
the new campaign of NAPol synthesis.
13.4.2. Perspectives
With prepared stable CCR5 surface more accurate kinetic parameters could be calculated. The
impact of the lacking sulfations on the N-terminal part of CCR5 could be better investigated.
The prepared CCR5/BAPol stable surface where anchorage occurs via the amphipol belt that sur-
rounds the protein leaves both the extracellular and intracellular parts of the receptor available.
Different complex reconstitution studies could now take place, ligand binding studies together
with the G protein interaction or any other GPCR partner could be characterized in the future.
However, for future SPR experiments a control that could rule out the non-specific interaction
between the chemokine and the amphipol is still required. Another GPCR folded in NAPol or
BNAPol could be used to confirm that it does not interact with the chemokine.
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en français
14.1. Etat de l’art au début de ma thèse de doctorat
Lorsque l’on travaille avec des RCPGs, chaque étape est délicate. En effet, leur surexpression, pu-
rification, stabilisation et cristallisation sont toujours difficiles. Différents systèmes d’expression
ont été testés pour la production de RCPGs tels que Escherichia coli (E. coli) [117], Saccha-
romyces cerevisiae (S. cerevisiae), Pichia pastoris (P. pastoris) [115, 377], les cellules d’insectes
[378], des lignées cellulaires de mammifères [379], ainsi que l’expression dans les cellules photoré-
ceptrices de la drosophile [380], Xenopus [381], la souris [382] et la synthèse acellulaire [383]. La
plupart des RCPGs dont la structure a été résolue ont été produites en cellules d’insecte. Dans
tous les cas, des modifications des protéines ont été nécessaires, leur séquence ont été souvent
fortement modifiées et la plupart d’entre elle contenait une fusion T4L. En outre l’expression en
cellules d’insecte est un système coûteux et n’est pas abordable pour de nombreux laboratoires.
De plus, les quantités de récepteurs produits sont limitées. Par conséquent, le développement de
stratégies alternatives pour la production de RCPGs fonctionnels en grande quantité est encore
d’un grand intérêt.
Notre équipe a fait partie d’un réseau financé par l’ANRS qui a testé un large panel de sys-
tèmes d’expression recombinante (E. coli, H. polymorpha, des cellules d’insectes, des cellules de
mammifères) pour la production des RCPGs, CCR5 et CXCR4. Cependant, après trois ans
d’investigations toutes les approches ont été abandonnées, sauf le système d’expression chez E.
coli. Au contraire du coûteux système d’expression eucaryote, l’expression chez E. coli peut
être une alternative intéressante pour l’expression des RCPGs. Les tentatives pour exprimer
RCPG dans la membrane interne de E. coli conduisent généralement à une toxicité élevée et
une expression limitée. Une approche alternative consiste en l’expression des RCPGs sous forme
de corps d’inclusion qui s’accumulent dans le cytoplasme de E. coli. Cette stratégie présente
plusieurs avantages: l’expression dans les corps d’inclusion n’est pas toxique, elle permet des
niveaux d’expression élevés et constitue une première étape de purification. Par conséquent, le
ciblage des RCPG dans les corps d’inclusion en utilisant une stratégie de protéine fusion a été
pris en considération.
Différentes fusions N-terminales ont été testées, comme la GST, ou encore le domaine de fixa-
tion des sucres d’une lectine (DC-SIGN), qui dans le laboratoire s’exprimaient fortement sous
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forme de corps d’inclusion. Ces stratégies n’ont pas permis de nette amélioration des quantité
exprimées (seule une légère augmentation a été observée avec la fusion à la séquence de la lec-
tine). Une collaboration avec Jean-Louis Banères (Institut des Biomolécules Max Mousseron
(IBMM), Montpellier) et Bernard Mouillac (Institut de Génomique Fonctionnelle, Montpellier)
a été établie. Nos collaborateurs ont développé une stratégie de fusion plutôt générique avec un
fragment de l’ntégrine α5 permettant de cibler l’expression des RCPGs vers les corps d’inclusion.
Cette approche initialement développée avec le récepteur BLT1 a également été appliquée au
récepteur de la sérotonine [384, 104, 385, 342, 386]. Plus récemment, cette stratégie a été éten-
due à plusieurs autres RCPG, y compris: le récepteur β3 adrénergique, le récepteur V2 de la
vasopressine récepteur, OTR le récepteur de l’ocytocine (OT), le récepteur cannabinoïde CB1,
BLT2 le récepteur des leucotriènes [104]. Ils ont tenté la fusion α5I avec récepteurs CCR5 et
CXCR4, mais bien que le premier ait été exprimé de manière efficace, une fusion double avec
α5I et un fragment du récepteur de la vasopressine a été nécessaire pour permettre l’expression
de CXCR4. Les gènes de CCR5 et CXCR4 ont été optimisés pour l’expression chez E. coli pour
contourner la limitation due à la présence de codons rares. La protéine de fusion a été extraite
des corps d’inclusion par des conditions dénaturantes, c’est à dire en présence d’urée, et purifiée
par chromatographie d’affinité sur une colonne Ni2+-NTA grâce à une étiquette polyhistidine
présence à l’extrémité C-terminale de la protéine de fusion. Une fois le partenaire de fusion clivé,
le RCPG a été re-purifié
Des tests préliminaires de repliement ont été réalisées par Jean-Louis Bañeres et ont clairement
suggérés un repliement beaucoup plus efficace en amphipoles qu’en présence de détergents. Le
développement de méthodes de repliement en amphipoles de RCPGs a été initiés dans le groupe
dans le cadre d’un contrat ANR (coordonné par J.-L. Popot) et soutenu par le réseau de formation
Marie Curie FP7, (SBMP), qui a financé mon doctorat focalisé sur le repliement de CCR5 et
CXCR4.
L’utilisation d’ amphipoles présente de nombreux avantages potentiels. Les amphipoles n’entrent
pas en compétition avec les interactions protéine-protéine, ils ne perturbent pas les complexes
protéiques leur permettant d’être dans la stoechiométrie nécessaire [328, 313]. Les complexes
protéine/amphipole sont également succeptibles d’accueillir facilement des lipides, et des co-
facteurs, qui pourraient être nécessaires à la stabilisation des protéines et/ou à leur activation.
Afin de valider la fonctionalité des récepteurs repliés en amphipoles nous avions besoin de mettre
en place un test d’interaction moléculaire entre le récepteur et son ligand naturel, la chimiokine.
Par conséquent, la production de chimiokines "faites maison" était nécessaire. À cette étape, j’ai
rejoint le projet et j’ai eu en charge de mettre en place une stratégie de production de chimiokines.
Nous avons profité de cette occasion pour produire des chimiokines "fonctionnalisées" c’est à dire
qui portent différentes étiquettes, telles que une étiquette His, une étiquette Strep ou encore un
site de fixation des lanthanide (LT), qui pourraient être utilisées pour différentes applications
telles que la purification par affinité, l’ancrage sur un support solide ou la visualisation de la
chimiokine.
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14.2. La production de chimiokines et de validation de leur
fonctionalité
14.2.1. Travaux accomplis
Afin de mettre en place une stratégie de production des chimiokines, des protocoles déjà publiés
dans la littérature ont été examinés. Deux approches différentes ont été envisagées pour la
production en E. coli. La première méthode était basée sur une fusion avec la protéine fixant le
Maltose (MBP) en partie N-terminale des chimiokines [361]. La deuxième méthode a consisté en
la production de chimiokines sous forme de corps d’inclusion [364]. Ne pouvant nous affranchir
de la production des récepteurs en corps d’inclusion nous avons d’abord voulu éviter l’étape de
repliement pour la production des chimiokines, par conséquent, la stratégie de fusion MBP a été
tentée en premier lieu.
Malheureusement, de nombreux problèmes ont été rencontrés avec les constructions fusionnées
à la MBP. Tout d’abord, la protéase (Facteur Xa) n’était pas spécifique. Une recherche sup-
plémentaire afin d’identifier une protéase appropriée a été réalisée. Après le clivage de la MBP,
des étapes de purification supplémentaires étaient nécessaires pour éliminer la protéine de fu-
sion clivée. Cette étape s’est avérée assez compliquée, des contaminations par la MBP étaient
observées. Néanmoins, après coupure de la MBP, les chimiokines précipitaient, seules celles qui
portaient l’étiquette LT restaient solubles. De plus, nous avons observé que l’ajout de l’étiquette
LT améliorait de manière de manière inattendue l’expression des chimiokines et leur solubilité.
Ceci était probablement dû aux charges portées par cette étiquette; les chimiokines sont des
protéines basiques (pI d’environ 9) et le LT supplémentaire déplace leur pI en dessous de 7. Au
final, la stratégie de fusion avec la MBP nous a permis d’obtenir de petites quantités de pro-
téines, qui n’étaient pas capables d’induire de chimiotactisme. En conséquence, la stratégie de
la production des chimiokines a été changée.
La deuxième approche a consisté en la production de chimiokines dans E. coli sous forme de
corps d’inclusion [364]. Tout d’abord, deux versions de SDF1α ont été produites: SDF1α-His et
SDF1α-LT-His. Leur repliement correct a été confirmé par la présence de deux ponts disulfures
révélés par l’analyse en spectroscopie de masse. Leur activité a, quant à elle, été confirmée
d’une part par un test de chimiotactisme et d’autre par en étudiant la liaison au récepteur et
la signalisation à l’aide d’une stratégie d’enregistrement d’électrophysiologique. En utilisant la
méthode de double électrode, la fixation du ligand au récepteur de chimiokine a été enregistré
en temps réel en mesurant l’activation des canaux ioniques (Figure 13.1).
A partir de là, d’autres constructions de chimiokine ont été conçues. Considérant les avan-
tages dans les étapes de production de l’étiquette LT, toutes les versions de chimiokines ont
été produites avec et sans le LT résultant en : SDF1α-Strep, SDF1α-LT-Strep, RANTES-Strep,
RANTES-LT-Strep. L’étiquette LT supplémentaire a radicalement changé les propriétés des
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chimiokines. Leur pI, très basique (RANTES-Strep – 9.00; SDF1α-Strep – 9.7) a été modifié
avec l’ajout LT (RANTES-LT-Strep – 4.81; SDF1α-LT-Strep – 5.89). Comme auparavant, le LT
a énormément augmenté l’expression des chimiokines et les taux de solubilité. Les différences
ont été observées dans la production de SDF1α en fonction de l’étiquette d’affinité utilisée: les
chimiokines marquées avec une étiquette Histidine ont été produites avec un rendement plus élevé
que les chimiokines possédant une étiquette Strep. La fonctionnalité de ces nouvelles chimiokines
a également été évaluée. L’enregistrement des données d’électrophysiologie ont permis de suivre
la liaison au récepteur et transduction du signal, elles ont démontré que l’ajout des étiquettes
His ou Strep du côté C-terminal des chimiokines ne modifie pas leur capacité à activer les pro-
téines Gi/o via leurs récepteurs. Ces observations valident notre approche initiale consistant en
fonctionnaliser les chimiokines par leur extrémité C-terminale. Cependant, nous avons observé
que la combinaison des étiquettes, His ou Strep avec le LT, avait résultait en des modulations
fine de l’affinité des chimiokines pour leur récepteur, sur leur efficacité, et sur la réversibilité de
liaison.
Dans l’ensemble, la production de chimiokines en corps d’inclusion dans E. coli a été satisfaisante.
Les chimiokines repliées étaient fonctionnelles et adaptées aux essais de liaison aux récepteurs.
Bien que la production de chimiokines n’ait pas été le but principal de ma thèse, un an et demi
ont été nécessaires pour mettre en place une stratégie production fonctionnelle.
14.2.2. Perspectives
Maintenant que la stratégie de production des chimiokines a été mise en place, différents mutants
incapables d’oligomériser ou ne pouvant pas interagir avec les héparanes sulfate pourraient être
produits et caractérisés à l’aide des différents tests disponibles: enregistrements électrophysi-
ologiques et essai de chimiotactisme.
L’étiquette LT pourrait introduire certaines propriétés fluorescentes utilisables pour l’étude de
l’interaction récepteur-ligand. Récemment, l’utilisation des lanthanides a été utilisés dans une
étude où les ligands de RCPG ont été marqués avec des lanthanides et utilisés pour étudier
la dimérisation des récepteurs dans des cellules vivantes en utilisant la stratégie de FRET en
temps résolu [369]. De plus, la production de chimiokines fonctionnalisées ouvrent la voie à des
expériences de précipitation ou des mesures de SPR.
Enfin, nous avons également développé un système d’expression fonctionnelle, en collaboration
avec le group de M. Vivaudou, qui va nous permettre d’effectuer des études structure/fonction
[387]. Ce système est basé l’expression hétérologue de canaux ioniques dans des ovocytes de
Xenopus. Kir6.2, un canal potassique rectifiant entrant n’est pas régulé par des protéines G,
mais a la particularité d’être régulé par SUR une autre protéine membranaire (récepteur des
sulfonylurées). Inspiré par ce design assez unique, nos collaborateurs C. Moreau et M. Vivaudou
(Grenoble, IBS) ont postulé que, si SUR pourrait être remplacé par un autre récepteur tel qu’un
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GPCR, un canal ionique sensible aux ligands des RCPG pourrait être créé et utilisé pour convertir
l’information chimique en un signal électrique direct (Figure 13.2) [387]. Ils ont créé un récepteur
couplé aux canaux ioniques (ICCR) entre un RCPG et le canal Kir6.2. Lors de la liaison de son
ligand sur un site extracellulaire, un RCPG transmembranaire adopte une conformation nouvelle
qui déclenche des changements d’ouverture de la protéine Kir6.2 qui lui est fusionnée reportant
ainsi la fixation du ligand sur le RCPG. La stratégie a été validée en utilisant des récepteurs
muscariniques M2 et a plus tard été appliquée aux récepteurs dopaminergiques D2. Afin de créer
des ICCR fonctionnels avec CXCR4 et CCR5 nous tentons de déterminer la séquence optimale
de liaison entre ces deux composantes, puisque la communication entre le GPCR et le canal
ionique doit être optimale pour chaque nouvelle construction.
Cette stratégie ouvre les voies à l’étude des relations structure/fonction puisque les conséquences
des modifications de séquence peuvent être directement évaluées en terme de transduction du
signal. Cela pourrait être d’un grand intérêt pour déterminer des constructions fonctionnelles
modifiées favorables à la cristallogenèse.
14.3. La production des récepteurs
14.3.1. Travaux accomplis
Avant mon arrivée, la stratégie de production de CCR5 a été mise au point et le repliement a
été réalisée en présence d’A8-35. La fonctionnalité du récepteur replié en amphipole devait être
évaluée. Des expériences de filtration de gel avaient été mis en place, avec d’une part CCR5 replié
en A8-35 et d’autre part avec CCR5 replié en A8-35 en complexe avec des chimiokines produites
chimiquement et marquées par fluorescence. Malheureusement, même si une claire co-élution de
la GPCR et la chimiokine a été observée, la possibilité d’une interaction non spécifique entre
la chimiokine, hydrophobe et cationique, et l’A8-35 chargé ne pouvait pas être exclue, puisqu’il
avait également été observé que la chimiokine fluorescente co-éluait avec l’amphipol libre. Par
conséquent, le NAPol, amphipole non chargé est apparu à ce moment comme une alternative
prometteuse pour effectuer le repliement des récepteurs. C’est cette étape que j’ai rejoint le
groupe.
La manipulation de protéines membranaires n’est jamais une tâche facile. Bien que la stratégie
d’expression ait été mise au point, la production n’était pas toujours satisfaisante. Tout d’abord
le niveau d’expression variait de rien à des niveaux modérés. Les problèmes rencontrés avec la
révélation par des anticorps anti-His en Western Blot ont compliqué la détection. A cette époque,
un nouvelle épitope, l’étiquette C9, a été ajouté à l’extrémité C-terminale des constructions
CCR5-His. Cette nouvelle étiquette a permis d’améliorer la détection de la protéine en Western
blot grâce à l’utilisation de l’anticorps 1D4, qui s’est avéré beaucoup plus sensible et fiable que
l’anticorps anti-His. A partir de là, la production de récepteur a pu être améliorées, nous avons
maintenant accès à une production de récepteur satisfaisante et reproductible.
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Une fois que le récepteur a été produit et purifié, son repliement a été testé. Le repliement des
récepteurs a été évaluée en utilisant trois amphipols différents: l’A8-35, le NAPol et le BAPol.
Il a été montré qu’un mélange de lipides et d’amphipoles améliore la solubilité et la stabilité de
CCR5.
La synthèse in vitro de CCR5 et CXCR4 a également été tentée. Toutes les constructions ont
été préparées et s’expriment de manière comparable.
14.3.2. Perspectives
La purification de CXCR4 doit encore être optimisée, les conditions de clivage par la thrombine
doivent être déterminées et la purification du récepteur doit être entreprise. Par la suite, le
protocole de repliement CXCR4 devra être établi avec des protocoles similaires à ceux utilisé
pour CCR5.
Les récepteurs fonctionnels et les chimiokines étant disponibles, leur complexe peut maintenant
être formé et caractériser par plusieurs techniques, gels BN-PAGE, MALS (Multi Angle Light
Scattering), filtration sur gel, ultracentrifugation analytique afin d’en évaluer l’homogénéité et
la stœchiométrie. L’accès au RCPG purifié pourrait également permettre la reconstitution de
complexes avec CD4/gp120 ou avec des protéines G et leur caractérisation au niveau moléculaire.
L’étiquette Strep qui a été ajoutée à la chimiokine, permettra la création ultérieure d’une colonne
d’affinité (Figure 13.3), La chimiokine liée à la colonne Strep-Trap pourra être utilisée pour piéger
les récepteurs correctement repliés en amphipoles.
Cette expérience nous permettrait d’estimer le rendement de repliement du récepteur par des
expériences de liaison de ligand. Ces outils seront également pratiques et nécessaires de séparer
les récepteurs correctement repliés à partir mélange de récepteurs fonctionnels et non fonctionnels
qui resulteront des étapes de repliement.
14.4. Resonance des plasmon de surface
14.4.1. Travaux accomplis
Afin d’évaluer la fonctionnalité du CCR5 produit, des expériences de SPR ont été réalisées.
L’utilisation de récepteurs repliés en amphipole pour les expériences SPR présente l’avantage de
ne pas avoir à ajouter d’ amphipole tous les tampons utilisés.
Le premier choix a été de fonctionnaliser le biocapteur NTA avec CCR5 replié en NAPols via
l’étiquette His C-terminale. En utilisant cette approche, le récepteur est orienté. Cependant la
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ligne de base n’était pas stable, ce qui a compliqué les dosages de liaison au ligand. Il s’agit d’un
problème courant lorsqu’on fixe des protéines avec des étiquettes His sur des biocapteurs NTA
[376]. Néanmoins, il est clair que notre récepteur produit est fonctionnel, peut lier spécifiquement
son ligand RANTES et n’a pas d’interaction avec SDF1α (ligand non spécifique).
L’extrémité N-terminale de CCR5, lorsqu’elle est produite dans des systèmes eucaryotes, compor-
tent des modifications post-traductionnelles. En particulier, l’addition de sulfate sur les tyrosines
3, 10, 14 et 15 est requise pour une interaction de forte affinité avec le ligand [388]. Certaines
études ont montré que le manque de sulfatation diminue l’affinité entre le récepteur et son ligand
[389]. Les différences d’affinité pour le ligand que nous avons observé entre notre récepteur et le
récepteur naturel (contenant des modifications post-traductionnelles) pourraient être expliquées
par ce fait.
Afin d’améliorer la stabilité de la ligne de base, nous avons utilisé la stratégie décrite par
Navratilova et ses collègues [372]. Pour cette approche, nous avons utilisé le biocapteur CM4
où l’anticorps 1D4 a été immobilisé sur la matrice de carboxydextran qui recouvre la surface.
CCR5 possédant une extrémité C-terminale C9 replié en NAPOL a été capturé. La spécificité de
CCR5 a été confirmée en utilisant SDF1α comme contrôle négatif (pas de liaison au récepteur),
et RANTES, ligand spécifique, qui interagit avec la surface CCR5. La capacité maximale de
liaison au récepteur théorique calculée était de 49 RU et la valeur obtenue pour la liaison de
RANTES était de 52 RU. Ces deux valeurs sont très proches et il est possible de conclure que
RANTES à la concentration utilisée (200 nM) est monomérique. Il est possible d’extrapoler
que RANTES interagit avec son récepteur avec un ratio de 1:1. À cette étape, il est également
possible d’estimer que la plupart des récepteurs capturés et repliés en NAPol sont fonctionnels.
La troisième surface de CCR5 a été préparé en utilisant des biocapteur SA, sur lesquels CCR5
replié en BAPols a été immobilisé par l’intermédiaire de son groupement biotine. A cette époque,
seulement RANTES-Strep était disponible ainsi, nous ne pouvions pas effectuer de test de liaison
de ligand. Cette expérience a été exécutée uniquement pour tester la stabilité de la ligne de base
de la surface. D’après nos observations et les calculs, la surface CCR5/BAPol sur biocapteur SA
est légèrement plus stable que la surface CM4 fonctionnalisé avec 1D4.
Dans les premières expériences de SPR, des différences ont été observées entre RANTES-Strep
et RANTES-LT-Strep en terme d’oligomérie. Il a été constaté que la liaison RANTES-LT-Strep
sur la surface de CCR5 était proche de la réponse théorique maximale alors que la liaison de
RANTES-Strep dépasse clairement cette valeur de plus de 10 fois suggérant une oligomérisation
de la chimiokine. L’impact des étiquette C-terminale sur l’oligomérie pourrait être mieux carac-
térisés. Maintenant que des surfaces de CCR5 stables sont disponibles, des titrations pourraient
être effectuées et les constantes de dissociation pourraient être calculées pour chaque construction
de chimiokine.
A ce stade, l’optimisation de la surface de SPR était nécessaire afin de mieux caractériser les
interactions. Malheureusement, à la fin de ma thèse de doctorat l’accès aux NAPol (via le
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laboratoire de J.-L. Popot) a été limitée par la difficulté de leur synthèse chimique. La suite de
ces travaux devra attendre les nouvelles synthèses de NAPol.
14.4.2. Perspectives
Avec des surfaces de CCR5 stables des paramètres cinétiques plus précis pourraient être calculés.
L’impact du manque des sulfations la partie N-terminale de CCR5 pourrait être mieux étudié.
La surface stable CCR5/BAPol où l’ancrage se fait par l’intermédiaire de la ceinture d’amphipole
qui entoure la protéine laisse les deux parties extracellulaire et intracellulaire du récepteur
disponible. Différentes études de reconstitution de complexes pourraient maintenant avoir lieu,
des études de liaison de ligand avec les protéines G ou tout autre partenaire de RCPG pourrait
être menées dans le futur.
Néanmoins, pour des expériences futures de SPR un contrôle qui pourrait exclure l’interaction
non spécifique entre la chimiokine et l’ amphipoel est toujours nécessaire. Un autre RCPG
replié en NAPol ou en BNAPol pourrait être utilisé afin de confirmer qu’il n’interagit pas avec
la chimiokine.
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15. Experiments
15.1. Chemokine purification
15.1.1. SDF1α-Strep purification
Inclusion bodies containing SDF1α-Strep were solubilized in 7.5 M Guanidine HCl and protein
was refolded overnight at 4°C in 50 mM Tris-HCl buffer. Refolded sample was centrifuged and
applied to the Capto S column (pI 9.70). Elution fractions from a Capto S column were analyzed
by the SDS-PAGE gel (Figure 15.1).
Figure 15.1.: SDF1α-Strep elution from Capto S column.
All elution fractions shown on the SDS-PAGE gel contained SDF1α-Strep and were pooled,
concentrated and injected to the Superdex 200 column. Elution fractions were analyzed on the
gel (Figure 15.2).
Figure 15.2.: SDF1α-Strep elution from Superdex 200 column.
Fractions containing SDF1α-Strep were pooled and concentrated. From one liter of bacterial
culture 0.2 mg of SDF1α-Strep were obtained.
239
Appendix
15.1.2. SDF1α-LT-Strep purification
Inclusion bodies containing SDF1α-LT-Strep were solubilized in 6M Urea and protein was refolded
overnight at 4°C. The refolded sample was centrifuged and applied to the Q sepharose column
(Figure 15.3).
Figure 15.3.: SDF1α-LT-Strep elution profile from Q sepharose column.
Elution fractions were analyzed on the gel. Fractions containing SDF1α-LT-Strep were pooled
and concentrated prior injection to a Superdex 200 gel filtration column (Figure 15.4).
Figure 15.4.: SDF1α-LT-Strep running profile in Superdex 200 column.
Elution fractions were analyzed on the gel. Fractions containing SDF1α-LT-Strep were pooled
and concentrated. From one liter of bacterial culture 3.2 mg of SDF1α-LT-Strep were obtained.
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15.2. In vitro synthesis
Clones of CCR5 and CXCR4 receptors were prepared for cell-free synthesis. Wild type sequences
as well as E. coli codon optimized sequences were cloned into two types of vectors pIVEX2.3d
and pIVEX2.4d optimized for in vitro expression. The vector pIVEX2.4d possesses a N-terminal
His tag while the vector pIVEX2.3d contains a C-terminal His tag. Seven clones were prepared
(Table 15.1).
Nr Construct name
1 pIVEX 2.3d CCR5 wt
2 pIVEX 2.3d CCR5 optimized
3 pIVEX 2.4d CCR5 optimized
4 pIVEX 2.3d CXCR4 optimized
5 pIVEX 2.4d CXCR4 optimized
6 pIVEX 2.4d CCR5 wt
7 pIVEX 2.3d CXCR4 wt
Table 15.1.: Clones for cell-free synthesis.
Synthesis was performed in 50 μl volume using commercial RTS 100 E. coli HY Kit. As a
control the vector encoding bacteriorhodopsin was used (sample 8 in both gels). The reactions
were carried out for 6 hours at 21°C. Samples were taken from each reaction and centrifuged
to separate the soluble proteins from the precipitants. All samples were analyzed on SDS-
polyacrylamide gel (Figure 15.5) and western blot using an anti-His antibody (Figure 15.6).
All constructs tested were expressed except sample 7 (CCR5 wt in pIVEX 2.4d vector). The
best expression was observed for the samples: 1 - pIVEX 2.3d CCR5 wt, 2 - pIVEX 2.3d CCR5
optimized, 4 - pIVEX 2.3d CXCR4 optimized and 6 - pIVEX 2.4d CCR5 wt.
Figure 15.5.: SDS-polyacrylamide gel analysis of chemokine receptors in cell-free synthesis.
M - marker, P - pellet, S - soluble fraction, 1-8 - numbers indicating the used constructs.
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Figure 15.6.: Western Blot of chemokine receptors expression in cell-free synthesis.
M - marker, P - pellet, S - soluble fraction, 1-8 - numbers indicating the used constructs.
As there were no amphipols or detergent in the reaction mix all expressed protein were found in
the pellet fraction.
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16. Molecular biology
Fragment amplification by PCR
The PCR reaction mix was prepared as follows:
• 1 μl of DNA template at 100 ng/ml
• 2.5 μl of primer 1 at 100 ng/ml
• 2.5 μl of primer 2 at 100 ng/ml
• 2 μl of dNTP at 10 mM
• 10 μl Pfu polymerase buffer
• 2 μl of Pfu polymerase
• add miliQ H2O up to 100 μl final volume
PCR amplification program:
Denaturation - 95°C – 2 min
Denaturation - 95°C – 1 min
Hybridization - 60°C – 1 min 25 cycles,
Elongation - 68°C – 3 min
Elongation - 68°C – 5 min
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Cloning of DNA
The ligation reaction mix was prepared as follows:
• 1 μl of previously digested vector
• 5 μl of previously digested insert
• 4 μl of 5x ligase buffer (Fermentas)
• 9 μl of miliQ H2O
• 1 μl of ligase
The mix was incubated for 30 min at room temperature.
Transformation to E. coli competent cells
• 5 μl of ligation reaction (or 1 μl of DNA plasmid [0.1 μg]) was added to 50 μl of competent
cells
• The reaction mix was incubated for 30 min on ice
• Heat shock at 42°C for 90 seconds
• Addition of 150 μl of SOC medium
• Incubation at 37°C with 220 rpm for 1 hour
• Plate the cells on LB + agar plates containing 100 ng/ml of ampicilin
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17. Used primers
Name Sequence 5’→3’
SDF-NdeI ggt act att tca gca tat gaa acc ggt gag cct gag c
SDF-XhoI gct gcc gcg gca cca gct cga gtt tgt tca ggg c
SDFLT-XhoI gct ggc gcg cgg cac cag ctc gag cgc cag cag ttc
SDF-LT-fw gcg ctg aac aaa ggc ccg ggc tat att gat acc
SDF-LT-rv ggt atc aat ata gcc cgg gcc ttt gtt cag cgc
SDF1aLTBF ctg gaa aaa gcg ctg aac aaa ggc ccg ggc tat att gat acc
SDF1aLTBR cgc gcg gca cca ggc cgc tcg cca gca gtt cat cgc ctt c
MALE-Fw ggt cgt cag act gtc gat gaa gcc
M13RV tgt aaa acg acg gcc agt
SDF1apc4xLTPreProF caa taa caa taa caa caa cct cgg gct cga ggt act att tca ggg acc
caa acc ggt gag cct gag cta tcg ctg ccc gtg
SDF1apc4xLTPreProR cac ggg cag cga tag ctc agg ctc acc ggt ttg ggt ccc tga aat agt acc
tcg agc ccg agg ttg ttg tta ttg tta ttg
RANTESXaPreProR c aat aac aac aac ctc ggg ctg gaa gtt ctg ttc cag ggg ccc att tca
gaa ttc agc ccg tat agc agc gat acc acc
RANTESXaPreProF c aat aac aac aac ctc ggg ctg gaa gtt ctg ttc cag ggg ccc agc ccg
tat agc agc gat acc acc
SDFStrepF ctg gaa aaa gcg ctg aac aaa ctc gag gta cta ttt cag gga ccc agc
gct tgg agc cac ccg cag ttc gaa aaa tag ggc gga tcc gaa ttc gag
SDFStrepR ctc gaa ttc gga tcc gcc cta ttt ttc gaa ctg cgg gtg gct cca agc gct
ggg tcc ctg aaa tag tac ctc gag ttt gtt cag cgc ttt ttc cag
SDFLTStrepF ggc gat gaa ctg ctg gcg ctc gag gta cta ttt cag gga ccc agc gct tgg
agc cac ccg cag ttc gaa aaa tag ctc gag cac cac cac cac
SDFLTStrepR gtg gtg gtg gtg ctc gag cta ttt ttc gaa ctg cgg gtg gct cca agc gct
ggg tcc ctg aaa tag tac ctc gag cgc cag cag ttc atc gcc
RANTESStrepF gat ata cat atg agc ccg tat agc agc gat acc
RANTESStrepR att aac agc ctg gaa atg agc ctc gag gta cta ttt cag gga ccc agc gct
tgg agc cac ccg cag ttc gaa aaa tag gga tcc gaa ttc
RANTESLTStrepR gaa ggc gat gaa ctg ctg gcg ctc gag gta cta ttt cag gga ccc agc gct
tgg agc cac ccg cag ttc gaa aaa tag gga tcc gaa ttc
Table 17.1.: Primers used for PCR.
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Name Sequence 5’→3’
PivexR5optF cgt tgc atc cat gga tta tca ggt gag cag ccc
PivexR5optR atg caa cgc ccg ggc agg ccc acg cta att tcc
PivexR5optstopR atg caa cgc ccg ggt tac agg ccc acg cta att tcc
PivexR5wtF cgt tgc atc cat gga tta tca agt gtc aag tcc
PivexR5wtR atg caa cgc ccg ggc aag ccc aca gat att tcc
PivexR5wtstopR atg caa cgc ccg ggt tac aag ccc aca gat att tcc
PivexX4optF cgt tgc atc cat gga agg cat tag cat tta tac c
PivexX4optR atg caa cgc ccg ggg ctg cta tga aag ctg ctg
PivexX4optstopR atg caa cgc ccg ggt tag ctg cta tga aag ctg ctg
PivexX4wtF cgt tgc atc cat gga ggg gat cag tat ata cac
PivexX4wtR atg caa cgc ccg ggg ctg gag tga aaa ctt gaa g
PivexX4wtstopR atg caa cgc ccg ggt tag ctg gag tga aaa ctt gaa g
Table 17.2.: Primers used for cell free constructs.
246
18. Sequences
Figure 18.1.: SDF1α DNA sequence in pUC57 vector and protein sequence.
Figure 18.2.: RANTES DNA sequence in pUC57 vector and protein sequence.
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Figure 18.3.: RANTES-LT DNA sequence in pUC57 vector and protein sequence.
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Figure 18.4.: DNA and protein MBP-PrePro-SDF1α-Strep sequence.
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Figure 18.5.: DNA and protein MBP-PrePro-SDF1α-LT-Strep sequence.
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Figure 18.6.: DNA and protein MBP-PrePro-RANTES-Strep sequence.
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Figure 18.7.: DNA and protein MBP-PrePro-RANTES-LT-Strep sequence.
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Figure 18.8.: DNA and protein SDF1α-His sequence.
Figure 18.9.: DNA and protein SDF1α-LT-His sequence.
Figure 18.10.: DNA and protein SDF1α-Strep sequence.
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Figure 18.11.: DNA and protein SDF1α-LT-Strep sequence.
Figure 18.12.: DNA and protein RANTES sequence.
254
Appendix
Figure 18.13.: DNA and protein RANTES-Strep sequence.
Figure 18.14.: DNA and protein RANTES-LT-Strep sequence.
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Figure 18.15.: DNA and protein α5I-CCR5-His sequence.
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Figure 18.16.: DNA and protein α5I-CCR5-His-C9 sequence.
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Figure 18.17.: Part I. DNA and protein α5I-V2-CXCR4-His sequence.
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Figure 18.18.: Part II. DNA and protein α5I-V2-CXCR4-His sequence.
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Figure 18.19.: DNA and protein pIVEX 2.3d CCR5 WT sequence.
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Figure 18.20.: DNA and protein pIVEX 2.3d CCR5 optimized sequence.
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Figure 18.21.: DNA and protein pIVEX 2.4d CCR5 optimized sequence.
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Figure 18.22.: DNA and protein pIVEX 2.3d CXCR4 optimized sequence.
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Figure 18.23.: DNA and protein pIVEX 2.4d CXCR4 optimized sequence.
264
Appendix
Figure 18.24.: DNA and protein pIVEX 2.4d CCR5 WT sequence.
265
Appendix
Figure 18.25.: DNA and protein pIVEX 2.3d CXCR4 WT sequence.
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Abstract: Chemokine receptors are critical regulators of cell migration in the context of immune
surveillance, inflammation and development. The GPCRs (G protein-coupled receptors) CCR5 and
CXCR4 are specifically implicated in cancer metastasis and HIV-1 infection. An expression system to
over-express these two GPCRs was developed. To overcome the toxicity problem of membrane protein
expression in bacterial system, the production approach consists in targeting the proteins towards
E. coli inclusion bodies thanks to a N-terminal fusion allowing a high yield expression. After purification
under denaturing conditions, these GPCRs were then folded using original polymeric surfactants: the
amphipols. The validation of this new approach for the chemokine receptor production is one of the
goals of this work. In order to assess the functionality of the folded proteins, series of tools have been
developed: engineered chemokine ligands (RANTES for CCR5 and SDF1α for CXCR4) were produced.
The functionality of chemokines was evaluated at cellular and molecular levels. Interaction between
the receptor folded in amphipols and its ligand was evaluated using Surface Plasmon Resonance (SPR)
technique. Several types of surfaces, functionalized with the chemokine receptor/amphipol complex
have been explored in this work. At the end of this project the productions of chemokines and their
receptors has been set up. These established tools open the way to future studies, at the molecular
level, in order to, for instance, investigate receptor dimerization and complex stoichiometry.
Keywords: GPCRs, Chemokine receptors, CXCR4, CCR5, chemokines, SDF1α, RANTES, E. coli
expression system, GPCR folding, amphipols, chemotaxis, Surface Plasmon Resonance, TEVC, Lan-
thanoid Binding Tag.
Résumé : Les récepteurs de chimiokines sont des régulateurs essentiels de la migration cellulaire
dans le cadre de la surveillance immunitaire, et le développement. Les récepteurs CCR5 et CXCR4
sont de plus spécifiquement impliqués dans les métastases cancéreuses et l’infection par le VIH. Nous
avons développé un système permettant de sur-exprimer ces deux RCPGs. Afin de s’affranchir des
problèmes de toxicité inhérents à l’expression des protéines membranaires en bactérie notre approche
de production consiste à adresser les protéines vers les corps d’inclusion d’E. coli grâce à une fusion
protéique N-terminale permettant de hauts niveaux d’expression. Après purification en conditions
dénaturantes, les protéines sont alors repliées en présence de surfactants originaux, les amphipoles. La
validation de cette nouvelle approche pour les récepteurs des chimiokines représente un des objectifs
principaux de ce travail. Afin de tester la fonctionnalité des protéines repliées, une série d’outils a été
développée : des versions modifiées des chimiokines ont été produites (RANTES pour CCR5 et SDF
1α pour CXCR4). La fonctionnalité des chimiokines a été évaluée au niveau moléculaire et cellulaire.
L’interaction entre le récepteur replié en amphipole et son ligand a été testé par résonance de plasmons
de surface (SPR). Différents types de surfaces fonctionalisées avec le récepteur de chimiokine replié en
amphipole ont été explorés au cours de ce travail. A la fin de ce projet, la production des chimiokines et
de leur récepteur a été mise au point. L’accès à ces outils ouvre la voie à de futures études moléculaires
telles que la compréhension de la dimérisation du récepteur ou la détermination de la stœchiométrie
du complexe.
Mots-clés: RCPG, récepteurs de chimiokines, CXCR4, CCR5, chimiokine, SDF1α, RANTES, ex-
pression dans E. coli, GPCR renaturation, amphipoles, chimiotactisme, Résonance Plasmonique de
Surface, TEVC, etiquette de Lanthanid.
